BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 3722] [Cited by in F6Publishing: 3826] [Article Influence: 744.4] [Reference Citation Analysis]
Number Citing Articles
1 Xiao Y, Yuan J, Yang C, Xiong J, Deng L, Liang Q, He C, Li L, He F, Huang X. (125)I Radioactive Particles Drive Protective Autophagy in Hepatocellular Carcinoma by Upregulating ATG9B. J Clin Transl Hepatol 2023;11:360-8. [PMID: 36643035 DOI: 10.14218/JCTH.2022.00023] [Reference Citation Analysis]
2 Eletreby R, Elsharkawy M, Taha AA, Hassany M, Abdelazeem A, El-Kassas M, Soliman A. Evaluation of GALAD Score in Diagnosis and Follow-up of Hepatocellular Carcinoma after Local Ablative Therapy. J Clin Transl Hepatol 2023;11:334-40. [PMID: 36643039 DOI: 10.14218/JCTH.2022.00013] [Reference Citation Analysis]
3 Zhong BY, Jin ZC, Chen JJ, Zhu HD, Zhu XL. Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol 2023;11:480-9. [PMID: 36643046 DOI: 10.14218/JCTH.2022.00293] [Reference Citation Analysis]
4 Schellhaas B, Jesper D, Strobel D; DEGUM CEUS HCC Study Group. Contrast-enhanced ultrasound pattern of hepatocellular carcinoma in noncirrhotic liver - results from the prospective multicentre DEGUM CEUS HCC study. Eur J Gastroenterol Hepatol 2023;35:313-9. [PMID: 36708302 DOI: 10.1097/MEG.0000000000002491] [Reference Citation Analysis]
5 Jiang W, Fu X, Wang G, Qi H, Chen Z, Gao F. Effect of Biliary Tract Invasion with Obstructive Jaundice on the Prognosis of Patients With Unresectable Hepatocellular Carcinoma. Acad Radiol 2023;30:483-91. [PMID: 36150964 DOI: 10.1016/j.acra.2022.08.010] [Reference Citation Analysis]
6 Kuo F, Eng H, Li W, Liu Y, Wang C, Lin C, Yong C, Yen Y. Tumor Necrosis Is an Indicator of Poor Prognosis Among Hepatoma Patients Undergoing Resection. Journal of Surgical Research 2023;283:1091-1099. [DOI: 10.1016/j.jss.2022.11.039] [Reference Citation Analysis]
7 Fu Y, Li X, Yang Z, Li S, Pan Y, Chen J, Wang J, Hu D, Zhou Z, Xu L, Chen M, Zhang Y. A risk-based postresection follow-up strategy for hepatocellular carcinoma patients. Cancer 2023;129:569-79. [PMID: 36541017 DOI: 10.1002/cncr.34601] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Nakagawa M, Inoue M, Ogasawara S, Maruta S, Okubo T, Itokawa N, Iino Y, Obu M, Haga Y, Seki A, Kikuchi Y, Kogure T, Yumita S, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Fujita N, Sakuma T, Kojima R, Kanzaki H, Koroki K, Taida T, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Ito K, Mizumoto H, Shinozaki M, Kato J, Kato N. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. Cancer 2023;129:590-9. [PMID: 36426410 DOI: 10.1002/cncr.34559] [Reference Citation Analysis]
9 Fang S, Zheng L, Shen L, Su Y, Ding J, Chen W, Chen X, Chen W, Shu G, Chen M, Zhao Z, Tu J, Ji J. Inactivation of KDM5A suppresses growth and enhances chemosensitivity in liver cancer by modulating ROCK1/PTEN/AKT pathway. Eur J Pharmacol 2023;940:175465. [PMID: 36566915 DOI: 10.1016/j.ejphar.2022.175465] [Reference Citation Analysis]
10 Kim JH, Yoon JH, Bae JS, Park S, Han S, Lee JM. Multiarterial Phase Acquisition in Gadoxetic Acid-Enhanced Liver MRI for the Detection of Hypervascular Hepatocellular Carcinoma in High-Risk Patients: Comparison of Compressed Sensing Versus View Sharing Techniques. Invest Radiol 2023;58:139-47. [PMID: 35976759 DOI: 10.1097/RLI.0000000000000910] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hong SB, Hong S, Choi SH, Park SY, Shim JH, Kim SY, Lee SS, Kim S. Multiple arterial-phase MRI with gadoxetic acid improves diagnosis of hepatocellular carcinoma ≤3.0 cm. Liver Int 2023;43:462-70. [PMID: 36317670 DOI: 10.1111/liv.15470] [Reference Citation Analysis]
12 Rossotti R, Merli M, Mazzarelli C, De Carlis RM, Travi G, Vecchi M, Viganò R, Lauterio A, Raimondi A, Belli LS, De Carlis LG, Puoti M. Similar survival but higher and delayed hepatocellular carcinoma recurrence in HIV-positive compared to negative cirrhotics undergoing liver transplantation. Dig Liver Dis 2023;55:268-75. [PMID: 35644890 DOI: 10.1016/j.dld.2022.05.001] [Reference Citation Analysis]
13 Hashem E, Sait S, Thomas DN, Watson C, Moeen S, Peddu P. Transarterial chemoembolisation for very early and early stage hepatocellular carcinoma: single-centre experience. Clin Radiol 2023;78:e113-22. [PMID: 36280515 DOI: 10.1016/j.crad.2022.09.120] [Reference Citation Analysis]
14 Wu YC, Yao Y, Tao LS, Wang SX, Hu Y, Li LY, Hu S, Meng X, Yang DS, Li H, Xu T. The role of acetaldehyde dehydrogenase 2 in the pathogenesis of liver diseases. Cell Signal 2023;102:110550. [PMID: 36464104 DOI: 10.1016/j.cellsig.2022.110550] [Reference Citation Analysis]
15 Buch S, Innes H, Lutz PL, Nischalke HD, Marquardt JU, Fischer J, Weiss KH, Rosendahl J, Marot A, Krawczyk M, Casper M, Lammert F, Eyer F, Vogel A, Marhenke S, von Felden J, Sharma R, Atkinson SR, McQuillin A, Nattermann J, Schafmayer C, Franke A, Strassburg C, Rietschel M, Altmann H, Sulk S, Thangapandi VR, Brosch M, Lackner C, Stauber RE, Canbay A, Link A, Reiberger T, Mandorfer M, Semmler G, Scheiner B, Datz C, Romeo S, Ginanni Corradini S, Irving WL, Morling JR, Guha IN, Barnes E, Ansari MA, Quistrebert J, Valenti L, Müller SA, Morgan MY, Dufour JF, Trebicka J, Berg T, Deltenre P, Mueller S, Hampe J, Stickel F. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut 2023;72:381-91. [PMID: 35788059 DOI: 10.1136/gutjnl-2022-327196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Shehab-Eldeen S, Metwaly MF, Saber SM, El-Kousy SM, Badr EAE, Essa A. MicroRNA-29a and MicroRNA-124 as novel biomarkers for hepatocellular carcinoma. Dig Liver Dis 2023;55:283-90. [PMID: 35525722 DOI: 10.1016/j.dld.2022.04.015] [Reference Citation Analysis]
17 Zhu L, Park J, Deng Y, Pan CQ. The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B. J Clin Gastroenterol 2023;57:127-38. [PMID: 36598804 DOI: 10.1097/MCG.0000000000001785] [Reference Citation Analysis]
18 Kim Y, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Goh MJ, Kang W, Kim SU. Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2023;35:191-7. [PMID: 36574310 DOI: 10.1097/MEG.0000000000002466] [Reference Citation Analysis]
19 Lee HJ, Kim JS, Lee JK, Lee HA, Pak S. Ultra-low-dose hepatic multiphase CT using deep learning-based image reconstruction algorithm focused on arterial phase in chronic liver disease: A non-inferiority study. Eur J Radiol 2023;159:110659. [PMID: 36584563 DOI: 10.1016/j.ejrad.2022.110659] [Reference Citation Analysis]
20 Tsai PC, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Chen CY, Yu ML; T-COACH Study Group. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol 2023;78:281-92. [PMID: 36208843 DOI: 10.1016/j.jhep.2022.09.019] [Reference Citation Analysis]
21 Moazzam Z, Alaimo L, Endo Y, Lima HA, Shaikh CF, Ratti F, Marques HP, Cauchy F, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Variations in Textbook Oncologic Outcomes After Curative-Intent Resection: Early Versus Intermediate Hepatocellular Carcinoma Based on Barcelona Clinic Liver Cancer Criteria and Child-Pugh Classification. Ann Surg Oncol 2023;30:750-9. [PMID: 36404380 DOI: 10.1245/s10434-022-12832-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Vaz J, Strömberg U, Midlöv P, Eriksson B, Buchebner D, Hagström H. Unrecognized liver cirrhosis is common and associated with worse survival in hepatocellular carcinoma: A nationwide cohort study of 3473 patients. J Intern Med 2023;293:184-99. [PMID: 36166276 DOI: 10.1111/joim.13570] [Reference Citation Analysis]
23 İnce O, Önder H, Gençtürk M, Cebeci H, Golzarian J, Young S. Prediction of Response of Hepatocellular Carcinoma to Radioembolization: Machine Learning Using Preprocedural Clinical Factors and MR Imaging Radiomics. J Vasc Interv Radiol 2023;34:235-243.e3. [PMID: 36384224 DOI: 10.1016/j.jvir.2022.11.004] [Reference Citation Analysis]
24 Cong R, Ma XH, Wang S, Feng B, Cai W, Chen ZW, Zhao XM. Application of ablative therapy for intrahepatic recurrent hepatocellular carcinoma following hepatectomy. World J Gastrointest Surg 2023; 15(1): 9-18 [DOI: 10.4240/wjgs.v15.i1.9] [Reference Citation Analysis]
25 Conticchio M, Inchingolo R, Delvecchio A, Ratti F, Gelli M, Anelli MF, Laurent A, Vitali GC, Magistri P, Assirati G, Felli E, Wakabayashi T, Pessaux P, Piardi T, di Benedetto F, de’Angelis N, Briceño J, Rampoldi A, Adam R, Cherqui D, Aldrighetti LA, Memeo R. Impact of body mass index in elderly patients treated with laparoscopic liver resection for hepatocellular carcinoma. World J Gastrointest Surg 2023; 15(1): 72-81 [DOI: 10.4240/wjgs.v15.i1.72] [Reference Citation Analysis]
26 Zhu Y, Wang E, Zhao S, Han D, Zhao Y, Chen H, Zhu J, Han T, Bai Y, Lou Y, Zhang Y, Yang M, Zuo L, Fan J, Chen X, Jia J, Wu W, Ren W, Bai T, Ma S, Xu F, Tang Y, Han Y, Zhao J, Qi X, Li J, Du X, Chen D, Liu L. Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.983554] [Reference Citation Analysis]
27 Zhang W, Ouyang D, Huang Z, Che X. Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1085166] [Reference Citation Analysis]
28 Tian F, Leng S, Chen J, Cao Y, Cao L, Wang X, Li X, Wang J, Zheng S, Li J. Long-term outcomes of laparoscopic liver resection versus open liver resection for hepatocellular carcinoma: A single-center 10-year experience. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1112380] [Reference Citation Analysis]
29 Lominadze Z, Hill K, Shaik MR, Canakis JP, Bourmaf M, Adams-mardi C, Abutaleb A, Mishra L, Shetty K. Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. IJMS 2023;24:2358. [DOI: 10.3390/ijms24032358] [Reference Citation Analysis]
30 Xu L, Chen L, Zhang B, Liu Z, Liu Q, Liang H, Chen Y, Chen X, Leng C, Zhang B. Alkaline phosphatase combined with γ-glutamyl transferase is an independent predictor of prognosis of hepatocellular carcinoma patients receiving programmed death-1 inhibitors. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1115706] [Reference Citation Analysis]
31 Xu J, Yin Y, Yang J, Chen L, Li Z, Shen J, Wang W, Ni C. Modified quantitative and volumetric response evaluation criteria for patients with hepatocellular carcinoma after transarterial chemoembolization. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.957722] [Reference Citation Analysis]
32 Yokoo T, Masaki N, Parikh ND, Lane BF, Feng Z, Mendiratta-Lala M, Lee CH, Khatri G, Marsh TL, Shetty K, Dunn CT, Al-Jarrah T, Aslam A, Davenport MS, Gopal P, Rich NE, Lok AS, Singal AG. Multicenter Validation of Abbreviated MRI for Detecting Early-Stage Hepatocellular Carcinoma. Radiology 2023;:220917. [PMID: 36692401 DOI: 10.1148/radiol.220917] [Reference Citation Analysis]
33 Heinze C, Damm R, Othmer M, Thormann M, Surov A, Hass P, Seidesticker R, Seidensticker M, Ricke J, Powerski M, Pech M, Omari J. Local tumor control of intermediate and advanced stage hepatocellular carcinoma after local ablative treatment with image-guided interstitial high-dose-rate brachytherapy: A subgroup analysis of 286 HCC nodules. Brachytherapy 2023:S1538-4721(22)00393-2. [PMID: 36697267 DOI: 10.1016/j.brachy.2022.11.014] [Reference Citation Analysis]
34 Loosen SH, Jördens MS, Schoon B, Antoch G, Luedde T, Minko P, Loberg C, Roderburg C. Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies. J Cancer Res Clin Oncol 2023. [PMID: 36689060 DOI: 10.1007/s00432-022-04519-8] [Reference Citation Analysis]
35 Xu B, Zhao X, Chen D, Zhao W, Wang X, Ding C, Yuan Z, Zhang H. Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer. BMC Cancer 2023;23:73. [PMID: 36681809 DOI: 10.1186/s12885-023-10519-9] [Reference Citation Analysis]
36 Biondi R, Renzulli M, Golfieri R, Curti N, Carlini G, Sala C, Giampieri E, Remondini D, Vara G, Cattabriga A, Cocozza MA, Pastore LV, Brandi N, Palmeri A, Scarpetti L, Tanzarella G, Cescon M, Ravaioli M, Castellani G, Coppola F. Machine Learning Pipeline for the Automated Prediction of MicrovascularInvasion in HepatocellularCarcinomas. Applied Sciences 2023;13:1371. [DOI: 10.3390/app13031371] [Reference Citation Analysis]
37 Hříbek P, Habartová L, Klasová J, Kubíčková K, Kupsa T, Tůma T, Setnička V, Urbánek P. LABORATORY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA - CONVENTIONAL BIOMARKERS AND BLOOD PLASMA SPECTROSCOPY. Mil Med Sci Lett 2023. [DOI: 10.31482/mmsl.2022.046] [Reference Citation Analysis]
38 Cassinotto C, Nogue E, Durand Q, Panaro F, Assenat E, Dohan A, Malafaye N, Guiu B, Molinari N. Life expectancy of patients with hepatocellular carcinoma according to the upfront treatment: A nationwide analysis. Diagn Interv Imaging 2023:S2211-5684(23)00002-5. [PMID: 36682959 DOI: 10.1016/j.diii.2023.01.002] [Reference Citation Analysis]
39 Chen L, Zhang R, Lin Z, Tan Q, Huang Z, Liang B. Radiation therapy in the era of immune treatment for hepatocellular carcinoma. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1100079] [Reference Citation Analysis]
40 Surial B, Mena AR, Roumet M, Limacher A, Smit C, Leleux O, Mocroft A, van der Valk M, Bonnet F, Peters L, Rockstroh JK, Günthard HF, Berzigotti A, Rauch A, Wandeler G; Swiss HIV Cohort Study, ATHENA Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection. J Hepatol 2023:S0168-8278(23)00011-9. [PMID: 36690280 DOI: 10.1016/j.jhep.2022.12.029] [Reference Citation Analysis]
41 Zhao Y, Tan X, Chen J, Tan H, Huang H, Luo P, Liang Y, Jiang X. Preoperative prediction of cytokeratin-19 expression for hepatocellular carcinoma using T1 mapping on gadoxetic acid-enhanced MRI combined with diffusion-weighted imaging and clinical indicators. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1068231] [Reference Citation Analysis]
42 Moawad AW, Morshid A, Khalaf AM, Elmohr MM, Hazle JD, Fuentes D, Badawy M, Kaseb AO, Hassan M, Mahvash A, Szklaruk J, Qayyum A, Abusaif A, Bennett WC, Nolan TS, Camp B, Elsayes KM. Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation. Sci Data 2023;10:33. [PMID: 36653372 DOI: 10.1038/s41597-023-01928-3] [Reference Citation Analysis]
43 Gao X, Zhao R, Ma H, Zuo S. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a systematic review and single-arm meta-analysis.. [DOI: 10.21203/rs.3.rs-2445357/v1] [Reference Citation Analysis]
44 Chen W, Hu S, Liu Z, Sun Y, Wu J, Shen S, Peng Z. Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy. Hepatol Int 2023. [PMID: 36645648 DOI: 10.1007/s12072-022-10478-6] [Reference Citation Analysis]
45 Deng J, Liao Z, Gao J. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Curr Oncol 2023;30:1243-54. [PMID: 36661745 DOI: 10.3390/curroncol30010096] [Reference Citation Analysis]
46 Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(1): 1-18 [PMID: 36684055 DOI: 10.4251/wjgo.v15.i1.1] [Reference Citation Analysis]
47 Chuang YH, Cheng YF, Tsang LL, Ou HY, Hsu HW, Lim WX, Huang PH, Weng CC, Yu CY. Efficacy and Safety of Combined Ethanol-Lipiodol Mixture and Drug-Eluting Bead TACE for Large HCC. J Hepatocell Carcinoma 2023;10:81-90. [PMID: 36685112 DOI: 10.2147/JHC.S398434] [Reference Citation Analysis]
48 Shen C, Jiang X, Li M, Luo Y. Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances. Cancers (Basel) 2023;15. [PMID: 36672482 DOI: 10.3390/cancers15020533] [Reference Citation Analysis]
49 Tovo CV, de Mattos AZ, Coral GP, Sartori GDP, Nogueira LV, Both GT, Villela-Nogueira CA, de Mattos AA. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World J Gastroenterol 2023; 29(2): 343-356 [DOI: 10.3748/wjg.v29.i2.343] [Reference Citation Analysis]
50 Cernea S, Onișor D. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World J Gastroenterol 2023; 29(2): 286-309 [DOI: 10.3748/wjg.v29.i2.286] [Reference Citation Analysis]
51 Lin CL, Liang KH, Hu CC, Chien CH, Chen LW, Chien RN, Lin YH, Yeh CT. A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36675198 DOI: 10.3390/ijms24021681] [Reference Citation Analysis]
52 Ji D, Tan L, Yang Y. Reply to "Biejia-Ruangan compound and incidence of hepatocellular carcinoma". J Hepatol 2023:S0168-8278(23)00008-9. [PMID: 36646213 DOI: 10.1016/j.jhep.2023.01.003] [Reference Citation Analysis]
53 Leal C, Strogoff-de-Matos J, Theodoro C, Teixeira R, Perez R, Guaraná T, de Tarso Pinto P, Guimarães T, Artimos S. Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals. Viruses 2023;15. [PMID: 36680260 DOI: 10.3390/v15010221] [Reference Citation Analysis]
54 Wei J, Jiang H, Zhou Y, Tian J, Furtado FS, Catalano OA. Radiomics: A radiological evidence-based artificial intelligence technique to facilitate personalized precision medicine in hepatocellular carcinoma. Dig Liver Dis 2023:S1590-8658(22)00863-5. [PMID: 36641292 DOI: 10.1016/j.dld.2022.12.015] [Reference Citation Analysis]
55 Yang C, Wu X, Liu J, Wang H, Jiang Y, Wei Z, Cai Q. Nomogram Based on Platelet-Albumin-Bilirubin for Predicting Tumor Recurrence After Surgery in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 2023;10:43-55. [PMID: 36660412 DOI: 10.2147/JHC.S396433] [Reference Citation Analysis]
56 Abasseri M, Hoque S, Slavica Kochovska BA, Caldwell K, Sheahan L, Zekry A. Barriers to palliative care in hepatocellular carcinoma: A review of the literature. J Gastroenterol Hepatol 2023. [PMID: 36634200 DOI: 10.1111/jgh.16107] [Reference Citation Analysis]
57 Yu CY, Huang PH, Tsang LL, Hsu HW, Lim WX, Weng CC, Huang TL, Hsu CC, Chen CL, Ou HY, Cheng YF. Yttrium-90 Radioembolization as the Major Treatment of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2023;10:17-26. [PMID: 36660410 DOI: 10.2147/JHC.S385478] [Reference Citation Analysis]
58 Lanari J, Caregari S, Billato I, Gringeri E, D'Amico F, Gemo G, Bassi D, D'Amico FE, Boetto R, Bertacco A, Marchini A, Lazzari S, Brolese M, Ballo M, Vitale A, Cillo U. Textbook Outcome of Laparoscopic Microwave Ablation for Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36672385 DOI: 10.3390/cancers15020436] [Reference Citation Analysis]
59 Shi Q, Zhou X, Zhang Z, Zhang W, Ma J, Yang M, Yu J, Luo J, Liu L, Yan Z. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance. Front Immunol 2022;13:1097625. [PMID: 36703965 DOI: 10.3389/fimmu.2022.1097625] [Reference Citation Analysis]
60 Yim HJ, Jung YK, Ahn SH, Kim W, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Sohn JH, Lee JW, Park SJ, Yim SY, Park JK, Um SH. Reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B receiving long-term besifovir therapy.. [DOI: 10.21203/rs.3.rs-2442726/v1] [Reference Citation Analysis]
61 Sirichindakul P, Sanguanlosit S, Taesombat W, Sutherasan M, Vorasittha A, Nonthasoot B. Cirrhotic and non-cirrhotic huge hepatocellular carcinoma (≥ 10 cm): a comparative study of surgical management and follow-up treatment in a single institution. Langenbecks Arch Surg 2023;408:18. [PMID: 36627380 DOI: 10.1007/s00423-023-02762-2] [Reference Citation Analysis]
62 Li Y, Zeng X. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma. Front Pharmacol 2022;13:1081952. [PMID: 36703728 DOI: 10.3389/fphar.2022.1081952] [Reference Citation Analysis]
63 Hsieh PM, Hsiao P, Chen YS, Yeh JH, Hung CM, Lin HY, Ma CH, Tang T, Huang YW, Cheng PN, Hsieh KC, Hu KC, Bair MJ, Lin CW. Clinical prognosis of surgical resection versus transarterial chemoembolization for single large hepatocellular carcinoma (≥5 cm): A propensity score matching analysis. Kaohsiung J Med Sci 2023. [PMID: 36625289 DOI: 10.1002/kjm2.12640] [Reference Citation Analysis]
64 Ciancio A, Ribaldone DG, Spertino M, Risso A, Ferrarotti D, Caviglia GP, Carucci P, Gaia S, Rolle E, Sacco M, Saracco GM. Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study. Biomedicines 2023;11. [PMID: 36672675 DOI: 10.3390/biomedicines11010166] [Reference Citation Analysis]
65 Long L, Chen B, Wang H, Zhao Y, Wu F, Wang L, Rong W, Wu J, Li Y, Wang W. Survival benefit of radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma: A propensity score-matched analysis based on phase II study. Radiother Oncol 2023;180:109462. [PMID: 36634853 DOI: 10.1016/j.radonc.2022.109462] [Reference Citation Analysis]
66 Endo Y, Lima HA, Alaimo L, Moazzam Z, Brown Z, Shaikh CF, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Shen F, Endo I, Pawlik TM. Preoperative risk score (PreopScore) to predict overall survival after resection for hepatocellular carcinoma. HPB (Oxford) 2023:S1365-182X(22)01685-9. [PMID: 36670007 DOI: 10.1016/j.hpb.2022.12.009] [Reference Citation Analysis]
67 Wang M, Yang X, Meng Y, Jin Z, Cao J, Xiong L, Xiong Z. Comprehensive analysis of the tumor-promoting effect and immune infiltration correlation MAZ from pan-cancer to hepatocellular carcinoma. Int Immunopharmacol 2023;115:109660. [PMID: 36623412 DOI: 10.1016/j.intimp.2022.109660] [Reference Citation Analysis]
68 Yen YH, Li WF, Kee KM, Wang CC, Cheng YF, Lu SN, Hung CH, Liu YW, Hu TH. Seven centimeters as an optimal cutoff value for prognosis stratification in large monofocal hepatocellular carcinoma. Langenbecks Arch Surg 2023;408:12. [PMID: 36609929 DOI: 10.1007/s00423-023-02753-3] [Reference Citation Analysis]
69 Kraglund F, Villadsen GE, Jepsen P. Effects of Curative-Intent Treatments on Hepatocellular Carcinoma Survival in Alcohol-Related Cirrhosis: A Nationwide Study. Clin Epidemiol 2023;15:39-48. [PMID: 36636732 DOI: 10.2147/CLEP.S393118] [Reference Citation Analysis]
70 Brackenier C, Kinget L, Cappuyns S, Verslype C, Beuselinck B, Dekervel J. Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36672297 DOI: 10.3390/cancers15020348] [Reference Citation Analysis]
71 Kato N, Kudo M, Tsuchiya K, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Okano N, Ikeda M, Morimoto M, Kuroda S, Kimura A. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study. Hepatol Res 2023. [PMID: 36601972 DOI: 10.1111/hepr.13876] [Reference Citation Analysis]
72 Wu T, Fan R, Bai J, Yang Z, Qian YS, Du LT, Wang CY, Wang YC, Jiang GQ, Zheng D, Fan XT, Zheng B, Liu JF, Deng GH, Shen F, Hu HP, Ye YN, Zhang QZ, Zhang J, Gao YH, Xia J, Yan HD, Liang MF, Yu YL, Sun FM, Gao YJ, Sun J, Zhong CX, Wang Y, Wang H, Kong F, Chen JM, Wen H, Wu BM, Wang CX, Wu L, Hou JL, Liu XL, Wang HY, Chen L. The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis. J Hematol Oncol 2023;16:1. [PMID: 36600307 DOI: 10.1186/s13045-022-01396-z] [Reference Citation Analysis]
73 Hou G, Liu B, Fan ZQ, Li C, Zhang JP, Guo YH, Zhang RY, Zheng Y, Zhu H, Wang NY. Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China. Front Oncol 2022;12:1094104. [PMID: 36686731 DOI: 10.3389/fonc.2022.1094104] [Reference Citation Analysis]
74 Tao S, Liang S, Zeng T, Yin D. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. Front Immunol 2022;13:1043667. [PMID: 36685594 DOI: 10.3389/fimmu.2022.1043667] [Reference Citation Analysis]
75 Berardi G, Ratti F, Sposito C, Nebbia M, D'Souza DM, Pascual F, Dogeas E, Tohme S, D'Amico FE, Alessandris R, Simonelli I, Del Basso C, Russolillo N, Moro A, Fiorentini G, Serenari M, Rotellar F, Zimmitti G, Famularo S, Ivanics T, Hoffman D, Onkendi E, Essaji Y, Lopez Ben S, Caula C, Rompianesi G, Chopra A, Abu Hilal M, Torzilli G, Sapisochin G, Corvera C, Alseidi A, Helton S, Troisi RI, Simo K, Conrad C, Cescon M, Cleary S, Kwon CHD, Ferrero A, Ettorre GM, Cillo U, Geller D, Cherqui D, Serrano PE, Ferrone C, Mazzaferro V, Aldrighetti L, Kingham TP. Model to predict major complications following liver resection for HCC in patients with metabolic syndrome. Hepatology 2023. [PMID: 36646670 DOI: 10.1097/HEP.0000000000000027] [Reference Citation Analysis]
76 Chen S, Huang C, Liao G, Sun H, Xie Y, Liao C, Wang J, He M, Hu H, Dai Z, Ren X, Zeng X, Lin Z, Zhang GP, Xie W, Shen S, Li S, Peng S, Kuang DM, Zhao Q, Duda DG, Kuang M. Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences. Gut 2023:gutjnl-2022-328428. [PMID: 36596711 DOI: 10.1136/gutjnl-2022-328428] [Reference Citation Analysis]
77 Visco Comandini U. Surveillance for Patients at Risk of Developing Hepatocellular Carcinoma. Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_22] [Reference Citation Analysis]
78 Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, Huang F, Tang R, Cheng Y, Huang Z, Liang Y, Fan H, Qiao L, Li F, Zhuang W, Peng B, Wang J, Li J, Kuang M. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). J Clin Oncol 2023;41:117-27. [PMID: 35921605 DOI: 10.1200/JCO.22.00392] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
79 Park SH, Heo S, Kim B, Lee J, Choi HJ, Sung PS, Choi J. Targetoid Primary Liver Malignancy in Chronic Liver Disease: Prediction of Postoperative Survival Using Preoperative MRI Findings and Clinical Factors. Korean J Radiol 2023;24. [DOI: 10.3348/kjr.2022.0560] [Reference Citation Analysis]
80 李 钊. Current Status of Ablation Therapy for Primary Liver Cancer. ACM 2023;13:134-139. [DOI: 10.12677/acm.2023.131021] [Reference Citation Analysis]
81 Mohamed AA, Esmail OE, Ibrahim AMA, Makled S, Al-Hussain E, Elsaid A, Alboraie M, El-Awady RR. The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients. J Med Virol 2023;95:e28343. [PMID: 36424348 DOI: 10.1002/jmv.28343] [Reference Citation Analysis]
82 Chi H, Chen D, Zhang Y, Cui Z, Bai Y, Zhang Y. Single-cell transcriptome analysis reveals a cancer-associated fibroblast marker gene signature in hepatocellular carcinoma that predicts prognosis. iLIVER 2023. [DOI: 10.1016/j.iliver.2022.12.002] [Reference Citation Analysis]
83 Roth GS, Neuzillet C, Sarabi M, Edeline J, Malka D, Lièvre A. Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ? Eur J Cancer 2023;179:1-14. [PMID: 36463640 DOI: 10.1016/j.ejca.2022.11.006] [Reference Citation Analysis]
84 Jean K, Tawheed A, Luong Nguyen LB, Heikal T, Eldaly U, Elhadidy N, Elghaieb A, Aboudonia A, Tondeur L, Dublineau A, Fontanet A, El-kassas M. Changes in Presentation, Treatment, and Survival of Patients with Hepatocellular Carcinoma in Damietta, Egypt, 2007–2019: A Retrospective Monocentric Cohort Study. JHC 2023;Volume 10:99-111. [DOI: 10.2147/jhc.s391511] [Reference Citation Analysis]
85 Avritscher R. Interventional Imaging in the Oncologic Patient. Oncologic Imaging : a Multidisciplinary Approach 2023. [DOI: 10.1016/b978-0-323-69538-1.00039-2] [Reference Citation Analysis]
86 Cillo U, Lanari J, Masutti M, D’amico FE, Vitale A, Gringeri E. Percutaneous and Laparoscopic-Assisted Ablation of Hepatocellular Carcinoma. Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_8] [Reference Citation Analysis]
87 Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Vogel A, Tovoli F, Ueshima K, Aikata H, López CL, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Tamai T, Saito K, Dutcus CE, Lencioni R. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. J Hepatol 2023;78:133-41. [PMID: 36341767 DOI: 10.1016/j.jhep.2022.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Hernaez R, Peck-Radosavljevic M. MAFLD, HCC and the dilemma of (changing) terminology in liver diseases. Gut 2023;72:9-11. [PMID: 35169004 DOI: 10.1136/gutjnl-2022-326992] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Pugliese N, Alfarone L, Arcari I, Giugliano S, Parigi TL, Rescigno M, Lleo A, Aghemo A. Clinical features and management issues of NAFLD-related HCC: what we know so far. Expert Rev Gastroenterol Hepatol 2023;17:31-43. [PMID: 36576057 DOI: 10.1080/17474124.2023.2162503] [Reference Citation Analysis]
90 Jo MG, Lee MW, Ahn S, Kang TW, Song KD, Cha DI, Min JH, Rhim H. Percutaneous radiofrequency ablation of hepatocellular carcinoma in a recent cohort at a tertiary cancer center: incidence and factors associated with major complications and unexpected hospitalization events. Ultrasonography 2023;42:41-53. [PMID: 36353791 DOI: 10.14366/usg.22041] [Reference Citation Analysis]
91 Wang L, Chen Y, Chen R, Mao F, Sun Z, Liu X. Risk modelling of single cell transcriptomes reveals the heterogeneity of immune infiltration in hepatocellular carcinoma. Journal of Biological Chemistry 2023. [DOI: 10.1016/j.jbc.2023.102948] [Reference Citation Analysis]
92 Joo I, Lee JM, Koh YH, Choi SH, Lee S, Chung JW. 2022 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for Imaging Diagnosis of Hepatocellular Carcinoma: What's New? Korean J Radiol 2023;24:1-5. [PMID: 36606612 DOI: 10.3348/kjr.2022.0538] [Reference Citation Analysis]
93 Wang F, Chen Q, Chen Y, Zhu Y, Zhang Y, Cao D, Zhou W, Liang X, Yang Y, Lin L, Hu H. A novel multimodal deep learning model for preoperative prediction of microvascular invasion and outcome in hepatocellular carcinoma. Eur J Surg Oncol 2023;49:156-64. [PMID: 36333180 DOI: 10.1016/j.ejso.2022.08.036] [Reference Citation Analysis]
94 Tefera J, Savic LJ, Gebauer B. Prinzipien der nicht-chirurgischen lokoregionären Therapie. Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-46764-0_179-1] [Reference Citation Analysis]
95 Sala L, Golse N, Joosten A, Vibert E, Vignon-Clementel I. Sensitivity Analysis of a Mathematical Model Simulating the Post-Hepatectomy Hemodynamics Response. Ann Biomed Eng 2023;51:270-89. [PMID: 36326994 DOI: 10.1007/s10439-022-03098-6] [Reference Citation Analysis]
96 Nakatsuka T, Tateishi R. Development and prognosis of hepatocellular carcinoma in patients with diabetes. Clin Mol Hepatol 2023;29:51-64. [PMID: 35903020 DOI: 10.3350/cmh.2022.0095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Lee HN, Hyun D. Complications Related to Transarterial Treatment of Hepatocellular Carcinoma: A Comprehensive Review. Korean J Radiol 2023;24. [DOI: 10.3348/kjr.2022.0395] [Reference Citation Analysis]
98 Grazi GL, Scarinci A. Liver Biopsy: How and When. Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_24] [Reference Citation Analysis]
99 Eschrich J, Kobus Z, Geisel D, Halskov S, Roßner F, Roderburg C, Mohr R, Tacke F. The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma-State of the Art and Future Perspectives. Cancers (Basel) 2023;15. [PMID: 36612297 DOI: 10.3390/cancers15010301] [Reference Citation Analysis]
100 Sohn W, Paik YH. Correspondence on Editorial regarding "Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease". Clin Mol Hepatol 2023;29:182-4. [PMID: 36417888 DOI: 10.3350/cmh.2022.0411] [Reference Citation Analysis]
101 Zerunian M, Di Stefano F, Bracci B, Caruso D, Laghi A. Imaging of Hepatocellular Carcinoma. Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_5] [Reference Citation Analysis]
102 Berardi G, Guglielmo N, Mariano G, Ettorre GM. Surgical Margins for Hepatocellular Carcinoma. Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_14] [Reference Citation Analysis]
103 Meng XQ, Miao H, Xia Y, Shen H, Qian Y, YanChen, Shen F, Guo J. A nomogram for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma based on spleen-volume-to-platelet ratio. Asian J Surg 2023;46:399-404. [PMID: 35599113 DOI: 10.1016/j.asjsur.2022.05.001] [Reference Citation Analysis]
104 Dieterich D, Graham C, Wang S, Kwo P, Lim Y, Liu C, Agarwal K, Sulkowski M. It Is Time for a Simplified Approach to Hepatitis B Elimination. Gastro Hep Advances 2023;2:209-218. [DOI: 10.1016/j.gastha.2022.10.004] [Reference Citation Analysis]
105 Hu L, Zheng Y, Lin J, Shi X, Wang A. Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2023;47:102061. [PMID: 36473632 DOI: 10.1016/j.clinre.2022.102061] [Reference Citation Analysis]
106 Berardi G, Meniconi RL, Mariano G, Ettorre GM. Major Hepatectomies for Hepatocellular Carcinoma. Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_15] [Reference Citation Analysis]
107 Giannelli V, Demma S, Pellicelli A, Ettorre GM. Hepatological Evaluation and Biomarkers. Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_7] [Reference Citation Analysis]
108 Coleman A, Smith EN, J. Galgano S, Porter KK. Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma. Oncologic Imaging : a Multidisciplinary Approach 2023. [DOI: 10.1016/b978-0-323-69538-1.00010-0] [Reference Citation Analysis]
109 Li S, Yin S, Ding H, Shao Y, Zhou S, Pu W, Han L, Wang T, Yu H. Polyphenols as potential metabolism mechanisms regulators in liver protection and liver cancer prevention. Cell Prolif 2023;56:e13346. [PMID: 36229407 DOI: 10.1111/cpr.13346] [Reference Citation Analysis]
110 Ho SY, Yuan MH, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Wang CL, Hou MC, Huo TI. Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Scand J Gastroenterol 2023;58:61-9. [PMID: 35830511 DOI: 10.1080/00365521.2022.2098052] [Reference Citation Analysis]
111 Kaneko S, Kurosaki M, Mashiba T, Marusawa H, Kondo M, Kojima Y, Uchida Y, Fujii H, Akahane T, Yagisawa H, Kusakabe A, Kobashi H, Abe T, Yoshida H, Ogawa C, Furuta K, Tamaki N, Tsuji K, Matsushita T, Izumi N; Japanese Red Cross Liver Study Group. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B. J Med Virol 2023;95:e28210. [PMID: 36222204 DOI: 10.1002/jmv.28210] [Reference Citation Analysis]
112 Yoshuantari N, Jeng Y, Liau J, Lee C, Tsai J. Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts. Modern Pathology 2023;36:100042. [DOI: 10.1016/j.modpat.2022.100042] [Reference Citation Analysis]
113 Pellat A, Barat M, Coriat R, Soyer P, Dohan A. Artificial intelligence: A review of current applications in hepatocellular carcinoma imaging. Diagn Interv Imaging 2023;104:24-36. [PMID: 36272931 DOI: 10.1016/j.diii.2022.10.001] [Reference Citation Analysis]
114 Yuan W, Zhao H, Zhou A, Wang S. Interference of EFNA4 suppresses cell proliferation, invasion and angiogenesis in hepatocellular carcinoma by downregulating PYGO2. Cancer Biology & Therapy 2022;23:1-12. [DOI: 10.1080/15384047.2022.2149039] [Reference Citation Analysis]
115 Zhang T, Hu H, Jia Y, Gao Y, Hao F, Wu J, Yang Z, Ren J, Li Z, Liu A, Wu H. Efficacy and safety of radiofrequency ablation and surgery for hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Medicine (Baltimore) 2022;101:e32470. [PMID: 36595979 DOI: 10.1097/MD.0000000000032470] [Reference Citation Analysis]
116 Toubert C, Guiu B, Al Taweel B, Assenat E, Panaro F, Souche FR, Ursic-Bedoya J, Navarro F, Herrero A. Prolonged Survival after Recurrence in HCC Resected Patients Using Repeated Curative Therapies: Never Give Up! Cancers (Basel) 2022;15. [PMID: 36612227 DOI: 10.3390/cancers15010232] [Reference Citation Analysis]
117 Minici R, Siciliano MA, Ammendola M, Santoro RC, Barbieri V, Ranieri G, Laganà D. Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology. Cancers (Basel) 2022;15. [PMID: 36612251 DOI: 10.3390/cancers15010257] [Reference Citation Analysis]
118 Sun B, Zhang L, Xiang D, Li Q, Ren Y, Cao Y, Sun T, Zhang W, Wu L, Zhu L, Chen L, Zhao H, Zheng C. The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization. J Oncol 2022;2022:7062105. [PMID: 36618073 DOI: 10.1155/2022/7062105] [Reference Citation Analysis]
119 Tian S, Li J, Xiang J, Peng P. The Clinical Relevance and Immune Correlation of SLC10 Family Genes in Liver Cancer. J Hepatocell Carcinoma 2022;9:1415-31. [PMID: 36606115 DOI: 10.2147/JHC.S392586] [Reference Citation Analysis]
120 Innes H. Genetic data not yet a "game-changer" for predicting individualised hepatocellular carcinoma risk. J Hepatol 2022:S0168-8278(22)03467-5. [PMID: 36592645 DOI: 10.1016/j.jhep.2022.12.015] [Reference Citation Analysis]
121 Yang X, Yuan C, Zhang Y, Li K, Wang Z. Predicting hepatocellular carcinoma early recurrence after ablation based on magnetic resonance imaging radiomics nomogram. Medicine (Baltimore) 2022;101:e32584. [PMID: 36596081 DOI: 10.1097/MD.0000000000032584] [Reference Citation Analysis]
122 Zaid Al-Kaylani AHA, Schuurmann RCL, Maathuis WD, Slart RHJA, De Vries JPM, Bokkers RPH. Clinical Applications of Quantitative Perfusion Imaging with a C-Arm Flat-Panel Detector-A Systematic Review. Diagnostics (Basel) 2022;13. [PMID: 36611421 DOI: 10.3390/diagnostics13010128] [Reference Citation Analysis]
123 Lei J, Yan T, Zhang L, Chen B, Cheng J, Gao X, Liu Z, Li Y, Zuo S, Lu Y. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors. Hepatol Int 2022. [PMID: 36580258 DOI: 10.1007/s12072-022-10450-4] [Reference Citation Analysis]
124 Tian S, Chen Y, Zhang Y, Xu X. Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma. J Clin Lab Anal 2023;37:e24823. [PMID: 36579611 DOI: 10.1002/jcla.24823] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Guo Z, Liang J. Characterization of a lipid droplet and endoplasmic reticulum stress related gene risk signature to evaluate the clinical and biological value in hepatocellular carcinoma. Lipids Health Dis 2022;21:146. [PMID: 36581927 DOI: 10.1186/s12944-022-01759-y] [Reference Citation Analysis]
126 Fischer J, Long S, Koukoulioti E, Müller T, Fueloep B, Heyne R, Eslam M, George J, Finkelmeier F, Waidmann O, Berg T, van Bömmel F. Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B. Pathogens 2022;12. [PMID: 36678401 DOI: 10.3390/pathogens12010054] [Reference Citation Analysis]
127 Tong Y, Li JX, Chang DH, Wang LZ, Cai WW, Bao Y, Cai R, Xiao YD. An Integrated Liver Function, Systemic Inflammation, and Tumor Characteristic Score Predicts Prognosis in Hepatocellular Carcinoma After Curative Resection. Ann Surg Oncol 2022. [PMID: 36581722 DOI: 10.1245/s10434-022-12899-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Li MF, Liang HL, Chiang CL, Tsai WL, Chen WC, Tsai CC, Chen IS. New Regimen of Combining Hepatic Arterial Infusion Chemotherapy and Lipiodol Embolization in Treating Hepatocellular Carcinoma with Main Portal Vein Invasion. J Pers Med 2022;13. [PMID: 36675749 DOI: 10.3390/jpm13010088] [Reference Citation Analysis]
129 Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M, Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang Y, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Mohamed YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Kudo M, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. Liver Int 2022. [PMID: 36577703 DOI: 10.1111/liv.15502] [Reference Citation Analysis]
130 Mouhoubi N, Bamba-Funck J, Sutton A, Blaise L, Seror O, Ganne-Carrié N, Ziol M, N'Kontchou G, Charnaux N, Nahon P, Nault JC, Guyot E. Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:1369-83. [PMID: 36597436 DOI: 10.2147/JHC.S382226] [Reference Citation Analysis]
131 Yue Q, Zhou Z, Zhang X, Xu X, Liu Y, Wang K, Liu Q, Wang J, Zhao Y, Yin Y. Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma. BMC Gastroenterol 2022;22:544. [PMID: 36577952 DOI: 10.1186/s12876-022-02586-2] [Reference Citation Analysis]
132 Bae JS, Lee JM, Kim SW, Park S, Han S, Yoon JH, Joo I, Hong H. Low-contrast-dose liver CT using low monoenergetic images with deep learning-based denoising for assessing hepatocellular carcinoma: a randomized controlled noninferiority trial. Eur Radiol 2022. [PMID: 36576547 DOI: 10.1007/s00330-022-09298-x] [Reference Citation Analysis]
133 Yan H, Xiang Z, Zhao C, Zou S, Huang M. Long-term Outcomes of Patients with Hepatocellular Carcinoma Who Underwent Microwave Ablation after Downstaging with Transarterial Chemoembolization to Barcelona Clinic Liver Cancer Stage A. J Vasc Interv Radiol 2022:S1051-0443(22)01893-0. [PMID: 36581194 DOI: 10.1016/j.jvir.2022.12.466] [Reference Citation Analysis]
134 Zhang W, Zhang Y, Wan Y, Liu Q, Zhu X. A bile acid-related prognostic signature in hepatocellular carcinoma. Sci Rep 2022;12:22355. [PMID: 36572736 DOI: 10.1038/s41598-022-26795-7] [Reference Citation Analysis]
135 Guo Y, Ren Y, Wu F, Dong X, Zheng C. Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor. Therap Adv Gastroenterol 2022;15:17562848221142417. [PMID: 36600683 DOI: 10.1177/17562848221142417] [Reference Citation Analysis]
136 Roth GS, Villeret F, Decaens T, Merle P, Nahon P. Immunotherapy in hepatocellular carcinoma: How does underlying liver disease influence therapeutic strategy and outcomes? Liver Int 2022. [PMID: 36571256 DOI: 10.1111/liv.15504] [Reference Citation Analysis]
137 Luo PQ, Ye ZH, Zhang LX, Song ED, Wei ZJ, Xu AM, Lu Z. Prognostic factors for disease-free survival in postoperative patients with hepatocellular carcinoma and construction of a nomogram model. World J Clin Cases 2022; 10(36): 13250-13263 [DOI: 10.12998/wjcc.v10.i36.13250] [Reference Citation Analysis]
138 Wang WQ, Lv X, Li J, Li J, Wang JL, Yuan T, Liu JJ, Zhu RH, Huang ZY, Zhang EL. Repeat hepatectomy versus microwave ablation for solitary and small (≤3 cm) recurrent hepatocellular carcinoma with early or late recurrence: A propensity score matched study. Eur J Surg Oncol 2022:S0748-7983(22)01362-2. [PMID: 36585301 DOI: 10.1016/j.ejso.2022.12.016] [Reference Citation Analysis]
139 Zhou L, Zhang M, Chen S. Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis. Ann Hepatol 2022;28:100890. [PMID: 36574929 DOI: 10.1016/j.aohep.2022.100890] [Reference Citation Analysis]
140 Han Y, Zhao W, Wu M, Qian Y. Efficacy and safety of single- and multiple-antenna microwave ablation for the treatment of hepatocellular carcinoma and liver metastases: A systematic review and network meta-analysis. Medicine (Baltimore) 2022;101:e32304. [PMID: 36595779 DOI: 10.1097/MD.0000000000032304] [Reference Citation Analysis]
141 Liu J, Zhang J, Wang Y, Shu G, Lou C, Du Z. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e32390. [PMID: 36595819 DOI: 10.1097/MD.0000000000032390] [Reference Citation Analysis]
142 Cheng S, Zhao H, Meng Y, Guo Y, Yao M, Xu X, Zhai X, Ling C. Impact of treatment-duration-ratio of traditional Chinese medicine on survival period of primary liver cancer -A real-world study. Heliyon 2022;8:e12358. [PMID: 36619473 DOI: 10.1016/j.heliyon.2022.e12358] [Reference Citation Analysis]
143 Tabari A, Chan SM, Omar OMF, Iqbal SI, Gee MS, Daye D. Role of Machine Learning in Precision Oncology: Applications in Gastrointestinal Cancers. Cancers (Basel) 2022;15. [PMID: 36612061 DOI: 10.3390/cancers15010063] [Reference Citation Analysis]
144 Zang C, Zhao Y, Liu G, Li K, Qin L, Zhang Y, Sun J, Wang Q, Ma L, Zhao P, Sun Y, Guo D, Yuan C, Dong T, Zhang Y. Variations in dynamic tumor-associated antigen-specific T cell responses correlate with HCC recurrence after thermal ablation. Front Immunol 2022;13:982578. [PMID: 36618423 DOI: 10.3389/fimmu.2022.982578] [Reference Citation Analysis]
145 Luo L, He Y, Zhu G, Xiao Y, Song S, Ge X, Wang T, Xie J, Deng W, Hu Z, Shan R. Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference? J Hepatocell Carcinoma 2022;9:1353-68. [PMID: 36578526 DOI: 10.2147/JHC.S388965] [Reference Citation Analysis]
146 Bilal Masokano I, Pei Y, Chen J, Liu W, Xie S, Liu H, Feng D, He Q, Li W. Development and validation of MRI-based model for the preoperative prediction of macrotrabecular hepatocellular carcinoma subtype. Insights Imaging 2022;13:201. [PMID: 36544029 DOI: 10.1186/s13244-022-01333-1] [Reference Citation Analysis]
147 Cui Q, Wang X, Zhang Y, Shen Y, Qian Y. Macrophage-derived MMP-9/MMP-2 are closely related to the rupture of the fibrous capsule of hepatocellular carcinoma leading to tumor invasion.. [DOI: 10.21203/rs.3.rs-2379884/v1] [Reference Citation Analysis]
148 Grisetti L, Võ NVT, Nguyễn NNQ, Crocè LS, Visintin A, Tiribelli C, Pascut D. MiR-3201 as a Prognostic Blood Biomarker for Curative Treatments in Hepatocellular Carcinoma. Technol Cancer Res Treat 2022;21:15330338221132924. [PMID: 36537076 DOI: 10.1177/15330338221132924] [Reference Citation Analysis]
149 Zhang H, Guo Y, Jiao J, Qiu Y, Miao Y, He Y, Li Z, Xia C, Li L, Cai J, Xu K, Liu X, Zhang C, Bay B, Song S, Yang Y, Peng M, Wang Y, Fan H. A hepatocyte-targeting nanoparticle for enhanced hepatobiliary magnetic resonance imaging. Nat Biomed Eng 2022. [DOI: 10.1038/s41551-022-00975-2] [Reference Citation Analysis]
150 Xian M, Li W, Lan W, Zeng D, Xie W, Lu M, Huang Y, Wang W. Strategy for Accurate Diagnosis by Contrast‐Enhanced Ultrasound of Focal Liver Lesions in Patients Not at High Risk for Hepatocellular Carcinoma. J of Ultrasound Medicine 2022. [DOI: 10.1002/jum.16151] [Reference Citation Analysis]
151 Li Q, Han J, Yang Y, Chen Y. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol 2022;13:1070961. [PMID: 36601120 DOI: 10.3389/fimmu.2022.1070961] [Reference Citation Analysis]
152 Filippo R, Conticchio M, Ratti F, Inchingolo R, Gelli M, Anelli FM, Laurent A, Vitali GC, Magistri P, Assirati G, Felli E, Wakabayashi T, Pessaux P, Piardi T, Di Benedetto F, de’Angelis N, Briceno DFJ, Rampoldi AG, Adam R, Cherqui D, Aldrighetti L, Memeo R. Liver resection versus radiofrequency ablation in octogenarian patients for hepatocellular carcinoma: a propensity score multicenter analysis. Surg Endosc 2022. [DOI: 10.1007/s00464-022-09826-2] [Reference Citation Analysis]
153 Huang Y, Zhang L, He M, Lai Z, Bu X, Wen D, Li Q, Xu L, Wei W, Zhang Y, Zhou Z, Chen M, Guo R, Shi M, Kan A. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. Technol Cancer Res Treat 2022;21:15330338221117389. [PMID: 36529949 DOI: 10.1177/15330338221117389] [Reference Citation Analysis]
154 Choi ES, Kim JS, Lee JK, Lee HA, Pak S. Prospective evaluation of low-dose multiphase hepatic computed tomography for detecting and characterizing hepatocellular carcinoma in patients with chronic liver disease. BMC Med Imaging 2022;22:219. [PMID: 36536325 DOI: 10.1186/s12880-022-00947-7] [Reference Citation Analysis]
155 Zhang L, Zhang X, Li Q, Makamure J, Liu Z, Zhao D, Li X, Shi H, Zheng C, Liu F, Liang B. Transarterial chemoembolization failure in patients with hepatocellular carcinoma: Incidence, manifestation and risk factors. Clin Res Hepatol Gastroenterol 2022;47:102071. [PMID: 36539181 DOI: 10.1016/j.clinre.2022.102071] [Reference Citation Analysis]
156 Huang Z, Shu Z, Zhu RH, Xin JY, Wu LL, Wang HZ, Chen J, Zhang ZW, Luo HC, Li KY. Deep learning-based radiomics based on contrast-enhanced ultrasound predicts early recurrence and survival outcome in hepatocellular carcinoma. World J Gastrointest Oncol 2022; 14(12): 2380-2392 [DOI: 10.4251/wjgo.v14.i12.2380] [Reference Citation Analysis]
157 Ye T, Shao SH, Ji K, Yao SL. Evaluation of short-term effects of drug-loaded microspheres and traditional transcatheter arterial chemoembolization in the treatment of advanced liver cancer. World J Gastrointest Oncol 2022; 14(12): 2367-2379 [DOI: 10.4251/wjgo.v14.i12.2367] [Reference Citation Analysis]
158 Dolgushin BI, Virschke ER, Buydenok YV, Pogrebnyakov IV, Peregudov NA, Frantsev DY. Results of Application of Saturable Microspheres of Domestic Production in Locoregional Endovascular Treatment of Inoperable Patients with Malignant Liver Tumors. jour 2022;5:96-106. [DOI: 10.37174/2587-7593-2022-5-4-96-106] [Reference Citation Analysis]
159 Oura K, Morishita A, Tani J, Masaki T. Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:1279-98. [PMID: 36545268 DOI: 10.2147/JHC.S392051] [Reference Citation Analysis]
160 Dong X, Wang Y, Hao J, Chen L, Sun T, Zhang W, Sun B, Zhu L, Guo Y, Zheng C. Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study. J Oncol 2022;2022:1090313. [PMID: 36568640 DOI: 10.1155/2022/1090313] [Reference Citation Analysis]
161 Long Y, Song X, Guan Y, Lan R, Huang Z, Li S, Zhang L. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022. [PMID: 36516040 DOI: 10.1111/jgh.16088] [Reference Citation Analysis]
162 Volponi C, Gazzillo A, Bonavita E. The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network. Cancers (Basel) 2022;14. [PMID: 36551635 DOI: 10.3390/cancers14246151] [Reference Citation Analysis]
163 Sijberden JP, Cipriani F, Lanari J, Russolillo N, Benedetti Cacciaguerra A, Osei-bordom D, Conci S, Görgec B, Primrose JN, Edwin B, López-ben S, D’hondt M, Rotellar F, Besselink MG, Dagher I, Giuliante F, Fuks D, Rozzini R, Ruzzenente A, Sutcliffe RP, Vivarelli M, Ferrero A, Cillo U, Aldrighetti LA, Abu Hilal M. Minimally invasive ver­sus open liver resection for hepatocellular carcinoma in the elderly: international multicentre propensity score-matched study. British Journal of Surgery 2022. [DOI: 10.1093/bjs/znac423] [Reference Citation Analysis]
164 Zhang H, Ren Y, Li H, Zheng C, Qian K. Renal and hepatic artery embolization with Pickering gel emulsion of lipiodol in rabbit. BMC Cancer 2022;22:1300. [PMID: 36510170 DOI: 10.1186/s12885-022-10337-5] [Reference Citation Analysis]
165 Sun L, Gu M, Cai J, Yang W, Pan B, Wang B, Zhang C, Guo W. Combining γ-GT, PIVKA-II, and AFP to predict long-term prognosis in patients with hepatocellular carcinoma after hepatectomy. Clin Exp Pharmacol Physiol 2022. [PMID: 36507841 DOI: 10.1111/1440-1681.13745] [Reference Citation Analysis]
166 Cochrane Hepato-Biliary Group, Jingxin Yan, Manjun Deng, Ting Li, Yaxuan Wang, Jiaxin Wu, LuShun Zhang, Haining Fan. Transarterial chemoembolisation plus I125 seeds implantation for people with unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2022;2022:CD015389. [ DOI: 10.1002/14651858.CD015389] [Reference Citation Analysis]
167 Ferral H, Schepis F, Gaba RC, Garcia-Tsao G, Zanetto A, Perez-Campuzano V, Haskal ZJ, Garcia-Pagan JC. Endovascular Assessment of Liver Hemodynamics in Patients with Cirrhosis Complicated by Portal Hypertension. J Vasc Interv Radiol 2022:S1051-0443(22)01411-7. [PMID: 36516940 DOI: 10.1016/j.jvir.2022.12.014] [Reference Citation Analysis]
168 Zhang F, Hu K, Liu W, Quan B, Li M, Lu S, Chen R, Ren Z, Yin X. Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment. Cell Mol Gastroenterol Hepatol 2022;15:573-91. [PMID: 36513250 DOI: 10.1016/j.jcmgh.2022.12.002] [Reference Citation Analysis]
169 Kim H, Kim SS, Shin HC, Choi S, Lee JE, Lee WH, Park CH, Lee HN, Kim SY, Park H, Heo NH. Gadoxetate disodium-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: late portal venous phase may improve identification of enhancing capsule. Abdom Radiol 2022. [DOI: 10.1007/s00261-022-03756-2] [Reference Citation Analysis]
170 Stoehr F, Kloeckner R, Pinto Dos Santos D, Schnier M, Müller L, Mähringer-Kunz A, Dratsch T, Schotten S, Weinmann A, Galle PR, Mittler J, Düber C, Hahn F. Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC-A Proof-of-Concept Study. Cancers (Basel) 2022;14. [PMID: 36551521 DOI: 10.3390/cancers14246036] [Reference Citation Analysis]
171 Cunha MF, Pellino G. Environmental effects of surgical procedures and strategies for sustainable surgery. Nat Rev Gastroenterol Hepatol 2022;:1-12. [PMID: 36481812 DOI: 10.1038/s41575-022-00716-5] [Reference Citation Analysis]
172 Zhou Y, Wang S, Wu W, Ling J, Li H, Jia Q, Zheng J, Zheng X, Yu R, Wu Q, Shi Y, Lieftink C, Beijersbergen RL, Yuan S, Bernards R, Jin H, Qin W. Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer. EBioMedicine 2023;87:104397. [PMID: 36502574 DOI: 10.1016/j.ebiom.2022.104397] [Reference Citation Analysis]
173 Li G, Xu S, Yang S, Wu C, Zhang L, Wang H. An immune infiltration-related long non-coding RNAs signature predicts prognosis for hepatocellular carcinoma. Front Genet 2022;13:1029576. [PMID: 36568382 DOI: 10.3389/fgene.2022.1029576] [Reference Citation Analysis]
174 Della Corte A, Rimini M, Steidler S, Palumbo D, Ratti F, Aldrighetti L, Cascinu S, Casadei-gardini A, De Cobelli F. Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments. Cardiovasc Intervent Radiol 2022. [DOI: 10.1007/s00270-022-03327-4] [Reference Citation Analysis]
175 Piñero F, Costentin C, Degroote H, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas A, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Dibenedetto F, Duque SH, Salame E, Cillo U, Marciano S, Vanlemmens C, Fagiuoli S, Carrilho F, Cherqui D, Burra P, Van Vlierberghe H, Lai Q, Silva M, Rubinstein F, Duvoux C; collaborative group for HCC and liver transplantation, France, Latin America, Italy, Belgium. AFP score and metroticket 2.0 perform similarly and could be used in a "within-ALL" clinical decision tool. JHEP Rep 2023;5:100644. [PMID: 36691474 DOI: 10.1016/j.jhepr.2022.100644] [Reference Citation Analysis]
176 Shao X, Zhu J, Shi Y, Fang H, Chen J, Zhang Y, Wang J, Jian H, Lan S, Jiang F, Zhong F, Zhang Y, Cao C. Upregulated UBE4B expression correlates with poor prognosis and tumor immune infiltration in hepatocellular carcinoma. Aging (Albany NY) 2022;14:9632-46. [PMID: 36470669 DOI: 10.18632/aging.204414] [Reference Citation Analysis]
177 Santana JG, Shewarega A, Nam D, Kahl V, Madoff DC, Zhang X, Chapiro J. Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride-Induced Cirrhosis of the Liver. J Vasc Interv Radiol 2022:S1051-0443(22)01388-4. [PMID: 36473611 DOI: 10.1016/j.jvir.2022.11.026] [Reference Citation Analysis]
178 Nischalke HD, Schmalz F, Buch S, Fischer J, Möller C, Matz-Soja M, Krämer B, Langhans B, Klüners A, Soyka M, Stickel F, Nattermann J, Berg T, Strassburg CP, Lutz P. Genetic Variation of SAMM50 Is Not an Independent Risk Factor for Alcoholic Hepatocellular Carcinoma in Caucasian Patients. Int J Mol Sci 2022;23. [PMID: 36499681 DOI: 10.3390/ijms232315353] [Reference Citation Analysis]
179 Cassese G, Han HS, Cho JY, Lee HW, Lee B, Troisi RI. Selecting the Best Approach for the Treatment of Multiple Non-Metastatic Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36497478 DOI: 10.3390/cancers14235997] [Reference Citation Analysis]
180 Jiayu F, Jiang Y, Zhou X, Zhou M, Pan J, Ke Y, Zhen J, Huang D, Jiang W. Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma. Aging (Albany NY) 2022;14:9550-78. [PMID: 36462500 DOI: 10.18632/aging.204312] [Reference Citation Analysis]
181 Sinner F, Pinter M, Scheiner B, Ettrich TJ, Sturm N, Gonzalez-Carmona MA, Waidmann O, Finkelmeier F, Himmelsbach V, De Toni EN, Ben Khaled N, Mohr R, Fründt TW, Kütting F, Bömmel FV, Lieb S, Krug S, Bettinger D, Schultheiß M, Jochheim LS, Best J, Müller C, Keitel V, Venerito M. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience. Cancers (Basel) 2022;14. [PMID: 36497447 DOI: 10.3390/cancers14235966] [Reference Citation Analysis]
182 Koffas A, Mak LY, Kennedy PTF. Hepatitis delta virus: Disease assessment and stratification. J Viral Hepat 2022. [PMID: 36458851 DOI: 10.1111/jvh.13777] [Reference Citation Analysis]
183 Han S, Lee JM, Kim SW, Park S, Nickel MD, Yoon JH. Evaluation of HASTE T2 weighted image with reduced echo time for detecting focal liver lesions in patients at risk of developing hepatocellular carcinoma. European Journal of Radiology 2022;157:110588. [DOI: 10.1016/j.ejrad.2022.110588] [Reference Citation Analysis]
184 Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022;77:1598-606. [PMID: 36208844 DOI: 10.1016/j.jhep.2022.08.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
185 Tamai Y, Iwasa M, Eguchi A, Shigefuku R, Sugimoto R, Tanaka H, Kobayashi Y, Mizuno S, Nakagawa H. The prognostic role of controlling nutritional status and skeletal muscle mass in patients with hepatocellular carcinoma after curative treatment. Eur J Gastroenterol Hepatol 2022;34:1269-76. [PMID: 36317773 DOI: 10.1097/MEG.0000000000002459] [Reference Citation Analysis]
186 Fujita N, Kanogawa N, Makishima H, Ogasawara S, Maruta S, Iino Y, Shiko Y, Kanzaki H, Koroki K, Kobayashi K, Kiyono S, Nakamura M, Kondo T, Nakamoto S, Chiba T, Wakatsuki M, Itobayashi E, Obu M, Koma Y, Azemoto R, Kawasaki Y, Kato J, Tsuji H, Kato N. Carbon-ion radiotherapy versus radiofrequency ablation as initial treatment for early-stage hepatocellular carcinoma. Hepatol Res 2022;52:1060-71. [PMID: 35951438 DOI: 10.1111/hepr.13827] [Reference Citation Analysis]
187 Ji D, Chen Y, Bi J, Shang Q, Liu H, Wang JB, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Wang X, Chen D, Li Z, Dong Z, Yang Y. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. J Hepatol 2022;77:1515-24. [PMID: 35985545 DOI: 10.1016/j.jhep.2022.07.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Rimini M, Kang W, Burgio V, Persano M, Aoki T, Shimose S, Tada T, Kumada T, Sho T, Lai E, Celsa C, Campani C, Tonnini M, Tamburini E, Hiraoka A, Takaguchi K, Nishida N, Iwamoto H, Itobayashi E, Tsuji K, Sakamoto N, Ishikawa T, Toyoda H, Kudo M, Kawaguchi T, Hatanaka T, Nouso K, Suda G, Cabibbo G, Marra F, Della Corte A, Ratti F, Pedica F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A. Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib. Hepatol Res 2022;52:1050-9. [PMID: 35960789 DOI: 10.1111/hepr.13824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
189 Chang JI, Sinn DH, Jeong WK, Hwang JA, Won HY, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development. Scand J Gastroenterol 2022;57:1470-7. [PMID: 35786290 DOI: 10.1080/00365521.2022.2093124] [Reference Citation Analysis]
190 Sroor FM, Basyouni WM, Aly HF, Younis EA, Mahrous KF, Haroun AA. Biochemical and histopathological studies of sulfonylurea derivative as a new chemotherapeutic agent against liver cancer in free- and nano-coated forms. Appl Biol Chem 2022;65:68. [DOI: 10.1186/s13765-022-00737-3] [Reference Citation Analysis]
191 Ishtiaq SM, Arshad MI, Khan JA. PPARγ signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications. Pharmacol Ther 2022;240:108298. [PMID: 36243148 DOI: 10.1016/j.pharmthera.2022.108298] [Reference Citation Analysis]
192 Nicolosi A, Gaia S, Risso A, Rosso C, Rolle E, Abate ML, Olivero A, Armandi A, Ribaldone DG, Carucci P, Fagoonee S, Pellicano R, Saracco GM, Bugianesi E, Caviglia GP. Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma. Minerva Gastroenterol (Torino) 2022;68:378-86. [PMID: 36222678 DOI: 10.23736/S2724-5985.21.03006-0] [Reference Citation Analysis]
193 Wang H, Mao Y, Zhang C, Hu X, Chen B, Mu L, Wang S, Lin Y, Xiang Z, Huang M. Prediction of effective percutaneous transhepatic biliary drainage in patients with hepatocellular carcinoma: A multi-central retrospective study. Liver Research 2022. [DOI: 10.1016/j.livres.2022.11.008] [Reference Citation Analysis]
194 Doukas P, Hellfritsch G, Krabbe H, Frankort J, Jacobs MJ, Gombert A, Simon F. Onset of Adverse Abdominal Events Due to Intestinal Ischemia-Reperfusion Injury after Aortic Cross-Clamping Is Associated with Elevated HSP70 Serum Levels in the Early Postoperative Phase. Int J Mol Sci 2022;23. [PMID: 36499389 DOI: 10.3390/ijms232315063] [Reference Citation Analysis]
195 Singal AG, Reig M, Villanueva A. Emerging Tools for Hepatocellular Carcinoma Surveillance. Am J Gastroenterol 2022;117:1948-51. [PMID: 36114768 DOI: 10.14309/ajg.0000000000002015] [Reference Citation Analysis]
196 Degasperi E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Scholtes C, Facchetti F, Loglio A, Monico S, Fraquelli M, Costantino A, Ceriotti F, Zoulim F, Lampertico P. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. J Hepatol 2022;77:1525-31. [PMID: 35973578 DOI: 10.1016/j.jhep.2022.07.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
197 Singal AG, Reddy S, Radadiya Aka Patel H, Villarreal D, Khan A, Liu Y, Cerda V, Rich NE, Murphy CC, Tiro JA, Kramer JR, Hernaez R. Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance. Clin Gastroenterol Hepatol 2022;20:2818-2825.e1. [PMID: 34902568 DOI: 10.1016/j.cgh.2021.12.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
198 Hong S, Choi WS, Purushothaman B, Koh J, Kim HC, Chung JW, Song JM, Choi JW. Drug delivery in transarterial chemoembolization of hepatocellular carcinoma: Ex vivo evaluation using transparent tissue imaging. Acta Biomater 2022;154:523-35. [PMID: 36374750 DOI: 10.1016/j.actbio.2022.10.044] [Reference Citation Analysis]
199 Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology 2022;76:1880-97. [PMID: 35239194 DOI: 10.1002/hep.32439] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
200 Jaffe A, Taddei TH, Giannini EG, Ilagan-Ying YC, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver Int 2022;42:2607-19. [PMID: 36161463 DOI: 10.1111/liv.15432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Lv JH, Chen WZ, Li YN, Wang JX, Fu YK, Zeng ZX, Wu JY, Wang SJ, Huang XX, Huang LM, Huang RF, Wei YG, Yan ML. Should associating liver partition and portal vein ligation for staged hepatectomy be applied to hepatitis B virus-related hepatocellular carcinoma patients with cirrhosis? A multi-center study. HPB (Oxford) 2022;24:2175-84. [PMID: 36280426 DOI: 10.1016/j.hpb.2022.10.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Fonseca LG, Uratani LF, Soares GF, Amaral PS, Alencar RSSM, Chagas AL, Alves VAF, Carrilho FJ. Early variation of inflammatory indexes refines prognostic prediction in patients with hepatocellular carcinoma under systemic treatment.. [DOI: 10.21203/rs.3.rs-2294812/v1] [Reference Citation Analysis]
203 Li JP, Zhao S, Jiang HJ, Jiang H, Zhang LH, Shi ZX, Fan TT, Wang S. Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation. Hepatobiliary Pancreat Dis Int 2022;21:569-76. [PMID: 35729000 DOI: 10.1016/j.hbpd.2022.06.003] [Reference Citation Analysis]
204 Rennert C, Thimme R. Metformin bei ausgeheilter Hepatitis-C-Virus-Infektion und Diabetes. Gastro-News 2022;9:21-23. [DOI: 10.1007/s15036-022-3149-z] [Reference Citation Analysis]
205 Heo S, Lee SS, Kim SY, Lim YS, Park HJ, Yoon JS, Suk HI, Sung YS, Park B, Lee JS. Prediction of Decompensation and Death in Advanced Chronic Liver Disease Using Deep Learning Analysis of Gadoxetic Acid-Enhanced MRI. Korean J Radiol 2022;23:1269-80. [PMID: 36447415 DOI: 10.3348/kjr.2022.0494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
206 Carty PG, Teljeur C, De Gascun CF, Gillespie P, Harrington P, McCormick A, O'Neill M, Smith SM, Ryan M. Another Step Toward Hepatitis C Elimination: An Economic Evaluation of an Irish National Birth Cohort Testing Program. Value Health 2022;25:1947-57. [PMID: 35778325 DOI: 10.1016/j.jval.2022.05.010] [Reference Citation Analysis]
207 Zhang D, Feng D, Ren M, Bai Y, Liu Z, Wang H. Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation. Ann Med 2022;54:2213-21. [PMID: 35930293 DOI: 10.1080/07853890.2022.2107233] [Reference Citation Analysis]
208 Tortajada P, Doamba R, Cano L, Ghallab M, Allard MA, Ciacio O, Pittau G, Salloum C, Cherqui D, Adam R, Sa Cunha A, Azoulay D, Pascale A, Vibert E, Golse N. Resectable and transplantable hepatocellular carcinoma: Integration of liver stiffness assessment in the decision-making algorithm. Surgery 2022;172:1704-11. [PMID: 36241470 DOI: 10.1016/j.surg.2022.08.012] [Reference Citation Analysis]
209 Lima HA, Endo Y, Alaimo L, Moazzam Z, Munir MM, Shaikh C, Resende V, Guglielmi A, Marques HP, Cauchy F, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Hugh T, Endo I, Kitago M, Shen F, Pawlik TM. Tumor Burden Score and Serum Alpha-fetoprotein Subclassify Intermediate-Stage Hepatocellular Carcinoma. J Gastrointest Surg 2022;26:2512-21. [PMID: 36171471 DOI: 10.1007/s11605-022-05469-9] [Reference Citation Analysis]
210 Zeng J, Wang Y, Wang H, Hou Y, He D. Comparison of 8spheres polyvinyl alcohol microsphere and gelatin sponge particle efficacy for transcatheter arterial chemoembolization in stages A to B patients with hepatocellular carcinoma. J Cancer Res Ther 2022;18:1981-7. [PMID: 36647959 DOI: 10.4103/jcrt.jcrt_736_22] [Reference Citation Analysis]
211 Schaefer N, Grözinger G, Pech M, Pfammatter T, Soydal C, Arnold D, Kolligs F, Maleux G, Munneke G, Peynircioglu B, Sangro B, Pereira H, Zeka B, de Jong N, Helmberger T; CIRT Principal Investigators. Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT. Clin Colorectal Cancer 2022;21:285-96. [PMID: 36270925 DOI: 10.1016/j.clcc.2022.09.002] [Reference Citation Analysis]
212 Kanneganti M, Marrero JA, Parikh ND, Kanwal F, Yokoo T, Mendiratta-Lala M, Rich NE, Gopal P, Singal AG. Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review. Liver Transpl 2022;28:1865-75. [PMID: 35980600 DOI: 10.1002/lt.26562] [Reference Citation Analysis]
213 Yang Y, Ren P, Liu X, Sun X, Zhang C, Du X, Xing B. PPP1R26 drives hepatocellular carcinoma progression by controlling glycolysis and epithelial-mesenchymal transition. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-022-02302-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
214 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 2022;23:1126-240. [PMID: 36447411 DOI: 10.3348/kjr.2022.0822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
215 Tong Y, Cai R, Li JX, Chang DH, Wang LZ, Cai WW, Xiao YD. Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability of treatment weighting analysis. Aliment Pharmacol Ther 2022;56:1602-14. [PMID: 36285593 DOI: 10.1111/apt.17263] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
216 Kan X, Zhou G, Zhang F, Ji H, Shin DS, Monsky W, Zheng C, Yang X. Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia. J Immunother Cancer 2022;10. [PMID: 36450380 DOI: 10.1136/jitc-2022-005619] [Reference Citation Analysis]
217 Chen J, Lai L, Luo J, Wang H, Li M, Huang M. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study. BMC Cancer 2022;22:1242. [PMID: 36451104 DOI: 10.1186/s12885-022-10361-5] [Reference Citation Analysis]
218 Dave S, Esteban J. Beyond Milan. Clinical Liver Disease 2022. [DOI: 10.1002/cld.1258] [Reference Citation Analysis]
219 Fronda M, Mistretta F, Calandri M, Ciferri F, Nardelli F, Bergamasco L, Fonio P, Doriguzzi Breatta A. The Role of Immediate Post-Procedural Cone-Beam Computed Tomography (CBCT) in Predicting the Early Radiologic Response of Hepatocellular Carcinoma (HCC) Nodules to Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE). J Clin Med 2022;11. [PMID: 36498664 DOI: 10.3390/jcm11237089] [Reference Citation Analysis]
220 Allignet B, Pradat P, Mornex F, Izarn F, Rode A, Mabrut J, Mohkam K, Merle P. Surgical resection versus transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma. Strahlenther Onkol 2022. [DOI: 10.1007/s00066-022-02022-0] [Reference Citation Analysis]
221 Schlosser S, Tümen D, Volz B, Neumeyer K, Egler N, Kunst C, Tews HC, Schmid S, Kandulski A, Müller M, Gülow K. HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1016952] [Reference Citation Analysis]
222 Hu XS, Yang HY, Leng C, Zhang ZW. Postoperative outcomes and recurrence patterns of intermediate-stage hepatocellular carcinoma dictated by the sum of tumor size and number. World J Gastroenterol 2022; 28(44): 6271-6281 [DOI: 10.3748/wjg.v28.i44.6271] [Reference Citation Analysis]
223 Ding JN, Feng TT, Sun W, Cai XY, Zhang Y, Zhao WF. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study. World J Gastrointest Surg 2022; 14(11): 1260-1271 [DOI: 10.4240/wjgs.v14.i11.1260] [Reference Citation Analysis]
224 Sun SS, Li WD, Chen JL. Transarterial chemoembolization combined with radiofrequency ablation in the treatment of large hepatocellular carcinoma with stage C. World J Clin Cases 2022; 10(33): 12156-12163 [DOI: 10.12998/wjcc.v10.i33.12156] [Reference Citation Analysis]
225 Wu YL, Fulgenzi CAM, D'Alessio A, Cheon J, Nishida N, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ, Ang C. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Cancers (Basel) 2022;14. [PMID: 36497316 DOI: 10.3390/cancers14235834] [Reference Citation Analysis]
226 Chua D, Low ZS, Cheam GX, Ng AS, Tan NS. Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm. Int J Mol Sci 2022;23. [PMID: 36499091 DOI: 10.3390/ijms232314762] [Reference Citation Analysis]
227 Kolligs F, Arnold D, Golfieri R, Pech M, Peynircioglu B, Pfammatter T, Ronot M, Sangro B, Schaefer N, Maleux G, Munneke G, Pereira H, Zeka B, de Jong N, Helmberger T; CIRT Principal Investigators. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study. JHEP Rep 2023;5:100633. [PMID: 36593888 DOI: 10.1016/j.jhepr.2022.100633] [Reference Citation Analysis]
228 Gorbatykh AV, Latkin OE, Prokhorikhin AA, Zubarev DD, Chernyavsky MA. Modern view on the treatment of oncological diseases by endovascular methods. Transl med (Print) 2022;9:33-40. [DOI: 10.18705/2311-4495-2022-9-4-33-40] [Reference Citation Analysis]
229 Rocha BA, Ferreira LC, Vianna LGR, Ferreira LGG, Ciconelle ACM, Da Silva Noronha A, Cortez Filho JM, Nogueira LSL, Leite JMRS, da Silva Filho MRM, da Costa Leite C, de Maria Felix M, Gutierrez MA, Nomura CH, Cerri GG, Carrilho FJ, Ono SK. Contrast phase recognition in liver computer tomography using deep learning. Sci Rep 2022;12:20315. [PMID: 36434070 DOI: 10.1038/s41598-022-24485-y] [Reference Citation Analysis]
230 Di Benedetto F, Magistri P, Di Sandro S, Sposito C, Oberkofler C, Brandon E, Samstein B, Guidetti C, Papageorgiou A, Frassoni S, Bagnardi V, Clavien PA, Citterio D, Kato T, Petrowsky H, Halazun KJ, Mazzaferro V; Robotic HPB Study Group. Safety and Efficacy of Robotic vs Open Liver Resection for Hepatocellular Carcinoma. JAMA Surg 2023;158:46-54. [PMID: 36416833 DOI: 10.1001/jamasurg.2022.5697] [Reference Citation Analysis]
231 Chen S, Zeng X, Su T, Xiao H, Lin M, Peng Z, Peng S, Kuang M. Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective. Front Immunol 2022;13:1033000. [PMID: 36505437 DOI: 10.3389/fimmu.2022.1033000] [Reference Citation Analysis]
232 Zhang L, Duan S, Qi Q, Li Q, Ren S, Liu S, Mao B, Zhang Y, Wang S, Yang L, Liu R, Liu L, Li Y, Li N, Zhang L. Noninvasive Prediction of Ki‐67 Expression in Hepatocellular Carcinoma Using Machine Learning‐Based Ultrasomics. J of Ultrasound Medicine 2022. [DOI: 10.1002/jum.16126] [Reference Citation Analysis]
233 Kumar S, Nadda N, Paul S, Gamanagatti S, Dash NR, Vanamail P, Saraya A, Shalimar, Nayak B. Evaluation of the cell-free DNA integrity index as a liquid biopsy marker to differentiate hepatocellular carcinoma from chronic liver disease. Front Mol Biosci 2022;9. [DOI: 10.3389/fmolb.2022.1024193] [Reference Citation Analysis]
234 Nahon P, Bamba-Funck J, Layese R, Trépo E, Zucman-Rossi J, Cagnot C, Ganne-Carrié N, Chaffaut C, Guyot E, Ziol M, Sutton A, Audureau E; ANRS CO12 CirVir and CIRRAL groups. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis. J Hepatol 2022:S0168-8278(22)03294-9. [PMID: 36427656 DOI: 10.1016/j.jhep.2022.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
235 Wang S, Zheng W, Zhang Z, Zhang GH, Huang DJ. Microvascular invasion risk scores affect the estimation of early recurrence after resection in patients with hepatocellular carcinoma: a retrospective study. BMC Med Imaging 2022;22:204. [PMID: 36419016 DOI: 10.1186/s12880-022-00940-0] [Reference Citation Analysis]
236 Möller K, Safai Zadeh E, Görg C, Dong Y, Cui X, Faiss S, Dietrich CF. Prevalence of benign focal liver lesions and non-hepatocellular carcinoma malignant lesions in liver cirrhosis. Z Gastroenterol 2022. [DOI: 10.1055/a-1890-5818] [Reference Citation Analysis]
237 Yang Z, Sun X, Tang Y, Xiong P, Xu L. Comparison of stereotactic body radiation therapy with hepatic resection and radiofrequency ablation as initial treatment in patients with early-stage hepatocellular carcinoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.948866] [Reference Citation Analysis]
238 Köpping-segerling CC, Pohl M, Canbay A, Best J. Hepatozelluläres Karzinom – Screening und Surveillance. Gastroenterologie 2022. [DOI: 10.1007/s11377-022-00651-6] [Reference Citation Analysis]
239 Morise Z. Current status of minimally invasive liver surgery for cancers. World J Gastroenterol 2022; 28(43): 6090-6098 [DOI: 10.3748/wjg.v28.i43.6090] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Filippi L, Bagni O, Notarianni E, Saltarelli A, Ambrogi C, Schillaci O. PET/CT with (18)F-choline or (18)F-FDG in Hepatocellular Carcinoma Submitted to (90)Y-TARE: A Real-World Study. Biomedicines 2022;10. [PMID: 36428565 DOI: 10.3390/biomedicines10112996] [Reference Citation Analysis]
241 Liu Y, Pan J, Gao F, Xu W, Li H, Qi X. Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Adv Ther 2022. [DOI: 10.1007/s12325-022-02371-3] [Reference Citation Analysis]
242 Bongolo CC, Thokerunga E, Fidele NB, Souraka TDM, Kisembo P, Rugera SP, Worley PF, Tu J. Upregulation of the long non-coding RNA, LIPCAR promotes proliferation, migration, and metastasis of hepatocellular carcinoma. CBM 2022;35:245-256. [DOI: 10.3233/cbm-220033] [Reference Citation Analysis]
243 Liu Y, Yan P, Bin Y, Qin X, Wu Z. Neutrophil extracellular traps and complications of liver transplantation. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1054753] [Reference Citation Analysis]
244 Park S, Mossmann D, Chen Q, Wang X, Dazert E, Colombi M, Schmidt A, Ryback B, Ng CKY, Terracciano LM, Heim MH, Hall MN. Transcription factors TEAD2 and E2A globally repress acetyl-CoA synthesis to promote tumorigenesis. Mol Cell 2022;82:4246-4261.e11. [PMID: 36400009 DOI: 10.1016/j.molcel.2022.10.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Li Z, Tan C, Liu X, Feng Z, Li K. Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma under antiviral therapy. Infect Agents Cancer 2022;17:56. [DOI: 10.1186/s13027-022-00468-6] [Reference Citation Analysis]
246 Tang B, Zhang X, Yang X, Wang W, Li R, Liu Y. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1013248] [Reference Citation Analysis]
247 Choi SJ, Choi SH, Kim DW, Kwag M, Byun JH, Won HJ, Shin YM. Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS. J Hepatol 2022:S0168-8278(22)03297-4. [PMID: 36402451 DOI: 10.1016/j.jhep.2022.11.006] [Reference Citation Analysis]
248 Li L, Mao S, Wang J, Zheng W, Shen J, Clevert D, Zhou J. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients. American Journal of Roentgenology 2022. [DOI: 10.2214/ajr.22.28420] [Reference Citation Analysis]
249 Qin Y, Wang S, Chen F, Liu H, Yue K, Wang X, Ning H, Dong P, Yu X, Wang G. Prediction of outcomes by diffusion kurtosis imaging in patients with large (≥5 cm) hepatocellular carcinoma after liver resection: A retrospective study. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.939358] [Reference Citation Analysis]
250 Zhang N, Lu C, Mo J, Wang X, Liao S, Liang N, Feng M, Tang T, Wu Y, Li Y, Lan C, Chen C, Shi Q, Wei L, Zheng Z, Lei Y, Zhang Z, Tang S, Li X. LCMT1 indicates poor prognosis and is essential for cell proliferation in hepatocellular carcinoma. Transl Oncol 2022;27:101572. [PMID: 36401967 DOI: 10.1016/j.tranon.2022.101572] [Reference Citation Analysis]
251 Farah M, Anugwom C, Ferrer JD, Baca EL, Mattos AZ, Possebon JPP, Arrese M, Prieto J, Balderramo D, Carrera E, Debes JD. Changing epidemiology of hepatocellular carcinoma in South America: A report from the South American liver research network. Ann Hepatol 2022;28:100876. [PMID: 36400386 DOI: 10.1016/j.aohep.2022.100876] [Reference Citation Analysis]
252 Geng Y, Shao W, Lin J. Spleen to non-cancerous liver volume ratio predicts liver cirrhosis in hepatocellular carcinoma patients. Abdom Radiol 2022. [DOI: 10.1007/s00261-022-03727-7] [Reference Citation Analysis]
253 Pang L, Yeung OWH, Ng KTP, Liu H, Zhu J, Liu J, Yang X, Ding T, Qiu W, Wang Y, Chiu TLS, Chen Z, Lo CM, Man K. Postoperative Plasmacytoid Dendritic Cells Secrete IFNα to Promote Recruitment of Myeloid-Derived Suppressor Cells and Drive Hepatocellular Carcinoma Recurrence. Cancer Res 2022;82:4206-18. [PMID: 36112065 DOI: 10.1158/0008-5472.CAN-22-1199] [Reference Citation Analysis]
254 Madani SP, Mirza‐aghazadeh‐attari M, Mohseni A, Pawlik T, Kamel IR. Diffuse infiltrative hepatocellular carcinoma: Multimodality imaging manifestations. Journal of Surgical Oncology 2022. [DOI: 10.1002/jso.27138] [Reference Citation Analysis]
255 Metwaly S, Psica A, Sogaolu O, Ahmed I, Mukhopadhya A, Delibegović M, Bekheit M. Volatile Organic Compounds for the Detection of Hepatocellular Carcinoma – a Systematic Review.. [DOI: 10.1101/2022.11.14.22282312] [Reference Citation Analysis]
256 Vincent JP, Ndow G, Ogawa S, Ceesay A, Njie R, Sanneh B, Baldeh I, D’alessandro U, Mendy M, Thursz M, Chemin I, Tanaka Y, Lemoine M, Shimakawa Y. Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa. J Glob Health 2022;12:04076. [DOI: 10.7189/jogh.12.04076] [Reference Citation Analysis]
257 Zhao Y, Huang F, Liu S, Jian L, Xia X, Lin H, Liu J. Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04467-3] [Reference Citation Analysis]
258 Hu S, Kang Y, Xie Y, Yang T, Yang Y, Jiao J, Zou Q, Zhang H, Zhang Y. 18F-FDG PET/CT-based radiomics nomogram for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma: a two-center study. Abdom Radiol 2022. [DOI: 10.1007/s00261-022-03722-y] [Reference Citation Analysis]
259 Mena E, Shih J, Chung J, Jones J, Rabiee A, Monge C, Turkbey B, Lindenberg L, Salerno KE, Kassin M, Wood B, Hernandez J, Maass-moreno R, Saboury B, Jakhete N, Molitoris JK, Unger KR, Choyke PL, Escorcia FE. Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma. PLoS ONE 2022;17:e0277407. [DOI: 10.1371/journal.pone.0277407] [Reference Citation Analysis]
260 Tornesello ML, Tornesello AL, Starita N, Cerasuolo A, Izzo F, Buonaguro L, Buonaguro FM. Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data. Expert Opinion on Therapeutic Targets 2022. [DOI: 10.1080/14728222.2022.2147062] [Reference Citation Analysis]
261 Trotovsek B, Hadzialjevic B, Cemazar M, Sersa G, Djokic M. Laparoscopic electrochemotherapy for the treatment of hepatocellular carcinoma: Technological advancement. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.996269] [Reference Citation Analysis]
262 Zhang Y, Huang H, Jin L, Lin S. Anticarcinogenic Effects of Isothiocyanates on Hepatocellular Carcinoma. Int J Mol Sci 2022;23. [PMID: 36430307 DOI: 10.3390/ijms232213834] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Ohama H, Hiraoka A, Tada F, Kato K, Fukunishi Y, Yanagihara E, Kato M, Saneto H, Izumoto H, Ueki H, Yoshino T, Kitahata S, Kawamura T, Kuroda T, Suga Y, Miyata H, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y. Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment. Cancers (Basel) 2022;14. [PMID: 36428616 DOI: 10.3390/cancers14225524] [Reference Citation Analysis]
264 Wu Y, Liu H, Chen Y, Zeng J, Huang Q, Zhang J, Zeng Y, Liu J. Prognostic significance of three‐tiered pathological classification for microvascular invasion in patients with combined hepatocellular‐cholangiocarcinoma following hepatic resection. Cancer Medicine 2022. [DOI: 10.1002/cam4.5328] [Reference Citation Analysis]
265 Hensen B, Winkelmann C, Wacker FK, Vogt B, Dewald CLA, Neumann T. Identification of Relevant Attributes for Liver Cancer Therapies (IRALCT): a maximum-difference-scaling analysis. Sci Rep 2022;12:19143. [PMID: 36351993 DOI: 10.1038/s41598-022-23097-w] [Reference Citation Analysis]
266 Shi F, Huang C, Ren Y, Deng C, Sun N, Shen X. Multiscale Element-Doped Nanowire Array-Coupled Machine Learning Reveals Metabolic Fingerprints of Nonreversible Liver Diseases. Anal Chem 2022. [DOI: 10.1021/acs.analchem.2c03743] [Reference Citation Analysis]
267 Wang T, Rao D, Yu C, Sheng J, Luo Y, Xia L, Huang W. RHO GTPase family in hepatocellular carcinoma. Exp Hematol Oncol 2022;11:91. [DOI: 10.1186/s40164-022-00344-4] [Reference Citation Analysis]
268 Wang Y, Gao P, Hao Z, Chen L, Li X, Jiao Y, Liu J, Li J, Zhang Y, Peng X, Ning B, Zhan X. The effect of neoadjuvant chemotherapy on the tumor immune microenvironment in gastrointestinal tumors. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1054598] [Reference Citation Analysis]
269 Lee JH, Shin SK, Kang SH, Kim TH, Yim HJ, Yim SY, Lee YS, Jung YK, Kim JH, Seo YS, Yeon JE, Kwon OS, Um SH, Byun KS. Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients. J Clin Med 2022;11. [PMID: 36431090 DOI: 10.3390/jcm11226613] [Reference Citation Analysis]
270 Xue J, Ge P, Wu Y. The prognosis and clinicopathological significance of histone deacetylase in hepatocellular carcinoma: a meta-analysis. Clin Exp Med 2022. [DOI: 10.1007/s10238-022-00934-w] [Reference Citation Analysis]
271 Prasoppokakorn T, Buntho A, Ingrungruanglert P, Tiyarattanachai T, Jaihan T, Kulkraisri K, Ariyaskul D, Phathong C, Israsena N, Rerknimitr R, Treeprasertsuk S, Chaiteerakij R. Circulating tumor cells as a prognostic biomarker in patients with hepatocellular carcinoma. Sci Rep 2022;12:18686. [PMID: 36333384 DOI: 10.1038/s41598-022-21888-9] [Reference Citation Analysis]
272 Gigante E, Haddad Y, Nault JC, Sutter O, Abou Ali E, Bonnet B, N'Kontchou G, Grando V, Ganne-Carrié N, Nahon P, Blaise L, Calderaro J, Barget N, Seror O, Ziol M. Imaging and histological features of tumor biopsy sample predict aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation. Sci Rep 2022;12:18712. [PMID: 36333426 DOI: 10.1038/s41598-022-23315-5] [Reference Citation Analysis]
273 Collettini F, Elkilany A, Seta MD, Steffen IG, Collettini JM, Penzkofer T, Schmelzle M, Denecke T. MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid. Sci Rep 2022;12:18583. [PMID: 36329107 DOI: 10.1038/s41598-022-23397-1] [Reference Citation Analysis]
274 Pinazo-bandera JM, García-cortés M, Segovia-zafra A, Lucena MI, Andrade RJ. Recreational Drugs and the Risk of Hepatocellular Carcinoma. Cancers 2022;14:5395. [DOI: 10.3390/cancers14215395] [Reference Citation Analysis]
275 Machairas N, Papaconstantinou D, Dorovinis P, Tsilimigras DI, Keramida MD, Kykalos S, Schizas D, Pawlik TM. Meta-Analysis of Repeat Hepatectomy versus Radiofrequency Ablation for Recurrence of Hepatocellular Carcinoma. Cancers 2022;14:5398. [DOI: 10.3390/cancers14215398] [Reference Citation Analysis]
276 Fortea JI, Crespo J, Puente Á. Cirrhosis, a Global and Challenging Disease. JCM 2022;11:6512. [DOI: 10.3390/jcm11216512] [Reference Citation Analysis]
277 Kang HJ, Lee JM, Yoon JH, Yoo J, Choi Y, Joo I, Han JK. Sonazoid™ versus SonoVue(®) for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study. Korean J Radiol 2022;23:1067-77. [PMID: 36196767 DOI: 10.3348/kjr.2022.0388] [Reference Citation Analysis]
278 Rasha F, Paul S, Simon TG, Hoshida Y. Hepatocellular Carcinoma Chemoprevention with Generic Agents. Semin Liver Dis 2022;42:501-13. [PMID: 36104114 DOI: 10.1055/a-1942-6693] [Reference Citation Analysis]
279 Driessens H, van Wijk L, Buis CI, Klaase JM. Low health literacy is associated with worse postoperative outcomes following hepato-pancreato-biliary cancer surgery. HPB (Oxford) 2022;24:1869-77. [PMID: 35927128 DOI: 10.1016/j.hpb.2022.07.006] [Reference Citation Analysis]
280 Vanderbecq Q, Grégory J, Dana J, Dioguardi Burgio M, Garzelli L, Raynaud L, Frémy S, Paulatto L, Bouattour M, Kavafyan-lasserre J, Vilgrain V, Ronot M. Improving pain control during transarterial chemoembolization for hepatocellular carcinoma performed under local anesthesia with multimodal analgesia. Diagnostic and Interventional Imaging 2022. [DOI: 10.1016/j.diii.2022.10.013] [Reference Citation Analysis]
281 Deforche M, Bucalau AM, Tancredi I, Tannouri F, Verset G. Duodenal Hemorrhage Due to an Invasive Hepatocellular Carcinoma Controlled by Transarterial Embolization. Cureus 2022;14:e32046. [PMID: 36600825 DOI: 10.7759/cureus.32046] [Reference Citation Analysis]
282 Xia F, Huang Z, Zhang Q, Ndhlovu E, Chen X, Zhang B, Zhu P. Clinically significant portal hypertension (CSPH) on early-stage HCC following hepatectomy: What's the impact? European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.11.005] [Reference Citation Analysis]
283 Huang J, Zhong B, Jiang N, Li W, Zhang S, Yin Y, Yang J, Shen J, Wang W, Zhu X. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma. JHC 2022;Volume 9:1217-1228. [DOI: 10.2147/jhc.s386672] [Reference Citation Analysis]
284 Song R, Ni H, Huang J, Yang C, Qin S, Wei H, Luo J, Huang Y, Xiang B. Prognostic Value of Inflammation-Immunity-Nutrition Score and Inflammatory Burden Index for Hepatocellular Carcinoma Patients After Hepatectomy. JIR 2022;Volume 15:6463-6479. [DOI: 10.2147/jir.s386407] [Reference Citation Analysis]
285 How GY, Pua U. Impact and the delivery of loco-regional treatment for hepatocellular carcinoma during the COVID-19 pandemic. Journal of Interventional Medicine 2022;5:180-183. [DOI: 10.1016/j.jimed.2022.09.004] [Reference Citation Analysis]
286 Chen S, Yuan B, Yu W, Wang X, He C, Chen C. Comparison of Arterial Infusion Chemotherapy and Chemoembolization for Locally Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study. J Gastrointest Surg 2022;26:2292-300. [PMID: 35920966 DOI: 10.1007/s11605-022-05421-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
287 Li W, Zhuang BW, Qiao B, Zhang N, Hu HT, Li C, Xie XH, Kuang M, Lu MD, Xie XY, Wang W. Circulating tumour cell counts and ultrasomics signature-based nomogram for preoperative prediction of early recurrence of hepatocellular carcinoma after radical treatment. Br J Radiol 2022;95:20211137. [PMID: 36165329 DOI: 10.1259/bjr.20211137] [Reference Citation Analysis]
288 Prince DS, Schlaphoff G, Davison SA, Huo YR, Xiang H, Chan MV, Lee AU, Thailakanathan C, Jebeili H, Rogan C, Al-Omary A, Gupta S, Lockart I, Tiwari N, Clark-Dickson M, Hillhouse JW, Laube R, Chang J, Nguyen V, Danta M, Cheng R, Strasser SI, Zekry A, Levy MT, Chan C, Liu K. Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study. J Gastroenterol Hepatol 2022;37:2173-81. [PMID: 36031345 DOI: 10.1111/jgh.15986] [Reference Citation Analysis]
289 Zhu HD, Li X, Ji JS, Huang M, Shao GL, Lu J, Zhao XY, Li HL, Yang ZQ, Tu JF, Zhou JM, Zeng CH, Teng GJ. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial. Eur Radiol 2022;32:7335-43. [PMID: 35776182 DOI: 10.1007/s00330-022-08848-7] [Reference Citation Analysis]
290 Dajti E, Ravaioli F, Marasco G, Alemanni LV, Colecchia L, Ferrarese A, Cusumano C, Gemini S, Vestito A, Renzulli M, Golfieri R, Festi D, Colecchia A. A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. Am J Gastroenterol 2022;117:1825-33. [PMID: 35973171 DOI: 10.14309/ajg.0000000000001887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
291 Nyman SS, Ahlström H, Creusen AD, Dahlgren D, Hedeland M, Heindryckx F, Johnson U, Khaled J, Kullenberg F, Nyman R, Rorsman F, Sheikhi R, Simonsson USH, Sjögren E, Wanders A, Lennernäs H, Ebeling Barbier C. Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival. BMJ Open 2022;12:e065839. [DOI: 10.1136/bmjopen-2022-065839] [Reference Citation Analysis]
292 Gofton C, Agar M, George J. Early Implementation of Palliative and Supportive Care in Hepatocellular Carcinoma. Semin Liver Dis 2022;42:514-30. [PMID: 36193677 DOI: 10.1055/a-1946-5592] [Reference Citation Analysis]
293 Lee TH, Hirshman N, Cardona DM, Berg CL, Fowler KJ, Bashir MR, Ronald J. LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR-TR Lesions. Dig Dis Sci 2022;67:5345-52. [PMID: 35257246 DOI: 10.1007/s10620-022-07428-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
294 Zhou Y, Sun S, Liu Q, Xu X, Zhang Y, Zhang Y. TED: Two-stage expert-guided interpretable diagnosis framework for microvascular invasion in hepatocellular carcinoma. Medical Image Analysis 2022;82:102575. [DOI: 10.1016/j.media.2022.102575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
295 Stefanini B, Bucci L, Santi V, Reggidori N, Rampoldi D, Lani L, Granito A, Sangiovanni A, Cabibbo G, Farinati F, Campani C, Foschi FG, Svegliati-Baroni G, Raimondo G, Gasbarrini A, Mega A, Biasini E, Sacco R, Morisco F, Caturelli E, Vidili G, Azzaroli F, Giannini EG, Rapaccini GL, Brunetto MR, Masotto A, Nardone G, Di Marco M, Magalotti D, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors. Dig Liver Dis 2022;54:1563-72. [PMID: 35906166 DOI: 10.1016/j.dld.2022.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
296 Köber C. Labordiagnostik in der Hausarztpraxis – mehr Effizienz durch Evidenz. Allgemeinmedizin up2date 2022;3:277-294. [DOI: 10.1055/a-1469-3904] [Reference Citation Analysis]
297 Rimola J, Sapena V, Brancatelli G, Darnell A, Forzenigo L, Mähringer-Kunz A, Paisant A, Renzulli M, Schima W, Terraz S, Valls C, Wagner M, Ayuso C, Vilgrain V, Reig M, Ronot M. Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. Hepatology 2022;76:1318-28. [PMID: 35349760 DOI: 10.1002/hep.32494] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
298 Zhang J, Zhao J, Wei S, Huang P, Tu X, Su G, Gan Y, Gong W, Xiang B. Developing and Validating an Autophagy Gene-Set-Based Prognostic Signature in Hepatocellular Carcinoma Patients. IJGM 2022;Volume 15:8399-8415. [DOI: 10.2147/ijgm.s388592] [Reference Citation Analysis]
299 Tse JR, Shen L, Bird KN, Yoon L, Kamaya A. Outcomes of LI-RADS US-2 Subthreshold Observations Detected on Surveillance Ultrasound. AJR Am J Roentgenol 2022;219:774-83. [PMID: 35703411 DOI: 10.2214/AJR.22.27812] [Reference Citation Analysis]
300 Zhou X, Li J, Zheng T, Chen H, Cai C, Ye S, Gao B, Xue T. Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy. Clin Exp Metastasis 2022. [DOI: 10.1007/s10585-022-10188-1] [Reference Citation Analysis]
301 Sun X, Feng W, Cui P, Ruan R, Ma W, Han Z, Sun J, Pan Y, Zhu J, Zhong X, Li J, Ma M, Hu R, Lv M, Huang Q, Zhang W, Feng M, Zhuang X, Huang B, Zhou X. Detection and monitoring of HBV-related hepatocellular carcinoma from plasma cfDNA fragmentation profiles. Genomics 2022;114:110502. [PMID: 36220554 DOI: 10.1016/j.ygeno.2022.110502] [Reference Citation Analysis]
302 Choi J. Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection". J Hepatol 2022;77:1472-4. [PMID: 35987276 DOI: 10.1016/j.jhep.2022.07.032] [Reference Citation Analysis]
303 Lai Z, Huang Y, Wen D, Lin X, Kan A, Li Q, Wei W, Chen M, Xu L, He M, Shi M. One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. BMC Med 2022;20:415. [PMID: 36310160 DOI: 10.1186/s12916-022-02608-6] [Reference Citation Analysis]
304 Franzè MS, Filomia R, Caccamo G, Pitrone C, Alibrandi A, Saitta C, Caspanello AR, Asero C, Arcadi V, Raimondo G, Cacciola I. Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance. J Pers Med 2022;12. [PMID: 36579534 DOI: 10.3390/jpm12111794] [Reference Citation Analysis]
305 Tong W, Cheng M, Lin M, Hu H, Pan J, Huang H, Wang Y, Xie X, Lu M, Kuang M, Huang Y, Wang W. Identification of the origin of tumor in vein: comparison between CEUS LI-RADS v2017 and v2016 for patients at high risk. BMC Med Imaging 2022;22:186. [DOI: 10.1186/s12880-022-00912-4] [Reference Citation Analysis]
306 Li H, Chen S, Lu L, Hu X, Lin S, Zhu L. Decision curve analysis to identify optimal candidates of liver resection for intermediate-stage hepatocellular carcinoma with hepatitis B cirrhosis: A cohort study. Medicine (Baltimore) 2022;101:e31325. [PMID: 36316942 DOI: 10.1097/MD.0000000000031325] [Reference Citation Analysis]
307 Cheng HY, Ho CM, Hsiao CY, Ho MC, Wu YM, Lee PH, Hu RH. Interval dynamics of transplantability for hepatocellular carcinoma after primary curative resection: risk factors for nontransplantable recurrence. HPB (Oxford) 2022:S1365-182X(22)01635-5. [PMID: 36376221 DOI: 10.1016/j.hpb.2022.10.010] [Reference Citation Analysis]
308 Mokhria RK, Singh J. Role of artificial intelligence in the diagnosis and treatment of hepatocellular carcinoma. Artif Intell Gastroenterol 2022; 3(4): 96-104 [DOI: 10.35712/aig.v3.i4.96] [Reference Citation Analysis]
309 Radu P, Ebadi M, Montano-loza AJ, Dufour JF. What Is the Role of Body Composition Assessment in HCC Management? Cancers 2022;14:5290. [DOI: 10.3390/cancers14215290] [Reference Citation Analysis]
310 Cassese G, Han HS, Lee B, Lee HW, Cho JY, Panaro F, Troisi RI. Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. World J Hepatol 2022; 14(10): 1862-1874 [DOI: 10.4254/wjh.v14.i10.1862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
311 Cao X, Shi H, Dou WQ, Zhao XY, Zheng YX, Ge YP, Cheng HC, Geng DY, Wang JY. Can DKI-MRI predict recurrence and invasion of peritumoral zone of hepatocellular carcinoma after transcatheter arterial chemoembolization? World J Gastrointest Surg 2022; 14(10): 1150-1160 [DOI: 10.4240/wjgs.v14.i10.1150] [Reference Citation Analysis]
312 Kimm MA, Kästle S, Stechele MMR, Öcal E, Richter L, Ümütlü MR, Schinner R, Öcal O, Salvermoser L, Alunni-fabbroni M, Seidensticker M, Goldberg SN, Ricke J, Wildgruber M. Early monocyte response following local ablation in hepatocellular carcinoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.959987] [Reference Citation Analysis]
313 Kuo H, Han M, Liao C, Lin Y, Wang C, Chen S, Chang T, Chen P, Lin S, Chen C, Chuang C, Wu I, Wu J, Hong T, Hsieh M, Lee Y, Wu H, Tsai H. Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. Pharmaceutics 2022;14:2263. [DOI: 10.3390/pharmaceutics14112263] [Reference Citation Analysis]
314 Hur J, Lee ES, Park HJ, Choi W, Park SB. Diagnostic performance of dual-energy computed tomography for HCC after transarterial chemoembolization: Utility of virtual unenhanced and low keV virtual monochromatic images. Medicine (Baltimore) 2022;101:e31171. [PMID: 36281184 DOI: 10.1097/MD.0000000000031171] [Reference Citation Analysis]
315 Sebagh M, Desterke C, Feray C, Hamelin J, Habib M, Samuel D, Rosmorduc O, Vibert E, Golse N. Indocyanine green fluorescence patterns of hepatocellular carcinoma correlate with pathological and molecular features. HPB (Oxford) 2022:S1365-182X(22)01631-8. [PMID: 36411232 DOI: 10.1016/j.hpb.2022.10.008] [Reference Citation Analysis]
316 Liu Y, Shi D, Ren Y, Li L, Zhao Y, Zheng C, Yang X. The immune-chemo-embolization effect of temperature sensitive gold nanomedicines against liver cancer. Nano Res . [DOI: 10.1007/s12274-022-4921-2] [Reference Citation Analysis]
317 Liao W, Jepsen P, Coupland C, Innes H, Matthews PC, Campbell C, Barnes E, Hippisley-Cox J; DeLIVER consortium. Development and validation of personalised risk prediction models for early detection and diagnosis of primary liver cancer among the English primary care population using the QResearch® database: research protocol and statistical analysis plan. Diagn Progn Res 2022;6:21. [PMID: 36261855 DOI: 10.1186/s41512-022-00133-x] [Reference Citation Analysis]
318 Hammad R, Aglan RB, Mohammed SA, Awad EA, Elsaid MA, Bedair HM, Khirala SK, Selim MA, Abo Elqasem AA, Rushdi A, Ali M, Abo-elkheir OI, Sanad EF, Hamdy NM. Cytotoxic T Cell Expression of Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) in Viral Hepatitis C-Mediated Hepatocellular Carcinoma. IJMS 2022;23:12541. [DOI: 10.3390/ijms232012541] [Reference Citation Analysis]
319 Thormann M, Surov A, Pech M, March C, Hass P, Damm R, Omari J. Local ablation of hepatocellular carcinoma by interstitial brachytherapy: prediction of outcome by diffusion-weighted imaging. Acta Radiol 2022;:2841851221129714. [PMID: 36262039 DOI: 10.1177/02841851221129714] [Reference Citation Analysis]
320 Di Martino M, Vitale A, Ferraro D, Maniscalco M, Pisaniello D, Arenga G, Falaschi F, Terrone A, Iacomino A, Galeota Lanza A, Esposito C, Cillo U, Vennarecci G. Downstaging Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis on Intention-to-Treat Outcomes. Cancers 2022;14:5102. [DOI: 10.3390/cancers14205102] [Reference Citation Analysis]
321 Ren Y, Liu Z, Makamure J, Kan X, Song S, Liu Y, Qian K, Zheng C, Liang B. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression. Technol Cancer Res Treat 2022;21:15330338221131385. [PMID: 36259117 DOI: 10.1177/15330338221131385] [Reference Citation Analysis]
322 Zhao H, Tsauo J, Zhang X, Ma H, Weng N, Yang Z, Li X. Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study. Chin Med J (Engl) 2022. [PMID: 36255217 DOI: 10.1097/CM9.0000000000002034] [Reference Citation Analysis]
323 Liu Y, Qiao Y, Zhou M, Guo J, Lin Y, Li W, An C, Li C. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. Cancer Med 2022. [PMID: 36254376 DOI: 10.1002/cam4.5366] [Reference Citation Analysis]
324 Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022;400:1345-62. [PMID: 36084663 DOI: 10.1016/S0140-6736(22)01200-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
325 Rusu I, Pirlog R, Chiroi P, Nutu A, Puia VR, Fetti AC, Rusu DR, Berindan-Neagoe I, Al Hajjar N. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC. Int J Mol Sci 2022;23:12370. [PMID: 36293225 DOI: 10.3390/ijms232012370] [Reference Citation Analysis]
326 Lee S, Yen C, Cheng Y, Shun Yang S, Lee T. The radiological prognostic factors of transcatheter arterial chemoembolization to hepatocellular carcinoma. Medicine 2022;101:e30875. [DOI: 10.1097/md.0000000000030875] [Reference Citation Analysis]
327 Liu JQ, Ren JY, Xu XL, Xiong LY, Peng YX, Pan XF, Dietrich CF, Cui XW. Ultrasound-based artificial intelligence in gastroenterology and hepatology. World J Gastroenterol 2022; 28(38): 5530-5546 [DOI: 10.3748/wjg.v28.i38.5530] [Reference Citation Analysis]
328 Li JX, Zhou P, Chang DH, Tong Y, Bao Y, Xiao YD, Zhou S, Cai WW. Ideal patients for liver resection in Barcelona Clinic Liver Cancer or Hong Kong Liver clinic systems for hepatocellular carcinoma: Conservative or aggressive? Front Med (Lausanne) 2022;9:977135. [PMID: 36314035 DOI: 10.3389/fmed.2022.977135] [Reference Citation Analysis]
329 Giangregorio F, Garolfi M, Mosconi E, Ricevuti L, Debellis MG, Mendozza M, Esposito C, Vigotti E, Cadei D, Abruzzese D. High frame-rate contrast enhanced ultrasound (HIFR-CEUS) in the characterization of small hepatic lesions in cirrhotic patients. J Ultrasound 2022. [PMID: 36227456 DOI: 10.1007/s40477-022-00724-w] [Reference Citation Analysis]
330 An C, Yao W, Zuo M, Li W, Chen Q, Wu P. Pesudo-capsulated Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transcatheter Arteial Chemoembolization.. [DOI: 10.21203/rs.3.rs-1911883/v1] [Reference Citation Analysis]
331 Wang X, Luo T, Lu S, Lu H, Jiang Z, Liu X, Zhao C, Li L, Chen J. Circular RNA hsa_circ_0005218 Promotes the Early Recurrence of Hepatocellular Carcinoma by Targeting the miR-31-5p/CDK1 Pathway.. [DOI: 10.21203/rs.3.rs-2138972/v1] [Reference Citation Analysis]
332 von Heesen M, Schuld J, Holländer S, Spiliotis AE, Merscher A, Scherber PR, Igna D, Gäbelein G, Glanemann M. Repeated hepatic resection for colorectal liver metastases: is this concept safe and feasible? Eur Surg 2022. [DOI: 10.1007/s10353-022-00783-7] [Reference Citation Analysis]
333 Chen D, Gao J, Ren L, Chen P, Yang Y, She S, Xie Y, Liao W, Chen H. A signature based on NKG2D ligands to predict the recurrence of hepatocellular carcinoma after radical resection. Cancer Medicine 2022. [DOI: 10.1002/cam4.5318] [Reference Citation Analysis]
334 Li W, Liu Y, Wang C, Yong C, Lin C, Yen Y. Radiographic tumor burden score is useful for stratifying the overall survival of hepatocellular carcinoma patients undergoing resection at different Barcelona Clinic Liver.. [DOI: 10.21203/rs.3.rs-2121956/v1] [Reference Citation Analysis]
335 Rodríguez-Perálvarez M. Transient Cytolysis after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. J Pers Med 2022;12:1663. [PMID: 36294802 DOI: 10.3390/jpm12101663] [Reference Citation Analysis]
336 Song L, Xu C, Zhang T, Chen S, Hu S, Cheng B, Tong H, Li X. Clinical neutrophil-associated genes as reliable predictors of hepatocellular carcinoma. Front Genet 2022;13:989779. [DOI: 10.3389/fgene.2022.989779] [Reference Citation Analysis]
337 Wang D, Liu J, Li T, Wang Y, Liu X, Bai Y, Wang C, Ju S, Huang S, Yang C, Zhou C, Zhang Y, Xiong B. A VEGFR targeting peptide-drug conjugate (PDC) suppresses tumor angiogenesis in a TACE model for hepatocellular carcinoma therapy. Cell Death Discov 2022;8:411. [PMID: 36202781 DOI: 10.1038/s41420-022-01198-9] [Reference Citation Analysis]
338 Shetty VV, Kellarai A. Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions. JCO Glob Oncol 2022;8:e2200118. [PMID: 36198133 DOI: 10.1200/GO.22.00118] [Reference Citation Analysis]
339 Minami Y, Aoki T, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M. Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response. Cancers 2022;14:4850. [DOI: 10.3390/cancers14194850] [Reference Citation Analysis]
340 Odedra D, Jandaghi AB, Bhayana R, Elbanna KY, Espin-Garcia O, Fischer SE, Ghanekar A, Sapisochin G, Jhaveri KS. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation. Cancer Imaging 2022;22:55. [PMID: 36195953 DOI: 10.1186/s40644-022-00497-9] [Reference Citation Analysis]
341 Lima HA, Endo Y, Moazzam Z, Alaimo L, Shaikh C, Munir MM, Resende V, Guglielmi A, Marques HP, Cauchy F, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Endo I, Kitago M, Shen F, Pawlik TM. TAC score better predicts survival than the BCLC following resection of hepatocellular carcinoma. J Surg Oncol 2022. [PMID: 36194039 DOI: 10.1002/jso.27116] [Reference Citation Analysis]
342 Zhan J, Tang Z, Leng H. Local Anesthesia vs. General Anesthesia for Percutaneous Microwave Ablation in Hepatocellular Carcinoma, an Efficacy, Safety, and Cost Analysis.. [DOI: 10.21203/rs.3.rs-1770369/v3] [Reference Citation Analysis]
343 Yan C, Niu Y, Ma L, Tian L, Ma J. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. J Transl Med 2022;20:452. [PMID: 36195876 DOI: 10.1186/s12967-022-03630-1] [Reference Citation Analysis]
344 Li D, Jia AY, Zorzi J, Griffith P, Kim AK, Dao D, Anders RA, Georgiades C, Liddell RP, Hong K, Azad NS, Ho WJ, Baretti M, Christenson E, Baghdadi A, Kamel IR, Meyer J, Ghabi E, Burkhart RA, Lafaro K, He J, Shubert C, Yarchoan M. Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer Clinic. Ann Surg Open 2022;3:e207. [PMID: 36590894 DOI: 10.1097/AS9.0000000000000207] [Reference Citation Analysis]
345 Beumer BR, van Vugt JLA, Sapisochin G, Yoon P, Bongini M, Lu D, Xu X, De Simone P, Pintore L, Golse N, Nowosad M, Bennet W, Tsochatzis E, Koutli E, Abbassi F, Claasen MPAW, Merli M, O'Rourke J, Gambato M, Benito A, Majumdar A, Tan EK, Ebadi M, Montano-Loza AJ, Berenguer M, Metselaar HJ, Polak WG, Mazzaferro V, IJzermans JNM; Collaborators. Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria. J Cachexia Sarcopenia Muscle 2022;13:2373-82. [PMID: 36622940 DOI: 10.1002/jcsm.13053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Xiang YJ, Sun JX, Wu JY, Wang K, Feng JK, Wei YG, Zhou JY, Zhang ZB, Zhang YQ, Qin YY, Yan ML, Cheng SQ. Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study. HPB (Oxford) 2022;24:1703-10. [PMID: 35523655 DOI: 10.1016/j.hpb.2022.04.007] [Reference Citation Analysis]
347 Yoo S, Kim JY, Lim YS, Han S, Choi J. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. J Hepatol 2022;77:939-46. [PMID: 35643206 DOI: 10.1016/j.jhep.2022.05.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
348 Chen Z, Qiu Z, Wang G, Wang G, Jiang W, Gao F. Safety and effectiveness of transjugular intrahepatic portosystemic shunt in hepatocellular carcinoma patients with portal hypertension: a systematic review and meta-analysis. Clinical Radiology 2022. [DOI: 10.1016/j.crad.2022.09.126] [Reference Citation Analysis]
349 Kim BH, Cho Y, Park JW. Surveillance for hepatocellular carcinoma: It is time to move forward. Clin Mol Hepatol 2022;28:810-3. [PMID: 36064304 DOI: 10.3350/cmh.2022.0257] [Reference Citation Analysis]
350 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583-705. [PMID: 36263666 DOI: 10.3350/cmh.2022.0294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
351 Kumada T, Toyoda H, Yasuda S, Ito T, Tsuji K, Fujioka S, Hiraoka A, Kariyama K, Nouso K, Ishikawa T, Tamai T, Tada T, Tanaka J. Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus. J Viral Hepat 2022;29:919-29. [PMID: 35790055 DOI: 10.1111/jvh.13728] [Reference Citation Analysis]
352 Cavalcante LN, Dezan MGF, Paz CLDSL, Lyra AC. RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Arq Gastroenterol 2022. [DOI: 10.1590/s0004-2803.202204000-93] [Reference Citation Analysis]
353 Leith A, Kiiskinen U, Girvan AC, Jen MH, Khela K, Rider A, Massey L, Piercy J. Physician- and patient-reported symptom concordance and association with quality of life in hepatocellular carcinoma. Future Oncol 2022;18:3727-40. [PMID: 36377818 DOI: 10.2217/fon-2022-0202] [Reference Citation Analysis]
354 Sohn W, Kang D, Kang M, Guallar E, Cho J, Paik YH. Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease. Clin Mol Hepatol 2022;28:851-63. [PMID: 36263667 DOI: 10.3350/cmh.2022.0037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
355 Kim SJ, Kim JM. Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review. Clin Mol Hepatol 2022;28:739-53. [PMID: 35468711 DOI: 10.3350/cmh.2022.0060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
356 Sun Y, Chen ZY, Gan X, Dai H, Cai D, Liu RH, Zhou JM, Zhang HL, Li ZH, Luo QQ, Jiang S, Wang T, Zhang KH. A novel four-gene signature for predicting the prognosis of hepatocellular carcinoma. Scand J Gastroenterol 2022;57:1227-37. [PMID: 35512233 DOI: 10.1080/00365521.2022.2069476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
357 Xiao X, Zhao J, Li S. Task relevance driven adversarial learning for simultaneous detection, size grading, and quantification of hepatocellular carcinoma via integrating multi-modality MRI. Medical Image Analysis 2022;81:102554. [DOI: 10.1016/j.media.2022.102554] [Reference Citation Analysis]
358 Johnson P, Zhou Q, Dao DY, Lo YMD. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022;19:670-81. [PMID: 35676420 DOI: 10.1038/s41575-022-00620-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
359 Wei H, Yang T, Chen J, Duan T, Jiang H, Song B. Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions. Liver Int 2022;42:2131-44. [PMID: 35808845 DOI: 10.1111/liv.15362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
360 Braga FA, Torres US, Iared W, D´ippolito G. Does hypointense HCC in the Hepatobiliary Phase at Gadoxetate-Enhanced MRI Predict Recurrence After Surgery? A Systematic Review and Meta-analysis. Academic Radiology 2022. [DOI: 10.1016/j.acra.2022.09.015] [Reference Citation Analysis]
361 Bhagat N, Verma N, Singh V. HCC prediction post SVR: Many tools yet limited generalizability! J Hepatol 2022;77:1226-8. [PMID: 35526784 DOI: 10.1016/j.jhep.2022.04.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
362 Ahn Y, Lee H, Han JE, Cho HJ, Cheong JY, Park B, Kim SS. Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment. J Liver Cancer 2022;22:125-135. [DOI: 10.17998/jlc.2022.05.24] [Reference Citation Analysis]
363 Xiong Y, Cao P, Lei X, Tang W, Ding C, Qi S, Chen G. Accurate prediction of microvascular invasion occurrence and effective prognostic estimation for patients with hepatocellular carcinoma after radical surgical treatment. World J Surg Oncol 2022;20:328. [PMID: 36180867 DOI: 10.1186/s12957-022-02792-y] [Reference Citation Analysis]
364 Wang Q, Li W, Zhang M, Zou Z, Dong X, Chen Y, Xu J, Zhu M, Li M, Lin B. α-Fetoprotein fragment synergizes with sorafenib to inhibit hepatoma cell growth and migration and promote the apoptosis. J Cell Mol Med 2022. [PMID: 36181321 DOI: 10.1111/jcmm.17565] [Reference Citation Analysis]
365 Chen SL, Ho CY, Lin WC, Lee CW, Chen YC, Chen JL, Chen HY. The Characteristics and Mortality of Chinese Herbal Medicine Users among Newly Diagnosed Inoperable Huge Hepatocellular Carcinoma (≥10 cm) Patients: A Retrospective Cohort Study with Exploration of Core Herbs. Int J Environ Res Public Health 2022;19. [PMID: 36231778 DOI: 10.3390/ijerph191912480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Penzkofer L, Mittler J, Heinrich S, Wachter N, Straub BK, Kloeckner R, Stoehr F, Gairing SJ, Bartsch F, Lang H. Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver-A Single Centre Study. J Clin Med 2022;11. [PMID: 36233670 DOI: 10.3390/jcm11195802] [Reference Citation Analysis]
367 Olbrich A, Gros O, Ebel S, Denecke T, Gößmann H, Linder N, Lordick F, Forstmeyer D, Seehofer D, Sucher R, Rademacher S, Niemeyer J, Matz-Soja M, Berg T, Bömmel FV. Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular Carcinomas. Cancers (Basel) 2022;14:4807. [PMID: 36230730 DOI: 10.3390/cancers14194807] [Reference Citation Analysis]
368 Kim D. Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma. J Liver Cancer 2022;22:93-102. [DOI: 10.17998/jlc.2022.03.28] [Reference Citation Analysis]
369 Li W, Shen H, Han L, Liu J, Xiao B, Li X, Ye Z, Kolla J. A Multiparametric Fusion Radiomics Signature Based on Contrast-Enhanced MRI for Predicting Early Recurrence of Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/3704987] [Reference Citation Analysis]
370 Xiaochun H, Feixiong P, Shengsong O, Xiaojiao W, Yuju X, Yanhua L, Schmalz G. Identification and Validation of an Inflammatory Response-Related Polygenic Risk Score as a Prognostic Marker in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-14. [DOI: 10.1155/2022/1739995] [Reference Citation Analysis]
371 De Souza S, de Long JK, Perone Y, Shetty S, Qurashi M, Jones R, Yip V, Ross P, Bettinger D, Reeves H, Geh D, Sharma R, Temperely L, Orr J, Banerjee A, Sturm L, Shah T, Allen B. Impact of COVID19 on clinical outcomes in hepatocellular carcinoma:A multicentre cohort study.. [DOI: 10.21203/rs.3.rs-2055736/v1] [Reference Citation Analysis]
372 Roth G, Teyssier Y, Benhamou M, Abousalihac M, Caruso S, Sengel C, Seror O, Ghelfi J, Seigneurin A, Ganne-Carrie N, Gigante E, Blaise L, Sutter O, Decaens T, Nault JC. Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization. World J Gastroenterol 2022; 28(36): 5324-5337 [DOI: 10.3748/wjg.v28.i36.5324] [Reference Citation Analysis]
373 Colosimo S, Tomlinson JW. Bile acids as drivers and biomarkers of hepatocellular carcinoma. World J Hepatol 2022; 14(9): 1730-1738 [DOI: 10.4254/wjh.v14.i9.1730] [Reference Citation Analysis]
374 Si T, Huang Z, Khorsandi SE, Ma Y, Heaton N. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis. Front Bioeng Biotechnol 2022;10:1010824. [DOI: 10.3389/fbioe.2022.1010824] [Reference Citation Analysis]
375 Maharaj AD, Lubel J, Lam E, Clark PJ, Duncan O, George J, Jeffrey GP, Lipton L, Liu H, McCaughan G, Neo EL, Philip J, Strasser SI, Stuart K, Thompson A, Tibballs J, Tu T, Wallace MC, Wigg A, Wood M, Zekry A, Greenhill E, Ioannou LJ, Ahlenstiel G, Bowers K, Clarke SJ, Dev A, Fink M, Goodwin M, Karapetis CS, Levy MT, Muller K, O'Beirne J, Pryor D, Seow J, Shackel N, Tallis C, Butler N, Olynyk JK, Reed-Cox K, Zalcberg JR, Roberts SK. Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus. Hepatol Commun 2022;6:3260-71. [PMID: 36153817 DOI: 10.1002/hep4.2089] [Reference Citation Analysis]
376 Müller L, Gairing SJ, Kloeckner R, Foerster F, Schleicher EM, Weinmann A, Mittler J, Stoehr F, Halfmann MC, Düber C, Galle PR, Hahn F. The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy. Cancer Imaging 2022;22. [DOI: 10.1186/s40644-022-00487-x] [Reference Citation Analysis]
377 Li Z, Gao H, Zhang X, Liu Q, Chen G. Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma: Prediction of stage I HCC prognosis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02496-3] [Reference Citation Analysis]
378 Wu Y, Zheng S, Zhang Z, Chen G, Chen X, Zheng T, Guo X, Chen H, Wang M, Xie X, Zhang B. Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization. Medicina 2022;58:1343. [DOI: 10.3390/medicina58101343] [Reference Citation Analysis]
379 Pallozzi M, Di Tommaso N, Maccauro V, Santopaolo F, Gasbarrini A, Ponziani FR, Pompili M. Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Cancers 2022;14:4631. [DOI: 10.3390/cancers14194631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
380 Verma M, Kalman R, Horrow J, Gallagher M, Woodrell C, Navarro V. Feasibility of a Palliative Care Intervention within Routine Care of Hepatocellular Carcinoma: A Pilot Randomized Controlled Trial. J Palliat Med 2022. [PMID: 36149682 DOI: 10.1089/jpm.2022.0338] [Reference Citation Analysis]
381 Rim CH, Lee JS, Kim SY, Seong J. Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis. JHEP Rep 2023;5:100594. [PMID: 36561128 DOI: 10.1016/j.jhepr.2022.100594] [Reference Citation Analysis]
382 Lei J, Yan T, Zhang L, Chen B, Cheng J, Gao X, Liu Z, Li Y, Zuo S, Lu Y. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitorsComparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.. [DOI: 10.21203/rs.3.rs-2069277/v1] [Reference Citation Analysis]
383 Tay BWR, Huang DQ, Mark M, Thong NW, Guan Huei L, Gee LS, Cheng LH, Mei LY, Thurairajah P, Chen LJ, Ng CH, Lim WH, Tan DJH, Maureen DC, Alfred KWC, Ganpathi IS, Seng TP, Young DY. Comparable Outcomes in Early Hepatocellular Carcinomas Treated with Trans-Arterial Chemoembolization and Radiofrequency Ablation. Biomedicines 2022;10:2361. [DOI: 10.3390/biomedicines10102361] [Reference Citation Analysis]
384 Uchida‐kobayashi S, Kageyama K, Takemura S, Matsumoto K, Odagiri N, Jogo A, Kotani K, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Yamamoto A, Fujii H, Tanaka S, Enomoto M, Tamori A, Miki Y, Kubo S, Kawada N. Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma. JGH Open 2022. [DOI: 10.1002/jgh3.12819] [Reference Citation Analysis]
385 Mohamed EA, Giama NH, Abdalla AO, Shaleh HM, Oseini AM, Ali HA, Ahmed F, Taha W, Ahmed Mohammed H, Cvinar J, Waaeys IA, Ali H, Allotey LK, Ali AO, Mohamed SA, Harmsen WS, Ahmmad EM, Bajwa NA, Afgarshe MD, Shire AM, Balls-Berry JE, Roberts LR. High prevalence of chronic viral hepatitis B and C in Minnesota Somalis contributes to rising hepatocellular carcinoma incidence. World J Gastroenterol 2022; 28(35): 5217-5229 [DOI: 10.3748/wjg.v28.i35.5217] [Reference Citation Analysis]
386 Leyh C, Heucke N, Schotten C, Büchter M, Bechmann LP, Wichert M, Dechêne A, Herrmann K, Heider D, Sydor S, Lemmer P, Ludwig JM, Pospiech J, Theysohn J, Damm R, March C, Powerski M, Pech M, Özcürümez M, Weigt J, Keitel V, Lange CM, Schmidt H, Canbay A, Best J, Gerken G, Manka PP. LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. Cancers 2022;14:4584. [DOI: 10.3390/cancers14194584] [Reference Citation Analysis]
387 Wu J, Wu J, Li Y, Qiu F, Zhou S, Yin Z, Chen Y, Li B, Zhou J, Yan M. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study. Front Oncol 2022;12:985380. [DOI: 10.3389/fonc.2022.985380] [Reference Citation Analysis]
388 da Cruz NS, Pasquarelli-do-nascimento G, e Oliveira ACP, Magalhães KG. Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression. Biomedicines 2022;10:2344. [DOI: 10.3390/biomedicines10102344] [Reference Citation Analysis]
389 An H, Bhatia I, Xie C. CT texture analysis in predicting treatment response and survival in patients with hepatocellular carcinoma treated with transarterial chemoembolization.. [DOI: 10.21203/rs.3.rs-2055732/v1] [Reference Citation Analysis]
390 Cheng R, Xu X. Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis. J Hepatocell Carcinoma 2022;9:987-97. [PMID: 36117526 DOI: 10.2147/JHC.S377435] [Reference Citation Analysis]
391 Ueda S, Hori S, Hori A, Makitani K, Wan K, Sonomura T. Retrospective Study of the Efficacy and Safety of Chemoembolization with Drug-Eluting Microspheres Combined with Intra-Arterial Infusion of Bevacizumab for Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:973-85. [PMID: 36117527 DOI: 10.2147/JHC.S380439] [Reference Citation Analysis]
392 Garcia-Monaco RD, Chung JW, Vilgrain V, Bouattour M, Covey AM. Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America. Br J Radiol 2022;95:20220179. [PMID: 35848758 DOI: 10.1259/bjr.20220179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
393 Goyal P, Salem R, Mouli SK. Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines. Br J Radiol 2022;95:20220379. [PMID: 35867889 DOI: 10.1259/bjr.20220379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
394 Chen S, Qiu Y, Zuo D, Shi S, Wang W, Dong Y. Imaging Features of Hepatocellular Carcinoma in the Non-Cirrhotic Liver with Sonazoid-Enhanced Contrast-Enhanced Ultrasound. Diagnostics 2022;12:2272. [DOI: 10.3390/diagnostics12102272] [Reference Citation Analysis]
395 Zhang W, Wan Y, Zhang Y, Liu Q, Zhu X. CSTF2 Acts as a Prognostic Marker Correlated with Immune Infiltration in Hepatocellular Carcinoma. Cancer Manag Res 2022;14:2691-709. [PMID: 36117731 DOI: 10.2147/CMAR.S359545] [Reference Citation Analysis]
396 Kirimker EO, Kirac AT, Celik SU, Boztug CY, Kaya MB, Balci D, Karayalcin MK. Comparison of Anatomic and Non-Anatomic Liver Resection for Hepatocellular Carcinoma: A Retrospective Cohort Study. Medicina (Kaunas) 2022;58:1305. [PMID: 36143982 DOI: 10.3390/medicina58091305] [Reference Citation Analysis]
397 Liu K, Zheng H, Sui X, Liu B, Meng M, Feng Y, Zhu Q, Zhao X. Microwave ablation versus surgical resection for subcapsular hepatocellular carcinoma: a propensity score–matched study of long-term therapeutic outcomes. Eur Radiol. [DOI: 10.1007/s00330-022-09135-1] [Reference Citation Analysis]
398 Rim CH, Lee WJ, Musaev B, Volichevich TY, Pazlitdinovich ZY, Nigmatovich TM, Rim JS; Consortium of Republican Specialized Scientific Practical-Medical Center of Oncology and Radiology and South Korean Oncology Advisory Group. Challenges and Suggestions in Management of Lung and Liver Cancer in Uzbekistan: The Second Report of the Uzbekistan-Korea Oncology Consortium. Int J Environ Res Public Health 2022;19. [PMID: 36142000 DOI: 10.3390/ijerph191811727] [Reference Citation Analysis]
399 Zhang B, Yue J, Shi X, Cui K, Li L, Zhang C, Sun P, Zhong J, Li Z, Zhao L. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma. BMJ Open 2022;12:e060955. [PMID: 36115673 DOI: 10.1136/bmjopen-2022-060955] [Reference Citation Analysis]
400 Lee J, Park SB, Byun S, Kim HI. Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance. PLoS ONE 2022;17:e0274747. [DOI: 10.1371/journal.pone.0274747] [Reference Citation Analysis]
401 Ailia MJ, Yoo SY. In Vivo Oncolytic Virotherapy in Murine Models of Hepatocellular Carcinoma: A Systematic Review. Vaccines (Basel) 2022;10:1541. [PMID: 36146619 DOI: 10.3390/vaccines10091541] [Reference Citation Analysis]
402 Qie Q, Shi J, Zhao M, Yin X, Han X, Yin X, Li N, Mi L, Yin F. Effects of TACE combined with sorafenib on survival of patients with hepatocellular carcinoma based on ALBI grades and tumor load layers And Establishment of prognosis prediction model.. [DOI: 10.21203/rs.3.rs-1971351/v1] [Reference Citation Analysis]
403 Wei X, Yao J, Shen W, Xie Q, Li Y, Ge L, Zeng X, Tang X. Capillarisenol C, a novel bisphenol from Artemisia capillaris, induces autophagic death in hepatocellular carcinoma through endoplasmic reticulum stress.. [DOI: 10.21203/rs.3.rs-2043984/v1] [Reference Citation Analysis]
404 Chen S, Liu P, Zhao L, Han P, Liu J, Yang H, Li J. A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma. Front Immunol 2022;13:954653. [DOI: 10.3389/fimmu.2022.954653] [Reference Citation Analysis]
405 Wang Q, Tan Y, Yang H, Zhang J, Lei X, Liu M, He L. Using radiomics to predict microvascular invasion in hepatocellular carcinoma based on multi-sequence gadoxetate disodium–enhanced MRI combined with clinical parameters.. [DOI: 10.21203/rs.3.rs-2055181/v1] [Reference Citation Analysis]
406 Huang Q, Pang M, Zeng Q, He X, Zheng R, Ge M, Li K. The frequency and risk factors of major complications after thermal ablation of liver tumours in 2,084 ablation sessions. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.1010043] [Reference Citation Analysis]
407 Hao F, Li H, Li N, Li J, Wu H. Laparoscopic repeat hepatectomy versus conventional open repeat hepatectomy for recurrent hepatocellular carcinoma: A systematic review and meta-analysis. Front Oncol 2022;12:960204. [DOI: 10.3389/fonc.2022.960204] [Reference Citation Analysis]
408 Alencar RSSM, Oliveira CP, Chagas AL, Fonseca LGD, Maccali C, Saud LRDC, Xerfan MP, Stefano JT, Herman P, D'Albuquerque LAC, Alves VAF, Carrilho FJ. Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series. Clinics (Sao Paulo) 2022;77:100097. [PMID: 36088887 DOI: 10.1016/j.clinsp.2022.100097] [Reference Citation Analysis]
409 Zheng Z, Guan R, Zou Y, Jian Z, Lin Y, Guo R, Jin H. Nomogram Based on Inflammatory Biomarkers to Predict the Recurrence of Hepatocellular Carcinoma-A Multicentre Experience. J Inflamm Res 2022;15:5089-102. [PMID: 36091335 DOI: 10.2147/JIR.S378099] [Reference Citation Analysis]
410 Yang X, Sun Y, Wang H, Li D, Xu G, Huang X. Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis. Front Oncol 2022;12:914385. [DOI: 10.3389/fonc.2022.914385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
411 Orimo T, Kamiyama T, Kakisaka T, Nagatsu A, Asahi Y, Aiyama T, Kamachi H, Taketomi A. Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas. Ann Surg Oncol. [DOI: 10.1245/s10434-022-12495-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
412 Kim M, Hui KM, Shi M, Reau N, Aloman C. Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma. Hepatol Commun 2022;6:3247-59. [PMID: 36097402 DOI: 10.1002/hep4.2079] [Reference Citation Analysis]
413 Cammarata F, Benuzzi L, Crespi M, Troci A, Pennacchi L, Schiavini M, Foschi D. Liver resection of hepatocellular carcinoma in HIV-HCV co-infected patients: a retrospective case series. Egypt Liver Journal 2022;12:53. [DOI: 10.1186/s43066-022-00215-x] [Reference Citation Analysis]
414 Sun B, Zhang L, Sun T, Ren Y, Cao Y, Zhang W, Zhu L, Guo Y, Gui Y, Liu F, Chen L, Xiong F, Zheng C. Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. Front Oncol 2022;12:982948. [DOI: 10.3389/fonc.2022.982948] [Reference Citation Analysis]
415 Brozzetti S, D’alterio C, Bini S, Antimi J, Rocco B, Fassari A, Lucatelli P, Nardis P, Di Martino M, De Sanctis GM, Corona M, Bagni O, Cortesi E, Bezzi M, Catalano C. Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients—A Retrospective Observational Study. Cancers 2022;14:4422. [DOI: 10.3390/cancers14184422] [Reference Citation Analysis]
416 Zhou Y, Zhou X, Liu Q, Zhang Z, Zhang W, Ma J, Yang M, Yu J, Luo J, Yan Z, Mei J. Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma. Disease Markers 2022;2022:1-15. [DOI: 10.1155/2022/8973721] [Reference Citation Analysis]
417 He P, Xiong Y, Luo B, Liu J, Zhang Y, Xiong Y, Su S, Fang C, Peng Y, Cheng H, Chu C, Mao J, Li J, Li B, Yin Z, Tian J, Liu G. An exploratory human study of superstable homogeneous lipiodol–indocyanine green formulation for precise surgical navigation in liver cancer. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10404] [Reference Citation Analysis]
418 Graafen D, Müller L, Halfmann M, Düber C, Hahn F, Yang Y, Emrich T, Kloeckner R. Photon-counting detector CT improves quality of arterial phase abdominal scans: A head-to-head comparison with energy-integrating CT. Eur J Radiol 2022;156:110514. [PMID: 36108479 DOI: 10.1016/j.ejrad.2022.110514] [Reference Citation Analysis]
419 Glantzounis GK, Korkolis D, Sotiropoulos GC, Tzimas G, Karampa A, Paliouras A, Asimakopoulos AG, Davakis S, Papalampros A, Moris D, Felekouras E. Individualized Approach in the Surgical Management of Hepatocellular Carcinoma: Results from a Greek Multicentre Study. Cancers (Basel) 2022;14:4387. [PMID: 36139548 DOI: 10.3390/cancers14184387] [Reference Citation Analysis]
420 Teerasarntipan T, Sritunyarat Y, Prathyajuta P, Pitakkitnukun P, Phathong C, Ariyaskul D, Kulkraisri K, Tangkijvanich P, Treeprasertsuk S, Rerknimitr R, Chaiteerakij R. Physician- and patient-reported barriers to hepatocellular carcinoma surveillance: A nationwide survey. Medicine (Baltimore) 2022;101:e30538. [PMID: 36086710 DOI: 10.1097/MD.0000000000030538] [Reference Citation Analysis]
421 J. Fitzgerald T, Laurie F, Iandoli M, Bishop-jodoin M, Smith K, Ulin K, Moni J, Giulia Cicchetti M, Kry S, Knopp M, Xiao Y, Rosen M, Prior F, Saltz J. Modern Clinical Trials in Radiation Oncology. Clinical Trials - Recent Advances [Working Title] 2022. [DOI: 10.5772/intechopen.107086] [Reference Citation Analysis]
422 Jean K, Tawheed A, Luong Nguye LB, Heikal T, Eldaly U, Elhadidy N, Elghaieb A, Aboudonia A, Tondeur L, Dublineau A, Fontanet A, El-kassas M. Changes in presentation, treatment, and survival of patients with hepatocellular carcinoma in Damietta, Egypt, 2007-2019: a retrospective monocentric cohort study.. [DOI: 10.1101/2022.09.07.22279666] [Reference Citation Analysis]
423 Ni Z, Wu B, Liu Z, Wang Q, Han X, Cheng W, Guo C. Clinical value of combined preoperative-postoperative neutrophil-to-lymphocyte ratio in predicting the prognosis of hepatocellular carcinoma after radiofrequency ablation.. [DOI: 10.21203/rs.3.rs-2013292/v1] [Reference Citation Analysis]
424 Bassegoda O, Rivera-Esteban J, Serra I, Morillas R, Broquetas T, Vergara M, Rodriguez A, Aracil C, Virolés S, Carrión JA, Pardo A, Rodríguez-Tajes S, Serra-Burriel M, Pericàs JM, Augustin S, Ginès P, Graupera I. High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study. Hepatol Commun 2022;6:3212-22. [PMID: 36073343 DOI: 10.1002/hep4.2056] [Reference Citation Analysis]
425 Elgenidy A, Awad AK, Afifi AM, Jalal PK. Serum angiopoietin 2 acts as a diagnostic biomarker for hepatocellular carcinoma: a meta-analysis of diagnostic test accuracy studies.. [DOI: 10.21203/rs.3.rs-1689476/v1] [Reference Citation Analysis]
426 Parikh ND, Tayob N, Singal AG. Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era? J Hepatol 2022:S0168-8278(22)03067-7. [PMID: 36089157 DOI: 10.1016/j.jhep.2022.08.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Peng TR, Wu CC, Chang SY, Chen YC, Wu TW, Hsu CS. Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma. Int Immunopharmacol 2022;112:109223. [PMID: 36084538 DOI: 10.1016/j.intimp.2022.109223] [Reference Citation Analysis]
428 Wang J, Miao Y, Li L, Wu Y, Ren Y, Cui Y, Cao H. Multi-omics data integration for hepatocellular carcinoma subtyping with multi-kernel learning. Front Genet 2022;13:962870. [DOI: 10.3389/fgene.2022.962870] [Reference Citation Analysis]
429 Nong S, Zhang T, Zhang T, Tian K, Wei Y, Ma X. Classification of combined hepatocellular and cholangiocarcinoma and hepatocellular carcinoma using contrast-enhanced CT based radiomics and machine-learning methods.. [DOI: 10.21203/rs.3.rs-2015072/v1] [Reference Citation Analysis]
430 Chen X, Zhang B, Lu Y, Li Z, Chen C, Yang Y, Chen Y, Ma D. A novel 16-gene alternative mRNA splicing signature predicts tumor relapse and indicates immune activity in stage I–III hepatocellular carcinoma. Front Pharmacol 2022;13:939912. [DOI: 10.3389/fphar.2022.939912] [Reference Citation Analysis]
431 Lu H, Mai R, Wang X, Liang R, Lin Y, Chen J, Wu F, Xiang B, Cheng S, Li L, Guo W, Ye J. A New Surgical Scheme for Determining Hepatectomy to Hepatocellular Carcinoma Patients with Clinically Significant Portal Hypertension.. [DOI: 10.21203/rs.3.rs-2013785/v1] [Reference Citation Analysis]
432 Orimo T, Kamiyama T, Taketomi A. ASO Author Reflections: Hepatectomy for Multiple Hepatocellular Carcinomas. Ann Surg Oncol 2022. [PMID: 36064992 DOI: 10.1245/s10434-022-12507-y] [Reference Citation Analysis]
433 Reincke M, Schultheiss M, Doppler M, Verloh N, Uller W, Sturm L, Thimme R, Goetz C, Bettinger D. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma. Hepatol Commun 2022;6:3223-33. [PMID: 36064940 DOI: 10.1002/hep4.2072] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
434 Ferreira da Silva AC, Cunha-silva M, Sevá-pereira T, Mazo DF. Evaluation of the Hepatocellular Carcinoma Predictive Scores PAGE-B and mPAGE-B among Brazilian Patients with Chronic Hepatitis B Virus Infection. Viruses 2022;14:1968. [DOI: 10.3390/v14091968] [Reference Citation Analysis]
435 Feng H, Xu F, Zhao Y, Jin T, Liu J, Li R, Zhou T, Dai C. Prognostic value of combined inflammatory and nutritional biomarkers in HCC within the Milan criteria after hepatectomy. Front Oncol 2022;12:947302. [DOI: 10.3389/fonc.2022.947302] [Reference Citation Analysis]
436 Prasoppokakorn T, Thanapirom K, Treeprasertsuk S. Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma. Case Reports in Hepatology 2022;2022:1-6. [DOI: 10.1155/2022/5101856] [Reference Citation Analysis]
437 Liu Z, Kan X, Zhang L, Makamure J, Li Q, Zhao D, Zhou G, Feng G, Zheng C, Liang B. Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors. CURR MED SCI 2022. [DOI: 10.1007/s11596-022-2620-6] [Reference Citation Analysis]
438 Guo S, Wang X, Zhou H, Gao Y, Wang P, Zhi H, Sun Y, Zhang Y, Gan J, Xiao Y, Ning S. PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity. Biomolecules 2022;12:1226. [PMID: 36139065 DOI: 10.3390/biom12091226] [Reference Citation Analysis]
439 Mossenta M, Busato D, Dal Bo M, Macor P, Toffoli G. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. Int J Mol Sci 2022;23:10038. [PMID: 36077433 DOI: 10.3390/ijms231710038] [Reference Citation Analysis]
440 Fraquelli M, Nadarevic T, Colli A, Manzotti C, Giljaca V, Miletic D, Štimac D, Casazza G. Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd013483.pub2] [Reference Citation Analysis]
441 Guo D, Qin L, Sun J, Li K, Zang C, Wang Q, Qiao W, Liu B, Zhao Y, Zhang Y. Dynamic changes in cytokine profiles and their impact on tumour recurrence following thermal ablation in hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-1998332/v1] [Reference Citation Analysis]
442 Zhang L, Qi Q, Li Q, Ren S, Liu S, Mao B, Li X, Wu Y, Yang L, Liu L, Li Y, Duan S, Zhang L. Ultrasomics prediction for cytokeratin 19 expression in hepatocellular carcinoma: A multicenter study. Front Oncol 2022;12:994456. [DOI: 10.3389/fonc.2022.994456] [Reference Citation Analysis]
443 Zanetto A, Campello E, Bulato C, Gavasso S, Farinati F, Russo FP, Tormene D, Burra P, Senzolo M, Simioni P. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. J Hepatol 2022;77:660-9. [PMID: 35364225 DOI: 10.1016/j.jhep.2022.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
444 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 2022;77:761-806. [PMID: 35738507 DOI: 10.1016/j.jhep.2022.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
445 Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about Hepatocellular Carcinoma: Recommendations for Health Authorities: An International Liver Cancer Association Advocacy Document. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100578] [Reference Citation Analysis]
446 Innes H, Hamill V, McDonald SA, Hayes PC, Johnson P, Dillon JF, Bishop J, Yeung A, Went A, Barclay ST, Fraser A, Bathgate A, Goldberg DJ, Hutchinson SJ. Comparing Predicted Probability of Hepatocellular Carcinoma in Patients With Cirrhosis With the General Population: An Opportunity to Improve Risk Communication? Am J Gastroenterol 2022;117:1454-61. [PMID: 35973177 DOI: 10.14309/ajg.0000000000001879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
447 Yu M, Yu M, Ji Y. Effects of sinomenine on apoptosis of human hepatoma cell line SMMC-7721 and its molecular mechanism in vitro. mat express 2022;12:1163-1173. [DOI: 10.1166/mex.2022.2265] [Reference Citation Analysis]
448 Liu F, Guo X, Zhang W, Zou M, Huang J, Dong W, Zhang J, Zhu X, Pan Z, Lau WY, Zhou W, Liu H. Simultaneous splenectomy improving the outcomes of patients with hepatocellular carcinoma, cirrhosis and portal hypertension treated with hepatectomy. Portal Hypertension & Cirrhosis 2022;1:90-100. [DOI: 10.1002/poh2.29] [Reference Citation Analysis]
449 Zhuang BW, Li W, Qiao B, Zhang N, Lin MX, Wang W, Kuang M, Lu MD, Xie XY, Xie XH. Preoperative prognostic value of alfa-fetoprotein density in patients with hepatocellular carcinoma undergoing radiofrequency ablation. Int J Hyperthermia 2022;39:1143-51. [PMID: 36039777 DOI: 10.1080/02656736.2022.2116491] [Reference Citation Analysis]
450 Thomas JA, Kendall BJ, Dalais C, Macdonald GA, Thrift AP. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer 2022;173:250-62. [PMID: 35944373 DOI: 10.1016/j.ejca.2022.06.051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
451 Wang L, Peng C, Chen J, Li H, Jiao Q, Zhang Z, Wang L, Yuan Q, Wang B, Huang Y, Ma X. Intermittent hilar occlusion attenuates or prevents renal ischaemia-reperfusion in mice. Biomedicine & Pharmacotherapy 2022;153:113457. [DOI: 10.1016/j.biopha.2022.113457] [Reference Citation Analysis]
452 Van Laeken C, Taelman T, Cappuyns S, Maleux G, Vandecaveye V, Verslype C, Deroose C, Dekervel J. Clinical factors associated with early disease progression after radioembolization for hepatocellular carcinoma and feasibility of post‐progression systemic therapy. Liver Cancer International 2022;3:128-136. [DOI: 10.1002/lci2.60] [Reference Citation Analysis]
453 Dioguardi Burgio M, Brancatelli G, Sartoris R, Cannella R, Zins M, Aubé C, Mulé S, Luciani A, Ronot M, Vilgrain V. L’acide gadoxétique, un « nouveau » produit de contraste hépatospécifique en IRM. Journal d'imagerie diagnostique et interventionnelle 2022;5:210-221. [DOI: 10.1016/j.jidi.2022.01.015] [Reference Citation Analysis]
454 Moon AM, Ioannou GN. Moving Away From a One-Size-Fits-All Approach to Hepatocellular Carcinoma Surveillance. Am J Gastroenterol 2022;117:1409-11. [PMID: 35973179 DOI: 10.14309/ajg.0000000000001897] [Reference Citation Analysis]
455 Hsu WF, Lai HC, Chuang PH, Su WP, Chen SH, Chen HY, Wang HW, Huang GT, Peng CY. Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents. J Viral Hepat 2022;29:785-94. [PMID: 35657121 DOI: 10.1111/jvh.13715] [Reference Citation Analysis]
456 Loo KF, Woodman RJ, Bogatic D, Chandran V, Muller K, Chinnaratha MA, Bate J, Campbell K, Maddison M, Narayana S, Le H, Pryor D, Wigg A. High rates of treatment stage migration for early hepatocellular carcinoma and association with adverse outcomes: An Australian multicenter study. JGH Open 2022;6:599-606. [DOI: 10.1002/jgh3.12793] [Reference Citation Analysis]
457 Norén S, Bengtsson B, Hagström H, Ljunggren G, Wahlin S. Hepatocellular carcinoma in Stockholm, Sweden 2003-2018: a population-based cohort study. Scand J Gastroenterol 2022;57:1080-8. [PMID: 35605144 DOI: 10.1080/00365521.2022.2062257] [Reference Citation Analysis]
458 Gan X, Ding D, Wang M, Yang Y, Sun D, Li W, Ding W, Yang F, Zhou W, Yuan S. DANCR deletion retards the initiation and progression of hepatocellular carcinoma based on gene knockout and patient-derived xenograft in situ hepatoma mice model. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215930] [Reference Citation Analysis]
459 Wu S, Zhou J, Wu X, Sun Y, Wang B, Kong Y, Zhan S, Jia J, Yang HI, You H. Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints. Am J Gastroenterol 2022;117:1444-53. [PMID: 35973147 DOI: 10.14309/ajg.0000000000001865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
460 Karaoğullarindan Ü, Gümürdülü Y, Üsküdar O, Odabaş E, Güler HS, Delik A, Kuran S. Prognostic factors of elderly patients with hepatocellular carcinoma: should we be more courageous in treatment? Eur J Gastroenterol Hepatol 2022;34:956-60. [PMID: 35830357 DOI: 10.1097/MEG.0000000000002396] [Reference Citation Analysis]
461 Xing H, Yang C, Tan B, Zhang M. Competitive risk analysis of the therapeutic value of liver transplantation for liver cancer in children: A population-based study. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.938254] [Reference Citation Analysis]
462 Dai Y, Gao Y, Chen L, Liu J, Zeng C, Zhou J, Wu H. Predicting prognosis and immune responses in hepatocellular carcinoma based on N7-methylguanosine-related long noncoding RNAs. Front Genet 2022;13:930446. [DOI: 10.3389/fgene.2022.930446] [Reference Citation Analysis]
463 Ho S, Liu P, Hsu C, Huang Y, Liao J, Su C, Hou M, Huo T. Radiofrequency Ablation versus Transarterial Chemoembolization for Hepatocellular Carcinoma within Milan Criteria: Prognostic Role of Tumor Burden Score. Cancers 2022;14:4207. [DOI: 10.3390/cancers14174207] [Reference Citation Analysis]
464 Liu S, Sun L, Yao L, Zhu H, Diao Y, Wang M, Xing H, Lau WY, Guan M, Pawlik TM, Shen F, Xu M, Tong X, Yang T. Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis. JCM 2022;11:5075. [DOI: 10.3390/jcm11175075] [Reference Citation Analysis]
465 Alhyari A, Görg C, Alakhras R, Dietrich CF, Trenker C, Safai Zadeh E. HCC or Something Else? Frequency of Various Benign and Malignant Etiologies in Cirrhotic Patients with Newly Detected Focal Liver Lesions in Relation to Different Clinical and Sonographic Parameters. Diagnostics 2022;12:2079. [DOI: 10.3390/diagnostics12092079] [Reference Citation Analysis]
466 Alafnan A, Alamri A, Alanazi J, Hussain T. Farnesiferol C Exerts Antiproliferative Effects on Hepatocellular Carcinoma HepG2 Cells by Instigating ROS-Dependent Apoptotic Pathway. Pharmaceuticals 2022;15:1070. [DOI: 10.3390/ph15091070] [Reference Citation Analysis]
467 Tang MJ, Eslick GD, Lubel JS, Majeed A, Majumdar A, Kemp W, Roberts SK. Outcomes of microwave versus radiofrequency ablation for hepatocellular carcinoma: A systematic review and meta-analysis. World J Meta-Anal 2022; 10(4): 220-237 [DOI: 10.13105/wjma.v10.i4.220] [Reference Citation Analysis]
468 Liava C, Sinakos E, Papadopoulou E, Giannakopoulou L, Potsi S, Moumtzouoglou A, Chatziioannou A, Stergioulas L, Kalogeropoulou L, Dedes I, Akriviadis E, Chourmouzi D. Liver Imaging Reporting and Data System criteria for the diagnosis of hepatocellular carcinoma in clinical practice: A pictorial minireview. World J Gastroenterol 2022; 28(32): 4540-4556 [DOI: 10.3748/wjg.v28.i32.4540] [Reference Citation Analysis]
469 Liu Y, Lin C, Weng C, Chang P, Chien C, Huang K, Hua M, Hu C. Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy. Diagnostics 2022;12:2085. [DOI: 10.3390/diagnostics12092085] [Reference Citation Analysis]
470 Choi J, Tayob N, Lim YS. Detecting Early Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Using Longitudinal α-Fetoprotein Screening. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00814-X. [PMID: 36031091 DOI: 10.1016/j.cgh.2022.08.018] [Reference Citation Analysis]
471 Manjunatha N, Ganduri V, Rajasekaran K, Duraiyarasan S, Adefuye M. Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review. Cureus 2022. [DOI: 10.7759/cureus.28439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Li A, Ye B, Lin F, Zhou P, Wang Y, Miao X, Jiang Y. Dissecting Novel Tumor Antigens and Immune Subtypes Guided mRNA Vaccine Development for HBV Related-Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-1962830/v1] [Reference Citation Analysis]
473 Zhang X, Luo Y, Tsauo J, Zhao H, Gong T, Li J, Li Y, Zeng H, Sun W, Li X. Transradial versus transfemoral access without closure device for transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized trial. Eur Radiol 2022. [PMID: 36018356 DOI: 10.1007/s00330-022-09038-1] [Reference Citation Analysis]
474 Duberg AS, Lybeck C, Fält A, Montgomery S, Aleman S. Reply. Hepatol Commun 2022;6:3593-4. [PMID: 36017781 DOI: 10.1002/hep4.2083] [Reference Citation Analysis]
475 Moazzam Z, Lima HA, Alaimo L, Endo Y, Shaikh CF, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Impact of tumor burden score on timing and patterns of recurrence after curative-intent resection of hepatocellular carcinoma. Surgery 2022:S0039-6060(22)00570-0. [PMID: 36031442 DOI: 10.1016/j.surg.2022.07.019] [Reference Citation Analysis]
476 Niu X, He X. A Nomogram Based on Preoperative Lipiodol Deposition after Sequential Retreatment with Transarterial Chemoembolization to Predict Prognoses for Intermediate-Stage Hepatocellular Carcinoma. JPM 2022;12:1375. [DOI: 10.3390/jpm12091375] [Reference Citation Analysis]
477 Wang Y, Xue R, Xing W, Li Q, Gei L, Yan F, Mai D, Zeng W, Yan Y, Chen D. Intraoperative low-dose dopamine is associated with worse survival in patients with hepatocellular carcinoma: A propensity score matching analysis. Front Oncol 2022;12:947172. [DOI: 10.3389/fonc.2022.947172] [Reference Citation Analysis]
478 Zhang NN, Zheng J, Wu Y, Lv JY, Zhang SW, Zhang YM, Jiang WT, Song TQ, Kim V, Tohme S, Liu T, Zhang W, Gu J, Wang ZY, Suo YH, Wang S, Li W, Zhang L, Xie Y, Zhou YH, Liu JY, Qiu YB, Shen ZY, Hao JH, Geller D, Lu W. Comparison of the long-term outcomes of patients with hepatocellular carcinoma within the Milan criteria treated by ablation, resection, or transplantation. Cancer Med 2022. [PMID: 36016484 DOI: 10.1002/cam4.5063] [Reference Citation Analysis]
479 Ningarhari M, Mourad A, Delacôte C, Ntandja Wandji LC, Lassailly G, Louvet A, Dharancy S, Mathurin P, Deuffic-Burban S. Benefits of tailored hepatocellular carcinoma screening in patients with cirrhosis on cancer-specific and overall mortality: A modeling approach. Hepatol Commun 2022. [PMID: 36004703 DOI: 10.1002/hep4.2059] [Reference Citation Analysis]
480 Damjanovska S, Alao H, Zebrowski E, Kowal C, Kostadinova L, Davitkov P, Falck-Ytter Y, Shive CL, Cartwright M, Richardson B, Wald D, Cameron M, Valadkhan S, Anthony DD. During HCV DAA Therapy Plasma Mip1B, IP10, and miRNA Profile Are Distinctly Associated with Subsequent Diagnosis of Hepatocellular Carcinoma: A Pilot Study. Biology (Basel) 2022;11. [PMID: 36138741 DOI: 10.3390/biology11091262] [Reference Citation Analysis]
481 Abdu S, Juaid N, Amin A, Moulay M, Miled N. Therapeutic Effects of Crocin Alone or in Combination with Sorafenib against Hepatocellular Carcinoma: In Vivo & In Vitro Insights. Antioxidants 2022;11:1645. [DOI: 10.3390/antiox11091645] [Reference Citation Analysis]
482 Chen ZX, Schwartz M, Gu LH, Liang L, Wang P, Cescon M, Li JD, Liang YJ, Pu JL, Zhou YH, Wang H, Gu WM, Chen TH, Chen ZY, Wang MD, Li C, Zhang CW, Pawlik TM, Lau WY, Shen F, Liu FB, Yang T. Development and validation of safety and efficacy-associated Risk calculator for hepatocellular Carcinoma in the elderly after resection (SEARCHER): A multi-institutional observational study. Int J Surg 2022;:106842. [PMID: 36030039 DOI: 10.1016/j.ijsu.2022.106842] [Reference Citation Analysis]
483 You H, Liu X, Guo J, Lin Y, Zhang Y, Li C. Hepatic arterial infusion chemotherapy and sequential ablation treatment in large hepatocellular carcinoma. Int J Hyperthermia 2022;39:1097-105. [PMID: 35993224 DOI: 10.1080/02656736.2022.2112307] [Reference Citation Analysis]
484 Wang T, Glampson B, Mercuri L, Papadimitriou D, Jones CR, Smith DA, Salih H, Campbell C, Freeman O, Harris S, Várnai KA, Roadknight G, Little S, Noble T, Woods K, Matthews PC, Davies J, Cooke GS, Barnes E, NIHR Health Informatics Collaborative Viral Hepatitis Theme Consortium. Identifying Hepatocellular Carcinoma from imaging reports using natural language processing to facilitate data extraction from electronic patient records.. [DOI: 10.1101/2022.08.23.22279119] [Reference Citation Analysis]
485 Liu YS, Chang PY, Liang PC, Ou MC, Hwang JI, Chen CH. Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T). J Hepatocell Carcinoma 2022;9:811-21. [PMID: 35996398 DOI: 10.2147/JHC.S374555] [Reference Citation Analysis]
486 Eguchi A, Iwasa M, Tamai Y, Yamada M, Okuno K, Shigefuku R, Yoshikawa K, Tempaku M, Sakaguchi K, Tanaka H, Sugimoto K, Kobayashi Y, Yamaguchi T, Nakagawa H. The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage. Front Oncol 2022;12:993705. [DOI: 10.3389/fonc.2022.993705] [Reference Citation Analysis]
487 Zhu Y, Gu L, Zhang F, Zheng G, Chen T, Jia W, Solimando AG. Long-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-9. [DOI: 10.1155/2022/7750140] [Reference Citation Analysis]
488 Aboelezz Ahmad AF, Elsawy AA, Omar HM, Abofrekha MH, Gabr MT. The role of shear wave elastography in differentiation between benign and malignant portal vein thrombosis in hepatocellular carcinoma. Egypt J Radiol Nucl Med 2022;53:188. [DOI: 10.1186/s43055-022-00872-3] [Reference Citation Analysis]
489 Osman AMA, Abdelaziz AO, Deweir M, Salah A, Harb STE, Nabeel MM, Abdelmaksoud AH, Shousha HI, Elbaz TM, Hashem MB. Hepatic resection versus microwave ablation for the treatment of early hepatocellular carcinoma: a comparative analysis of treatment outcomes and survival predictors. Egypt Liver Journal 2022;12:48. [DOI: 10.1186/s43066-022-00210-2] [Reference Citation Analysis]
490 Song S, Chen L, Feng G, Liu Y, Zheng C. Liver abscess after transarterial chemoembolization combined with molecular targeted drugs and immunotherapy in the treatment of liver cancer: A case series report.. [DOI: 10.21203/rs.3.rs-1975008/v1] [Reference Citation Analysis]
491 Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI. Tumor burden score as a new prognostic surrogate in patients with hepatocellular carcinoma undergoing radiofrequency ablation: role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35999514 DOI: 10.1080/17474124.2022.2117156] [Reference Citation Analysis]
492 Gan L, Ren S, Lang M, Li G, Fang F, Chen L, Liu Y, Han R, Zhu K, Song T. Predictive Value of Preoperative Serum AFP, CEA, and CA19-9 Levels in Patients with Single Small Hepatocellular Carcinoma: Retrospective Study. J Hepatocell Carcinoma 2022;9:799-810. [PMID: 35990213 DOI: 10.2147/JHC.S376607] [Reference Citation Analysis]
493 Cao M, Li H, Sun D, He S, Yang F, Yan X, Zhang S, Zha Z, Zhou J, Luo P, Gong J, Ma H, Zhang S, Sun X, Xia C, Peng J, Chen W. Assessment of the compliance, influencing factors, and yielding results of liver cancer screening in a high-risk population: A cross-sectional study. Cancer 2022. [PMID: 35996957 DOI: 10.1002/cncr.34418] [Reference Citation Analysis]
494 Androutsakos T, Bakasis AD, Pouliakis A, Gazouli M, Vallilas C, Hatzis G. Single Nucleotide Polymorphisms of Toll-like Receptor 4 in Hepatocellular Carcinoma-A Single-Center Study. Int J Mol Sci 2022;23:9430. [PMID: 36012696 DOI: 10.3390/ijms23169430] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
495 Müller L, Mähringer-kunz A, Auer TA, Fehrenbach U, Gebauer B, Haubold J, Theysohn JM, Kim M, Kleesiek J, Diallo TD, Eisenblätter M, Bettinger D, Steinle V, Mayer P, Zopfs D, Pinto dos Santos D, Kloeckner R. Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study. Eur Radiol. [DOI: 10.1007/s00330-022-09069-8] [Reference Citation Analysis]
496 Xu W, Li B, Yang Z, Li J, Liu F, Liu Y. Rethinking Liver Fibrosis Staging in Patients with Hepatocellular Carcinoma: New Insights from a Large Two-Center Cohort Study. J Hepatocell Carcinoma 2022;9:751-81. [PMID: 35983561 DOI: 10.2147/JHC.S372577] [Reference Citation Analysis]
497 Chen L, Zhang W, Sun T, Ren Y, Sun B, Zhu L, Zhao H, Zheng C. Effect of Transarterial Chemoembolization Plus Percutaneous Ethanol Injection or Radiofrequency Ablation for Liver Tumors. J Hepatocell Carcinoma 2022;9:783-97. [PMID: 35983562 DOI: 10.2147/JHC.S370486] [Reference Citation Analysis]
498 Chartampilas E, Rafailidis V, Georgopoulou V, Kalarakis G, Hatzidakis A, Prassopoulos P. Current Imaging Diagnosis of Hepatocellular Carcinoma. Cancers 2022;14:3997. [DOI: 10.3390/cancers14163997] [Reference Citation Analysis]
499 Ren Y, Pan F, Kan X, Wang J, Han P, Yan J, Li L, Sun P, Liu CY, Bao Q, Yang L, Zheng C. Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor. Mol Pharm 2022. [PMID: 35976154 DOI: 10.1021/acs.molpharmaceut.2c00474] [Reference Citation Analysis]
500 Xie X, Zheng M, Guo W, Zhou Y, Xiang Z, Li Y, Yang J. Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma. Sci Rep 2022;12:13969. [PMID: 35978032 DOI: 10.1038/s41598-022-18197-6] [Reference Citation Analysis]
501 Słomka A, Wang B, Mocan T, Horhat A, Willms AG, Schmidt-Wolf IGH, Strassburg CP, Gonzalez-Carmona MA, Lukacs-Kornek V, Kornek MT. Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts? Theranostics 2022;12:5836-55. [PMID: 35966579 DOI: 10.7150/thno.73400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
502 Willemssen F, de Lussanet de la Sablonière Q, Bos D, Ijzermans J, De Man R, Dwarkasing R. Potential of a Non-Contrast-Enhanced Abbreviated MRI Screening Protocol (NC-AMRI) in High-Risk Patients under Surveillance for HCC. Cancers 2022;14:3961. [DOI: 10.3390/cancers14163961] [Reference Citation Analysis]
503 Kwag M, Choi SH, Choi SJ, Byun JH, Won HJ, Shin YM. Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI. Radiology 2022;:220659. [PMID: 35972362 DOI: 10.1148/radiol.220659] [Reference Citation Analysis]
504 Sidali S, Trépo E, Sutter O, Nault JC. New concepts in the treatment of hepatocellular carcinoma. United European Gastroenterol J 2022. [PMID: 35975347 DOI: 10.1002/ueg2.12286] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
505 Adhoute X, De Matharel M, Mineur L, Pénaranda G, Ouizeman D, Toullec C, Tran A, Castellani P, Rollet A, Oules V, Perrier H, Si Ahmed SN, Bourliere M, Anty R. Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching. World J Gastrointest Oncol 2022; 14(8): 1510-1527 [DOI: 10.4251/wjgo.v14.i8.1510] [Reference Citation Analysis]
506 Wang K, Yu HM, Xiang YJ, Cheng YQ, Ni QZ, Guo WX, Shi J, Feng S, Zhai J, Cheng SQ. Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase 2 trial. Future Oncol 2022. [PMID: 35968836 DOI: 10.2217/fon-2022-0188] [Reference Citation Analysis]
507 Renzulli M, Pecorelli A, Brandi N, Marasco G, Adduci F, Tovoli F, Stefanini B, Granito A, Golfieri R. Radiological Features of Microvascular Invasion of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. Gastroenterology Insights 2022;13:275-285. [DOI: 10.3390/gastroent13030028] [Reference Citation Analysis]
508 Hříbek P, Klasová J, Tůma T, Kupsa T, Urbánek P. Etiopathogenetic Factors of Hepatocellular Carcinoma, Overall Survival, and Their Evolution over Time-Czech Tertiary Center Overview. Medicina (Kaunas) 2022;58:1099. [PMID: 36013566 DOI: 10.3390/medicina58081099] [Reference Citation Analysis]
509 Tan XP, Xiong BH, Zhang YX, Wang SL, Zuo Q, Li J. FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma. Eur J Pharmacol 2022;931:175186. [PMID: 35977595 DOI: 10.1016/j.ejphar.2022.175186] [Reference Citation Analysis]
510 Gongye X, Tian M, Xia P, Qu C, Chen Z, Wang J, Zhu Q, Li Z, Yuan Y. Multi-omics analysis revealed the role of extracellular vesicles in hepatobiliary & pancreatic tumor. J Control Release 2022;350:11-25. [PMID: 35963466 DOI: 10.1016/j.jconrel.2022.08.010] [Reference Citation Analysis]
511 Bischoff SC, Barazzoni R, Busetto L, Campmans-Kuijpers M, Cardinale V, Chermesh I, Eshraghian A, Kani HT, Khannoussi W, Lacaze L, Léon-Sanz M, Mendive JM, Müller MW, Ockenga J, Tacke F, Thorell A, Vranesic Bender D, Weimann A, Cuerda C. European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline. United European Gastroenterol J 2022. [PMID: 35959597 DOI: 10.1002/ueg2.12280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
512 Sharma A, Cressman E, Attaluri A, Kraitchman DL, Ivkov R. Current Challenges in Image-Guided Magnetic Hyperthermia Therapy for Liver Cancer. Nanomaterials (Basel) 2022;12. [PMID: 36014633 DOI: 10.3390/nano12162768] [Reference Citation Analysis]
513 Bischoff SC, Barazzoni R, Busetto L, Campmans-Kuijpers M, Cardinale V, Chermesh I, Eshraghian A, Kani HT, Khannoussi W, Lacaze L, Léon-Sanz M, Mendive JM, Müller MW, Ockenga J, Tacke F, Thorell A, Vranesic Bender D, Weimann A, Cuerda C. European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN/UEG guideline. Clin Nutr 2022:S0261-5614(22)00239-4. [PMID: 35970666 DOI: 10.1016/j.clnu.2022.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
514 Higuera M, Vargas-accarino E, Torrens M, Gregori J, Salcedo MT, Martínez-campreciós J, Torres G, Bermúdez-ramos M, Bilbao I, Guerrero-murillo M, Serres-créixams X, Merino X, Rodríguez-frías F, Quer J, Mínguez B. Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management. Cancers 2022;14:3875. [DOI: 10.3390/cancers14163875] [Reference Citation Analysis]
515 Wang J, Li S. Applications of rare earth elements in cancer: Evidence mapping and scientometric analysis. Front Med 2022;9. [DOI: 10.3389/fmed.2022.946100] [Reference Citation Analysis]
516 Zajkowska M, Mroczko B. Chemokines in Primary Liver Cancer. IJMS 2022;23:8846. [DOI: 10.3390/ijms23168846] [Reference Citation Analysis]
517 Shekh R, Tiwari RK, Ahmad A, Ahmad I, Alabdallah NM, Saeed M, Ansari IA, Mishra A, Ashfaque M, Bajpai P. Ethanolic extract of Coleus aromaticus leaves impedes the proliferation and instigates apoptotic cell death in liver cancer HepG2 cells through repressing JAK/STAT cascade. J Food Biochem 2022;:e14368. [PMID: 35945689 DOI: 10.1111/jfbc.14368] [Reference Citation Analysis]
518 Brown AM, Kassab I, Massani M, Townsend W, Singal AG, Soydal C, Moreno-Luna L, Roberts LR, Chen VL, Parikh ND. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis. Cancer Med 2022. [PMID: 35943116 DOI: 10.1002/cam4.5125] [Reference Citation Analysis]
519 Wu Y, Hao X, Wei H, Sun R, Chen Y, Tian Z. Blockade of T-cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV-related HCC in mice. Hepatology 2022. [PMID: 35938354 DOI: 10.1002/hep.32715] [Reference Citation Analysis]
520 Dong SC, Bai DS, Wang FA, Jin SJ, Zhang C, Zhou BH, Jiang GQ. Radiofrequency ablation is an inferior option to liver resection for solitary hepatocellular carcinoma ≤ 5 cm without cirrhosis: A population-based study with stratification by tumor size. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00187-4. [PMID: 35977873 DOI: 10.1016/j.hbpd.2022.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
521 Risaliti M, Bartolini I, Campani C, Arena U, Xodo C, Adotti V, Rosi M, Taddei A, Muiesan P, Amedei A, Batignani G, Marra F. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis. World J Gastroenterol 2022; 28(29): 3981-3993 [DOI: 10.3748/wjg.v28.i29.3981] [Reference Citation Analysis]
522 Malik J, Klammer M, Rolny V, Chan HLY, Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, Swiatek-de Lange M. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma. World J Gastroenterol 2022; 28(29): 3917-3933 [DOI: 10.3748/wjg.v28.i29.3917] [Reference Citation Analysis]
523 Gozzo C, Hermida M, Herrero A, Panaro F, Cassinotto C, Mohamad AM, Assenat E, Guillot C, Allimant C, Schembri V, Basile A, Dharancy S, Ursic-Bedoya J, Guiu B. Non-transplantable recurrence after percutaneous thermal ablation of ≤3-cm HCC: Predictors and implications for treatment allocation. Hepatol Commun 2022. [PMID: 35932178 DOI: 10.1002/hep4.2063] [Reference Citation Analysis]
524 Wu QQ, Chen YX, Du SS, Hu Y, Yang P, Sun J, Wang XY, Wu WX, Zhang SM, Zeng ZC. Effect of the normal liver mean dose on intrahepatic recurrence in patients with hepatocellular carcinoma after receiving liver stereotactic body radiation therapy. Transl Oncol 2022;25:101492. [PMID: 35944415 DOI: 10.1016/j.tranon.2022.101492] [Reference Citation Analysis]
525 Wang X, Li Y, Shi Y, Luo J, Zhang Y, Pan Z, Wu F, Tian J, Yu W. Comprehensive analysis to identify the neurotransmitter receptor-related genes as prognostic and therapeutic biomarkers in hepatocellular carcinoma. Front Cell Dev Biol 2022;10:887076. [DOI: 10.3389/fcell.2022.887076] [Reference Citation Analysis]
526 Paturel A, Hall J, Chemin I. Poly(ADP-Ribose) Polymerase Inhibition as a Promising Approach for Hepatocellular Carcinoma Therapy. Cancers (Basel) 2022;14:3806. [PMID: 35954469 DOI: 10.3390/cancers14153806] [Reference Citation Analysis]
527 Xin Y, Cao F, Yang H, Zhang X, Chen Y, Cao X, Zhou X, Li X, Zhou J. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Front Immunol 2022;13:929141. [DOI: 10.3389/fimmu.2022.929141] [Reference Citation Analysis]
528 Petzold G. Role of Ultrasound Methods for the Assessment of NAFLD. J Clin Med 2022;11:4581. [PMID: 35956196 DOI: 10.3390/jcm11154581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
529 Feng MY, Chan LL, Chan SL. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Curr Oncol 2022;29:5489-507. [PMID: 36005172 DOI: 10.3390/curroncol29080434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
530 Liu W, Song K, Zheng W, Huo L, Zhang S, Xu X, Wang P, Jia N. Hepatobiliary Phase Features of Preoperative Gadobenate-Enhanced MR can Predict Early Recurrence of Hepatocellular Carcinoma in Patients Who Underwent Anatomical Hepatectomy. Front Oncol 2022;12:862967. [DOI: 10.3389/fonc.2022.862967] [Reference Citation Analysis]
531 Liang BY, Gu J, Xiong M, Zhang EL, Zhang ZY, Lau WY, Wang SF, Guan Y, Chen XP, Huang ZY. Histological Severity of Cirrhosis Influences Surgical Outcomes of Hepatocellular Carcinoma After Curative Hepatectomy. J Hepatocell Carcinoma 2022;9:633-47. [PMID: 35909916 DOI: 10.2147/JHC.S368302] [Reference Citation Analysis]
532 Zheng WJ, Wang PX, Sun YF, Cheng JW, Zhong YC, Xu Y, Guo W, Hu B, Zhou J, Fan J, Chen X, Yang XR. Uncovering the Heterogeneity and Clinical Relevance of Circulating Tumor-Initiating Cells in Hepatocellular Carcinoma Using an Integrated Immunomagnetic-Microfluidic Platform. ACS Appl Mater Interfaces 2022. [PMID: 35917454 DOI: 10.1021/acsami.2c09085] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
533 Dong MP, Thanh Thuy LT, Hoang DV, Hai H, Hoang TH, Sato-matsubara M, Hieu VN, Daikoku A, Hanh NV, Urushima H, Dat NQ, Uchida-kobayashi S, Enomoto M, Ohtani N, Tamori A, Kawada N. Soluble Immune Checkpoint Protein CD27 Is a Novel Prognostic Biomarker of Hepatocellular Carcinoma Development in Hepatitis C Virus–Sustained Virological Response Patients. The American Journal of Pathology 2022. [DOI: 10.1016/j.ajpath.2022.07.003] [Reference Citation Analysis]
534 Semmler G, Mandorfer M. Reply to: 'Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan'. J Hepatol 2022;77:571-2. [PMID: 35526785 DOI: 10.1016/j.jhep.2022.04.031] [Reference Citation Analysis]
535 Sun LY, Li ZL, Yang T. Editorial: non-viral hepatocellular carcinoma surveillance-an increasingly severe public health issue. Aliment Pharmacol Ther 2022;56:748-9. [PMID: 35879900 DOI: 10.1111/apt.17116] [Reference Citation Analysis]
536 Shi Q, Wang F, Du N, Zhou Y, Zhou X, Ma J, Yang M, Zhang Z, Yu J, Zhang W, Luo J, Liu L, Yan Z. Microwave ablation combined with lipiodol-microsphere mixed or conventional transarterial chemoembolization for the treatment of colorectal liver metastases: A retrospective study. Clin Res Hepatol Gastroenterol 2022;46:101986. [PMID: 35772684 DOI: 10.1016/j.clinre.2022.101986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
537 Wang L, Zhang L, Jiang B, Zhao K, Zhang Y, Xie X. Clinical application of deep learning and radiomics in hepatic disease imaging: a systematic scoping review. Br J Radiol 2022;95:20211136. [PMID: 35816550 DOI: 10.1259/bjr.20211136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
538 Wei JW, Fu SR, Zhang J, Gu DS, Li XQ, Chen XD, Zhang ST, He XF, Yan JF, Lu LG, Tian J. CT-based radiomics to predict development of macrovascular invasion in hepatocellular carcinoma: A multicenter study. Hepatobiliary Pancreat Dis Int 2022;21:325-33. [PMID: 34674948 DOI: 10.1016/j.hbpd.2021.09.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
539 Shi T, Xu C, Feng Y, Wei Y, Lv H, Zhu Q. Surgical resection versus radiofrequency ablation for early recurrent hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2022;34:844-51. [PMID: 35694799 DOI: 10.1097/MEG.0000000000002393] [Reference Citation Analysis]
540 Prateepchaiboon T, Chang A, Pungpipattrakul N, Akarapatima K, Rattanasupar A, Songjamrat A, Pakdeejit S, Piratvisuth T. Factors affecting prognosis in hepatocellular carcinoma patients post-transarterial chemoembolization. Indian J Gastroenterol 2022;41:352-61. [PMID: 36029371 DOI: 10.1007/s12664-021-01227-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
541 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol 2022;77:479-502. [PMID: 35662478 DOI: 10.1016/j.jhep.2022.03.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
542 Li N, Zheng H, Yu Q, Chen F, Su X, Qiu X. Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma. J Int Med Res 2022;50:030006052211152. [DOI: 10.1177/03000605221115251] [Reference Citation Analysis]
543 Mai R, Bai T, Luo X, Wu G. Indocyanine Green Retention Test as a Predictor of Postoperative Complications in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. TCRM 2022;Volume 18:761-72. [DOI: 10.2147/tcrm.s363849] [Reference Citation Analysis]
544 Nadalin S, Peters M, Königsrainer A. Operative Therapiestrategien bei primären Lebertumoren, hepatozellulären und Cholangio- inkl. Gallenblasenkarzinomen. Allgemein- und Viszeralchirurgie up2date 2022;16:313-331. [DOI: 10.1055/a-1739-8909] [Reference Citation Analysis]
545 Xiang YJ, Wang K, Yu HM, Li XW, Cheng YQ, Wang WJ, Feng JK, Bo MH, Qin YY, Zheng YT, Shan YF, Zhou LP, Zhai J, Cheng SQ. Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma. Hepatol Res 2022;52:721-9. [PMID: 35536197 DOI: 10.1111/hepr.13773] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
546 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2022;42:2067-79. [PMID: 34515412 DOI: 10.1111/liv.15052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
547 Li W, Pei Y, Wang Z, Liu J. Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Front Oncol 2022;12:930868. [DOI: 10.3389/fonc.2022.930868] [Reference Citation Analysis]
548 de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'. J Hepatol 2022;77:567-8. [PMID: 35526788 DOI: 10.1016/j.jhep.2022.04.029] [Reference Citation Analysis]
549 Bhangui P. Liver transplantation and portal vein tumour thrombus: futile enterprise? Curr Opin Organ Transplant 2022;27:312-9. [PMID: 36354257 DOI: 10.1097/MOT.0000000000000997] [Reference Citation Analysis]
550 Lee HA, Seo YS, Shin I, Yoon WS, Lee HY, Rim CH. Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis. International Journal of Surgery 2022;104:106753. [DOI: 10.1016/j.ijsu.2022.106753] [Reference Citation Analysis]
551 Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2022;42:1955-68. [PMID: 34459096 DOI: 10.1111/liv.15046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
552 Park HJ, Kim SY, Singal AG, Lee SJ, Won HJ, Byun JH, Choi SH, Yokoo T, Kim MJ, Lim YS. Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high-risk patients. Liver Int 2022;42:2080-92. [PMID: 34817921 DOI: 10.1111/liv.15110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
553 Yoon JK, Choi JY, Rhee H, Park YN. MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification. Eur Radiol 2022;32:5119-33. [PMID: 35258675 DOI: 10.1007/s00330-022-08643-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
554 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2022;42:2055-66. [PMID: 34780081 DOI: 10.1111/liv.15101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
555 Ohtaka T, Shiba S, Shibuya K, Okazaki S, Miyasaka Y, Tomizawa K, Okamoto M, Ohno T. Long-term survivor of hepatocellular carcinoma treated with repeated carbon ion radiotherapy and transarterial chemoembolization: a case report. Clin J Gastroenterol 2022;15:771-775. [DOI: 10.1007/s12328-022-01642-4] [Reference Citation Analysis]
556 Wu Q, Chen Y, Du S, Hu Y, Yang P, Zeng Z. Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy. Clinical and Translational Radiation Oncology 2022. [DOI: 10.1016/j.ctro.2022.03.010] [Reference Citation Analysis]
557 Singal AG, Chen Y, Sridhar S, Mittal V, Fullington H, Shaik M, Waljee AK, Tiro J. Novel Application of Predictive Modeling: A Tailored Approach to Promoting HCC Surveillance in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2022;20:1795-1802.e2. [PMID: 33662594 DOI: 10.1016/j.cgh.2021.02.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
558 Auer TA, Sofue K, Ueshima E, Rauer N, Yamaguchi T, Gebauer B, Hamm B, Murakami T, Althoff C. Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study. JHC 2022;Volume 9:695-705. [DOI: 10.2147/jhc.s359705] [Reference Citation Analysis]
559 Li L, Zhang H, Zhao H, Shi D, Zheng C, Zhao Y, Yang X. Radiofrequency-thermal effect of cisplatin-crosslinked nanogels for triple therapies of ablation-chemo-embolization. Chemical Engineering Journal 2022. [DOI: 10.1016/j.cej.2022.138421] [Reference Citation Analysis]
560 Pu Q, Yu L, Wang X, Yan H, Xie Y, Du J, Yang Z. . OTT 2022;Volume 15:925-40. [DOI: 10.2147/ott.s373631] [Reference Citation Analysis]
561 Caviglia GP, Nicolosi A, Abate ML, Carucci P, Rosso C, Rolle E, Armandi A, Aneli S, Olivero A, Risso A, Ribaldone DG, Fermer C, Saracco GM, Gaia S, Bugianesi E. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. Current Oncology 2022;29:5457-5465. [DOI: 10.3390/curroncol29080431] [Reference Citation Analysis]
562 Huang J, Zhong J, Zhang J, Gong W, Ma L, Li L, Xiang B. Hepatectomy combined with targeted and immunotherapy for CNLC stage IIIb hepatocellular carcinoma: a single-arm clinical trials protocol.. [DOI: 10.1101/2022.07.29.22278175] [Reference Citation Analysis]
563 Sun N, Zhang C, Lee YT, Tran BV, Wang J, Kim H, Lee J, Zhang RY, Wang JJ, Hu J, Zhang Z, Alsudaney MS, Hou KC, Tang H, Zhang TX, Liang IY, Zhou Z, Chen M, Yeh AH, Li W, Zhou XJ, Chang HR, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Noureddin M, Ayoub WS, Kuo A, Sundaram V, Al-Ghaieb B, Palomique J, Kosari K, Kim IK, Todo T, Nissen NN, Tomasi ML, You S, Posadas EM, Wu JX, Wadehra M, Sim MS, Li Y, Wang HL, French SW, Lu SC, Wu L, Pei R, Liang L, Yang JD, Agopian VG, Tseng HR, Zhu Y. HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Hepatology 2022. [PMID: 35908246 DOI: 10.1002/hep.32692] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
564 Yang C, Luo YG, Yang HC, Yao ZH, Li X. Effects of Early TACE Refractoriness on Survival in Patients with Hepatocellular Carcinoma: A Real-World Study. J Hepatocell Carcinoma 2022;9:621-31. [PMID: 35903756 DOI: 10.2147/JHC.S373112] [Reference Citation Analysis]
565 Chai B, Xiang D, Wang W, Ren Y, Wang F, Wang J, Zhou G, Zheng C. Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE. Cancer Imaging 2022;22:38. [PMID: 35908071 DOI: 10.1186/s40644-022-00477-z] [Reference Citation Analysis]
566 Lim DH, Casadei-Gardini A, Lee MA, Lonardi S, Kim JW, Masi G, Chon HJ, Rimini M, Kim I, Cheon J, Hwang JE, Kang JH, Lim HY, Yoo C. Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib. Future Oncol 2022. [PMID: 35903991 DOI: 10.2217/fon-2022-0524] [Reference Citation Analysis]
567 Pagano D, Khouzam S, Magro B, Barbara M, Cintorino D, di Francesco F, Li Petri S, Bonsignore P, Calamia S, Deiro G, Cammà C, Canzonieri M, Gruttadauria S. How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation? Front Oncol 2022;12:929607. [DOI: 10.3389/fonc.2022.929607] [Reference Citation Analysis]
568 Qian X, Liu Y, Wu F, Zhang S, Gong J, Nan Y, Hu B, Chen J, Zhao J, Chen X, Pan W, Dang S, Lu F. The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients. Viruses 2022;14:1669. [DOI: 10.3390/v14081669] [Reference Citation Analysis]
569 Chen G, Chen H, Huang X, Cheng S, Zheng S, Wu Y, Zheng T, Chen X, Guo X, Zhang Z, Xie X, Zhang B. Recurrence Outcome in Hepatocellular Carcinoma within Milan Criteria Undergoing Microwave Ablation with or without Transarterial Chemoembolization. Medicina 2022;58:1016. [DOI: 10.3390/medicina58081016] [Reference Citation Analysis]
570 Renzulli M, Pecorelli A, Brandi N, Brocchi S, Tovoli F, Granito A, Carrafiello G, Ierardi AM, Golfieri R. The Feasibility of Liver Biopsy for Undefined Nodules in Patients under Surveillance for Hepatocellular Carcinoma: Is Biopsy Really a Useful Tool? JCM 2022;11:4399. [DOI: 10.3390/jcm11154399] [Reference Citation Analysis]
571 da Fonseca LG, Araujo RLC. Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. World J Gastroenterol 2022; 28(28): 3573-3585 [DOI: 10.3748/wjg.v28.i28.3573] [Reference Citation Analysis]
572 Fernandes DA, Dal Lago EA, Oliver FA, Loureiro BMC, Martins DL, Penachim TJ, Barros RHO, Araújo Filho JAB, Eloy da Costa LB, da Silva ÁMO, de Ataíde EC, Boin IFSF, Caserta NMG. Hepatobiliary phases in magnetic resonance imaging using liver-specific contrast for focal lesions in clinical practice. World J Hepatol 2022; 14(7): 1459-1469 [DOI: 10.4254/wjh.v14.i7.1459] [Reference Citation Analysis]
573 Nakai M, Morikawa K, Hosoda S, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Ohara M, Sho T, Suda G, Ogawa K, Sakamoto N. Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma. World J Hepatol 2022; 14(7): 1480-1494 [DOI: 10.4254/wjh.v14.i7.1480] [Reference Citation Analysis]
574 Chen M, Fan Q, Wu X, Yu T. Three Effects of Β-Catenin Factors in Liver Cancer and Its Treatment. HSET 2022;6:101-110. [DOI: 10.54097/hset.v6i.950] [Reference Citation Analysis]
575 Meng Z, Xue H, Wang T, Chen B, Dong X, Yang L, Dai J, Lou X, Xia F. Aggregation-induced emission photosensitizer-based photodynamic therapy in cancer: from chemical to clinical. J Nanobiotechnology 2022;20:344. [PMID: 35883086 DOI: 10.1186/s12951-022-01553-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
576 Öcal O, Zech CJ, Fabritius MP, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Berg T, Sengel C, Bargellini I, Iezzi R, Benito A, Pech M, Gasbarrini A, Sangro B, Malfertheiner P, Ricke J, Seidensticker M. Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression. Eur Radiol 2022. [PMID: 35881180 DOI: 10.1007/s00330-022-09000-1] [Reference Citation Analysis]
577 Ghidaglia J, Golse N, Pascale A, Sebagh M, Besson FL. 18F-FDG /18F-Choline Dual-Tracer PET Behavior and Tumor Differentiation in HepatoCellular Carcinoma. A Systematic Review. Front Med (Lausanne) 2022;9:924824. [PMID: 35872754 DOI: 10.3389/fmed.2022.924824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
578 Wu C, Chen J, Fan Y, Zhao M, He X, Wei Y, Ge W, Liu Y. Nomogram Based on CT Radiomics Features Combined With Clinical Factors to Predict Ki-67 Expression in Hepatocellular Carcinoma. Front Oncol 2022;12:943942. [PMID: 35875154 DOI: 10.3389/fonc.2022.943942] [Reference Citation Analysis]
579 Wang H, Wang X, Ye X, Ju Y, Cao N, Wang S, Cai J. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma. BMC Cancer 2022;22:814. [PMID: 35879685 DOI: 10.1186/s12885-022-09861-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
580 Zhao Y, Haroun RR, Sahu S, Schernthaner RE, Smolka S, Lin MD, Hong KK, Georgiades C, Duran R. Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment? Cancers (Basel) 2022;14:3615. [PMID: 35892874 DOI: 10.3390/cancers14153615] [Reference Citation Analysis]
581 van Dijk AM, Coppens BJP, van Beers MA, Bruins Slot AS, Verstraete CJR, de Bruijne J, Vleggaar FP, van Erpecum KJ. Nutritional status in patients with hepatocellular carcinoma: Potential relevance for clinical outcome. Eur J Intern Med 2022:S0953-6205(22)00250-3. [PMID: 35902333 DOI: 10.1016/j.ejim.2022.07.002] [Reference Citation Analysis]
582 Jang E. Hyperoside as a Potential Natural Product Targeting Oxidative Stress in Liver Diseases. Antioxidants 2022;11:1437. [DOI: 10.3390/antiox11081437] [Reference Citation Analysis]
583 Zhang Z, Li C, Liao W, Huang Y, Wang Z. A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus. Cancers (Basel) 2022;14:3619. [PMID: 35892878 DOI: 10.3390/cancers14153619] [Reference Citation Analysis]
584 Herman P, Fonseca GM, Coelho FF, Kruger JAP, Makdissi FF, Jeismann VB, Carrilho FJ, D'Albuquerque LAC, Nahas SC. Two decades of liver resection with a multidisciplinary approach in a single institution: What has changed? Analysis of 1409 cases. Clinics (Sao Paulo) 2022;77:100088. [PMID: 35901605 DOI: 10.1016/j.clinsp.2022.100088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
585 Cai S, Lin X, Sun Y, Lin Z, Wang X, Lin N, Zhao X. Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma. Eur J Radiol 2022;154:110449. [PMID: 35901599 DOI: 10.1016/j.ejrad.2022.110449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
586 Müller L, Gairing SJ, Kloeckner R, Foerster F, Weinmann A, Mittler J, Stoehr F, Emrich T, Düber C, Galle PR, Hahn F. Baseline Splenic Volume Outweighs Immuno-Modulated Size Changes with Regard to Survival Outcome in Patients with Hepatocellular Carcinoma under Immunotherapy. Cancers 2022;14:3574. [DOI: 10.3390/cancers14153574] [Reference Citation Analysis]
587 Gelardi F, Rodari M, Pini C, Zanca R, Artesani A, Tosi G, Chiti A, Sollini M. ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization. Front Nucl Med 2022;2. [DOI: 10.3389/fnume.2022.934446] [Reference Citation Analysis]
588 Gairing SJ, Müller L, Penzkofer L, Stoehr F, Michel M, Shmanko K, Galle PR. Diagnostik und Therapie des primären Leberzellkarzinoms. Gastroenterologie 2022. [DOI: 10.1007/s11377-022-00636-5] [Reference Citation Analysis]
589 Matsumoto H, Tsuchiya K, Nakanishi H, Hayakawa Y, Yasui Y, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Ishido S, Yamada M, Keitoku T, Nobusawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Tamaki N, Takahashi Y, Kurosaki M, Asahina Y, Okamoto R, Izumi N. Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers 2022;14:3551. [DOI: 10.3390/cancers14143551] [Reference Citation Analysis]
590 Vidili G, Arru M, Solinas G, Calvisi DF, Meloni P, Sauchella A, Turilli D, Fabio C, Cossu A, Madeddu G, Babudieri S, Zocco MA, Iannetti G, Di Lembo E, Delitala AP, Manetti R. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis. World J Gastroenterol 2022; 28(27): 3488-3502 [DOI: 10.3748/wjg.v28.i27.3488] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
591 Tabrizian P, Holzner ML, Mehta N, Halazun K, Agopian VG, Yao F, Busuttil RW, Roberts J, Emond JC, Samstein B, Brown RS Jr, Najjar M, Chapman WC, Doyle MM, Florman SS, Schwartz ME, Llovet JM. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma. JAMA Surg 2022. [PMID: 35857294 DOI: 10.1001/jamasurg.2022.2800] [Reference Citation Analysis]
592 Chen S, Yuan B, Yu W, Wang X, He C, Chen C. Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: A propensity score-matching cohort study. J Surg Oncol 2022. [PMID: 35856502 DOI: 10.1002/jso.27023] [Reference Citation Analysis]
593 Hu Y, Tang C, Zhu W, Ye H, Lin Y, Wang R, Zhou T, Wen S, Yang J, Fang C. Identification of chromosomal instability-associated genes as hepatocellular carcinoma progression-related biomarkers to guide clinical diagnosis, prognosis and therapy. Comput Biol Med 2022;148:105896. [PMID: 35868048 DOI: 10.1016/j.compbiomed.2022.105896] [Reference Citation Analysis]
594 Feng ZH, Wang MD, Chen Z, Sun LY, Xu X, Kong QY, Chen ZX, Zeng YY, Liang YJ, Chen ZY, Wang H, Zhou YH, Chen TH, Yao LQ, Li C, Pawlik TM, Lau WY, Shen F, Yang T. Risk factors and long-term prognosis of beyond-Milan recurrence after hepatectomy for BCLC stage 0/A hepatocellular carcinoma: A large-scale multicenter study. Surgery 2022:S0039-6060(22)00408-1. [PMID: 35868902 DOI: 10.1016/j.surg.2022.05.023] [Reference Citation Analysis]
595 Safcak D, Drazilova S, Gazda J, Andrasina I, Adamcova-selcanova S, Balazova L, Barila R, Mego M, Rac M, Skladany L, Zigrai M, Janicko M, Jarcuska P. Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers. JCM 2022;11:4183. [DOI: 10.3390/jcm11144183] [Reference Citation Analysis]
596 Zhang H, Du X, Dong H, Xu W, Zhou P, Liu S, Qing X, Zhang Y, Yang M, Zhang Y. Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database. BMC Gastroenterol 2022;22:348. [PMID: 35854221 DOI: 10.1186/s12876-022-02424-5] [Reference Citation Analysis]
597 Heo S, Choi SH, Hong S, Kim DW. Visualization Score of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging: The Effect on the Diagnostic Accuracy for Hepatocellular Carcinoma. J Magn Reson Imaging 2022. [PMID: 35849038 DOI: 10.1002/jmri.28357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
598 Zheng Y, Ji S, Li X, Feng Q. Active ingredients and molecular targets of Taraxacum mongolicum against hepatocellular carcinoma: network pharmacology, molecular docking, and molecular dynamics simulation analysis. PeerJ 2022;10:e13737. [PMID: 35873910 DOI: 10.7717/peerj.13737] [Reference Citation Analysis]
599 Zhang SB, Hu ZX, Xing ZQ, Li A, Zhou XB, Liu JH. Portal vein thrombosis in a noncirrhotic patient after hemihepatectomy: A case report and review of literature. World J Clin Cases 2022; 10(20): 7130-7137 [DOI: 10.12998/wjcc.v10.i20.7130] [Reference Citation Analysis]
600 Howell J, Majumdar A, Fink M, Byrne M, Mccaughan G, Strasser SI, Crawford M, Hodgkinson P, Stuart KA, Tallis C, Chen J, Wigg A, Jones R, Jaques B, Jeffrey G, Adams L, Wallace MC, Gane E, Thompson A, Gow P. The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand. Transplantation Direct 2022;8:e1345. [DOI: 10.1097/txd.0000000000001345] [Reference Citation Analysis]
601 Kang H, Lee JY, Lee JM. The Principle of Contrast-enhanced Ultrasound and the Diagnosis of Hepatocellular Carcinoma. Korean J Abdom Radiol 2022;6:12-21. [DOI: 10.52668/kjar.2022.00129] [Reference Citation Analysis]
602 Menshikov KV, Sultanbaev AV, Musin SI, Rakhmatullina IR, Menshikova IA, Abdeev RR, Sultanbaeva NI, Popova EV, Serebrennikov GA. Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. Kreativnaâ hirurgiâ i onkologiâ 2022;12:139-150. [DOI: 10.24060/2076-3093-2022-12-2-139-150] [Reference Citation Analysis]
603 Wang J, Zhang Z, Shang D, Li J, Liu C, Yu P, Wang M, Liu D, Miao H, Li S, Zhang B, Huang A, Zhang Y, Chen S, Qi X. Noninvasively Assessed Portal Hypertension Grade Predicts Post-Hepatectomy Liver Failure in Patients With HepatocellCarcinoma: A Multicenter Study. Front Oncol 2022;12:934870. [DOI: 10.3389/fonc.2022.934870] [Reference Citation Analysis]
604 Pérez-López A, Martín-Sabroso C, Gómez-Lázaro L, Torres-Suárez AI, Aparicio-Blanco J. Embolization therapy with microspheres for the treatment of liver cancer: State-of-the-art of clinical translation. Acta Biomater 2022:S1742-7061(22)00412-3. [PMID: 35842035 DOI: 10.1016/j.actbio.2022.07.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
605 Xu M, Xu D, Dong G, Ren Z, Zhang W, Aji T, Zhao Q, Chen X, Jiang T. The Safety and Efficacy of Nanosecond Pulsed Electric Field in Patients With Hepatocellular Carcinoma: A Prospective Phase 1 Clinical Study Protocol. Front Oncol 2022;12:869316. [DOI: 10.3389/fonc.2022.869316] [Reference Citation Analysis]
606 Cheng C, Lai Y, Hung H, Lee J, Wang Y, Wu T, Lee C, Wu T, Chou H, Chan K, Lee W. Recurrence Patterns After Hepatectomy With Very Narrow Resection Margins for Hepatocellular Carcinoma. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.926728] [Reference Citation Analysis]
607 Yang D, Su Y, Zhao F, Chen C, Zhao K, Xiong X, Ding Y. A Practical Nomogram and Risk Stratification System Predicting the Cancer-Specific Survival for Patients With Advanced Hepatocellular Carcinoma. Front Oncol 2022;12:914192. [DOI: 10.3389/fonc.2022.914192] [Reference Citation Analysis]
608 Zhang D, Feng D, He X, Zhang X, Li L, Li Z, Niu X, Zhuang Y, Liu Z, Gao X, Wang H. The Combination of AFP and “Up-To-Seven” Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients. Front Oncol 2022;12:959151. [DOI: 10.3389/fonc.2022.959151] [Reference Citation Analysis]
609 Bai S, Hu L, Liu J, Sun M, Sun Y, Xue F. Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus–related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection. Front Oncol 2022;12:919824. [DOI: 10.3389/fonc.2022.919824] [Reference Citation Analysis]
610 Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, Inglis P, Camacho JC, Nezami N. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:3351. [PMID: 35884412 DOI: 10.3390/cancers14143351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
611 Schneider KM, Mohs A, Gui W, Galvez EJC, Candels LS, Hoenicke L, Muthukumarasamy U, Holland CH, Elfers C, Kilic K, Schneider CV, Schierwagen R, Strnad P, Wirtz TH, Marschall HU, Latz E, Lelouvier B, Saez-Rodriguez J, de Vos W, Strowig T, Trebicka J, Trautwein C. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nat Commun 2022;13:3964. [PMID: 35803930 DOI: 10.1038/s41467-022-31312-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
612 Marzi L, Mega A, Gitto S, Pelizzaro F, Seeber A, Spizzo G. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Cancers 2022;14:3332. [DOI: 10.3390/cancers14143332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
613 Crouchet E, Li S, Sojoodi M, Bandiera S, Fujiwara N, El Saghire H, Zhu S, Qian T, Rasha FA, Del Zompo F, Barrett SC, Schaeffer E, Oudot MA, Ponsolles C, Durand SC, Ghoshal S, Arora G, Giannone F, Chung RT, Slovic N, Van Renne N, Felli E, Pessaux P, Lupberger J, Pochet N, Schuster C, Tanabe KK, Hoshida Y, Fuchs BC, Baumert TF. Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. JCI Insight 2022;7:e159254. [PMID: 35801591 DOI: 10.1172/jci.insight.159254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
614 Tanaka T, Takata K, Yokoyama K, Fukuda H, Yamauchi R, Fukunaga A, Shakado S, Sakisaka S, Hirai F. Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. Current Oncology 2022;29:4799-4810. [DOI: 10.3390/curroncol29070381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
615 Wu C, Yu S, Zhang Y, Zhu L, Chen S, Liu Y. CT-Based Radiomics Nomogram Improves Risk Stratification and Prediction of Early Recurrence in Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2022;12:896002. [DOI: 10.3389/fonc.2022.896002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
616 Baumgartner R, Gilg S, Björnsson B, Hasselgren K, Ghorbani P, Sauter C, Stål P, Sandstöm P, Sparrelid E, Engstrand J. Impact of post-hepatectomy liver failure on morbidity and short- and long-term survival after major hepatectomy. BJS Open 2022;6:zrac097. [PMID: 35849062 DOI: 10.1093/bjsopen/zrac097] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
617 Long X, Zhang L, Wang WQ, Zhang EL, Lv X, Huang ZY. Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review. Onco Targets Ther 2022;15:703-16. [PMID: 35791424 DOI: 10.2147/OTT.S365652] [Reference Citation Analysis]
618 Johnson PJ, Innes H, Hughes DM, Kalyuzhnyy A, Kumada T, Toyoda H. Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify. Br J Cancer 2022. [PMID: 35798825 DOI: 10.1038/s41416-022-01851-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
619 Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med 2022. [PMID: 35796150 DOI: 10.1111/joim.13531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
620 Kim M, Cho Y, Kim E, Choe J, Park J, Lee J, Lee J, Moon S, Kim Y, Kim S, Choi E. Cellular Prion Protein Is Closely Associated with Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma. Diagnostics 2022;12:1635. [DOI: 10.3390/diagnostics12071635] [Reference Citation Analysis]
621 Schütte K, Kupčinskas J, Morkunas E, Öcal O, Schinner R, Seidensticker M, De Toni EN, Ben Khaled N, Pech M, Palmer D, Berg T, Sengel C, Basu B, Valle JW, Benckert J, Gasbarrini A, Sangro B, Malfertheiner P, Ricke J. Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial. Front Gastroenterol 2022;1. [DOI: 10.3389/fgstr.2022.939192] [Reference Citation Analysis]
622 Zhao H, Chen C, Song H, Wang X, Zhang L, Zhao H, He J. Single-cell RNA Sequencing Analysis Reveals New Immune Disorder Complexities in Hypersplenism. Front Immunol 2022;13:921900. [DOI: 10.3389/fimmu.2022.921900] [Reference Citation Analysis]
623 Li X, Fu Z, Chen X, Cao K, Zhong J, Liu L, Ding N, Zhang X, Zhai J, Qu Z. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. Front Oncol 2022;12:950266. [DOI: 10.3389/fonc.2022.950266] [Reference Citation Analysis]
624 Caparroz C, Forner A, Rimola J, Darnell A, García-Criado Á, Ayuso JR, Reig M, Bruix J, Ayuso C. Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoxetic acid MR. Radiol Oncol 2022. [PMID: 35776837 DOI: 10.2478/raon-2022-0024] [Reference Citation Analysis]
625 Mueller PP, Chen Q, Ayer T, Nemutlu GS, Hajjar A, Bethea ED, Peters MLB, Lee BP, Janjua NZ, Kanwal F, Chhatwal J. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. J Hepatol 2022;77:55-62. [PMID: 35157959 DOI: 10.1016/j.jhep.2022.01.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
626 Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, Parikh ND, Marrero JA. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol 2022;77:128-39. [PMID: 35139400 DOI: 10.1016/j.jhep.2022.01.023] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 24.0] [Reference Citation Analysis]
627 Celik F, Bektas H. The role of nursing in the hepatic rehabilitation of patients with liver cirrhosis. Gastrointestinal Nursing 2022;20:S18-S25. [DOI: 10.12968/gasn.2022.20.sup6.s18] [Reference Citation Analysis]
628 Gnanasegaran G, Agrawal K, Wan S. 18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies. PET Clin 2022;17:369-88. [PMID: 35717098 DOI: 10.1016/j.cpet.2022.03.007] [Reference Citation Analysis]
629 Kelley RK, Rimassa L, Cheng A, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo B, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00326-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
630 Tsai MC, Yang SS, Lin CC, Wang WL, Hsu YC, Chen YS, Hu JT, Lin JY, Yu ML, Lin CW. Association of Heavy Alcohol Intake and ALDH2 rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus-Related Cirrhosis. JAMA Netw Open 2022;5:e2223511. [PMID: 35877121 DOI: 10.1001/jamanetworkopen.2022.23511] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
631 Ogushi K, Chuma M, Numata K, Nozaki A, Moriya S, Uojima H, Kondo M, Morimoto M, Maeda S. Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients. Eur J Gastroenterol Hepatol 2022;34:774-81. [PMID: 35102114 DOI: 10.1097/MEG.0000000000002346] [Reference Citation Analysis]
632 Yang P, Li N. Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm. J Int Med Res 2022;50:3000605221111281. [PMID: 35861264 DOI: 10.1177/03000605221111281] [Reference Citation Analysis]
633 An C, Yang H, Yu X, Han Z, Cheng Z, Liu F, Dou J, Li B, Li Y, Li Y, Yu J, Liang P. A Machine Learning Model Based on Health Records for Predicting Recurrence After Microwave Ablation of Hepatocellular Carcinoma. JHC 2022;Volume 9:671-84. [DOI: 10.2147/jhc.s358197] [Reference Citation Analysis]
634 Guan H, Wang C, Zhao Z, Han S. Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China. Adv Ther 2022;39:3334-46. [PMID: 35644019 DOI: 10.1007/s12325-022-02185-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
635 U MRA, Shen EY, Cartlidge C, Alkhatib A, Thursz MR, Waked I, Gomaa AI, Holmes E, Sharma R, Taylor-Robinson SD. Optimized Systematic Review Tool: Application to Candidate Biomarkers for the Diagnosis of Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev 2022;31:1261-74. [PMID: 35545293 DOI: 10.1158/1055-9965.EPI-21-0687] [Reference Citation Analysis]
636 Baker T, Tabrizian P, Zendejas I, Gamblin TC, Kazimi M, Boudjema K, Geller D, Salem R. Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group. HPB (Oxford) 2022;24:1007-18. [PMID: 35012876 DOI: 10.1016/j.hpb.2021.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
637 Altinmakas E, Taouli B. Abbreviated Liver Magnetic Resonance Imaging Protocols and Applications. Radiologic Clinics of North America 2022. [DOI: 10.1016/j.rcl.2022.04.002] [Reference Citation Analysis]
638 Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology 2022;76:139-54. [PMID: 35030279 DOI: 10.1002/hep.32341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
639 Schoenberger H, Chong N, Fetzer DT, Rich NE, Yokoo T, Khatri G, Olivares J, Parikh ND, Yopp AC, Marrero JA, Singal AG. Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2022;20:1561-1569.e4. [PMID: 34119640 DOI: 10.1016/j.cgh.2021.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
640 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de la Tijera F, Huitzil-melendez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. II Consenso mexicano de carcinoma hepatocelular. Parte II: tratamiento. Revista de Gastroenterología de México 2022;87:362-379. [DOI: 10.1016/j.rgmx.2022.01.006] [Reference Citation Analysis]
641 Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions. J Hepatol 2022;77:219-36. [PMID: 35157957 DOI: 10.1016/j.jhep.2022.01.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
642 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de la Tijera F, Huitzil-melendez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. Revista de Gastroenterología de México (English Edition) 2022;87:362-379. [DOI: 10.1016/j.rgmxen.2022.01.004] [Reference Citation Analysis]
643 Pelizzaro F, Peserico G, D'Elia M, Cazzagon N, Russo FP, Vitale A, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA) Study Group. Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. Dig Liver Dis 2022;54:927-36. [PMID: 34580038 DOI: 10.1016/j.dld.2021.08.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
644 Lu HZ, Mai RY, Wang XB, Chen J, Bai T, Ma L, Xiang BD, Cheng SQ, Guo WX, Li LQ, Ye JZ. Developmental artificial neural network model to evaluate the preoperative safe limit of future liver remnant volume for HCC combined with clinically significant portal hypertension. Future Oncol 2022;18:2683-94. [PMID: 35699041 DOI: 10.2217/fon-2021-1297] [Reference Citation Analysis]
645 Sessa A, Mulé S, Brustia R, Regnault H, Galletto Pregliasco A, Rhaiem R, Leroy V, Sommacale D, Luciani A, Calderaro J, Amaddeo G. Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge. JHC 2022;Volume 9:661-70. [DOI: 10.2147/jhc.s364703] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
646 Piscaglia F. Microwave ablation in skilled hands. A treatment opportunity gaining room in the field of single HCC 3-5 cm. Hepatology 2022;76:6-8. [PMID: 35092021 DOI: 10.1002/hep.32370] [Reference Citation Analysis]
647 Liu J, Liu B, Diao G, Zhang Z. Tissue factor promotes HCC carcinogenesis by inhibiting BCL2-dependent autophagy. Bulletin du Cancer 2022;109:795-804. [DOI: 10.1016/j.bulcan.2022.04.007] [Reference Citation Analysis]
648 Chen ZH, Zhang XP, Feng JK, Li LQ, Zhang F, Hu YR, Zhong CQ, Wang K, Chai ZT, Wei XB, Shi J, Guo WX, Wu MC, Lau WY, Cheng SQ. Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China. HPB (Oxford) 2022;24:1063-73. [PMID: 34961677 DOI: 10.1016/j.hpb.2021.11.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
649 Chavez-tapia NC, Murúa-beltrán Gall S, Ordoñez-vázquez AL, Nuño-lambarri N, Vidal-cevallos P, Uribe M. Understanding the Role of Metabolic Syndrome as a Risk Factor for Hepatocellular Carcinoma. JHC 2022;Volume 9:583-93. [DOI: 10.2147/jhc.s283840] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
650 Pavlides M, Mózes FE, Harrison SA. Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back? Gut 2022;71:1453-4. [PMID: 34706868 DOI: 10.1136/gutjnl-2021-326313] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
651 Rothenberger NJ, Yu Q, Ramasamy SK, Van Ha T, Zangan S, Navuluri R, Ahmed O. Segmental Yttrium-90 Radioembolization as an Initial Treatment for Solitary Unresectable HCC. The Arab Journal of Interventional Radiology 2022;06:056-062. [DOI: 10.1055/s-0042-1758698] [Reference Citation Analysis]
652 Alnammi M, Wortman J, Therrien J, Afnan J. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review. Abdom Radiol (NY) 2022;47:2299-313. [PMID: 35524803 DOI: 10.1007/s00261-022-03526-0] [Reference Citation Analysis]
653 Wang Z, Liu M, Zhang DZ, Wu SS, Hong ZX, He GB, Yang H, Xiang BD, Li X, Jiang TA, Li K, Tang Z, Huang F, Lu M, Chen JA, Lin YC, Lu X, Wu YQ, Zhang XW, Zhang YF, Cheng C, Ye HL, Wang LT, Zhong HG, Zhong JH, Wang L, Chen M, Liang FF, Chen Y, Xu YS, Yu XL, Cheng ZG, Liu FY, Han ZY, Tang WZ, Yu J, Liang P. Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC. Hepatology 2022;76:66-77. [PMID: 35007334 DOI: 10.1002/hep.32323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
654 Spearman CW, Dusheiko G, Jonas E, Abdo A, Afihene M, Cunha L, Desalegn H, Kassianides C, Katsidzira L, Kramvis A, Lam P, Lesi OA, Micah EA, Musabeyezu E, Ndow G, Nnabuchi CV, Ocama P, Okeke E, Rwegasha J, Shewaye AB, Some FF, Tzeuton C, Sonderup MW. Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00041-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
655 Reeves HL, Reicher J, Priona G, Manas DM, Littler P. Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England. Frontline Gastroenterol 2023;14:45-51. [PMID: 36561784 DOI: 10.1136/flgastro-2022-102137] [Reference Citation Analysis]
656 Fei Z, Wang Y, Gu Y, Xie R, Hao Q, Jiang Y. CircKIF5B Promotes Hepatocellular Carcinoma Progression by Regulating the miR-192 Family/XIAP Axis. Front Oncol 2022;12:916246. [DOI: 10.3389/fonc.2022.916246] [Reference Citation Analysis]
657 Chen Y, Hu H, Yuan X, Fan X, Zhang C. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Front Immunol 2022;13:896752. [PMID: 35757756 DOI: 10.3389/fimmu.2022.896752] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
658 Yuan G, Xie F, Song Y, Li Q, Li R, Hu X, Zang M, Cheng X, Lu G, Huang J, Fan W, Rong X, Sun J, Chen J. Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. Front Immunol 2022;13:868809. [PMID: 35757765 DOI: 10.3389/fimmu.2022.868809] [Reference Citation Analysis]
659 Li D, Yang ZY. Concerns Regarding Robotic vs Laparoscopic Right and Extended Right Hepatectomy. JAMA Surg 2022. [PMID: 35767268 DOI: 10.1001/jamasurg.2022.2239] [Reference Citation Analysis]
660 Zhao J, Zeng G, Lin E, Cai C, Li P, Zou B, Li J. Combined HIF-1α and SHH Up-Regulation Is a Potential Biomarker to Predict Poor Prognosis in Postoperative Hepatocellular Carcinoma. J Invest Surg 2022;:1-8. [PMID: 35768071 DOI: 10.1080/08941939.2022.2090034] [Reference Citation Analysis]
661 Wang Y, Li X, Yu J, Cheng Z, Hou Q, Liang P. Prognostic Nutritional Index in Hepatocellular Carcinoma Patients With Hepatitis B Following US-Guided Percutaneous Microwave Ablation: A Retrospective Study With 1,047 Patients. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.878737] [Reference Citation Analysis]
662 Li YM, Zhu YM, Gao LM, Han ZW, Chen XJ, Yan C, Ye RP, Cao DR. Radiomic analysis based on multi-phase magnetic resonance imaging to predict preoperatively microvascular invasion in hepatocellular carcinoma. World J Gastroenterol 2022; 28(24): 2733-2747 [DOI: 10.3748/wjg.v28.i24.2733] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
663 Adetutu Adisa R, Adegboyega Sulaimon L. Hepatocellular Carcinoma. Hepatotoxicity [Working Title] 2022. [DOI: 10.5772/intechopen.105473] [Reference Citation Analysis]
664 Xu X, Huang A, Guo DZ, Wang YP, Zhang SY, Yan JY, Wang XY, Cao Y, Fan J, Zhou J, Fu XT, Shi YH. Integration of Inflammation-Immune Factors to Build Prognostic Model Predictive of Prognosis and Minimal Residual Disease for Hepatocellular Carcinoma. Front Oncol 2022;12:893268. [PMID: 35756674 DOI: 10.3389/fonc.2022.893268] [Reference Citation Analysis]
665 Carissimi F, Scotti MA, Ciulli C, Fogliati A, Uggeri F, Chiarelli M, Braga M, Romano F, Garancini M. COVID-19 and Liver Surgery: How the Pandemic Affected an Italian Medium-Volume HBP Center. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.918348] [Reference Citation Analysis]
666 Xie Z, Peng Z, Zou Y, Xiao H, Li B, Zhou Q, Chen S, Xu L, Shen J, Mo Y, Peng S, Kuang M, Long J, Feng ST. Non-invasive diagnosis strategy of hepatocellular carcinoma in low-risk population. BMC Cancer 2022;22:709. [PMID: 35761201 DOI: 10.1186/s12885-022-09812-w] [Reference Citation Analysis]
667 Yan XH, Yue ZD, Zhao HW, Wang L, Fan ZH, Wu YF, Meng MM, Zhang K, Jiang L, Ding HG, Zhang YN, Yang YP, Liu FQ. Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein tumor thrombosis with cirrhotic portal hypertension. World J Gastrointest Surg 2022; 14(6): 567-579 [DOI: 10.4240/wjgs.v14.i6.567] [Reference Citation Analysis]
668 Zhang S, Zhong BY, Zhang L, Wang WS, Ni CF. Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. World J Gastrointest Surg 2022; 14(6): 528-537 [DOI: 10.4240/wjgs.v14.i6.528] [Reference Citation Analysis]
669 Li B, Ge YZ, Yan WW, Gong B, Cao K, Zhao R, Li C, Zhang YW, Jiang YH, Zuo S. DNASE1L3 inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with β-catenin to promote its ubiquitin degradation pathway. Cell Prolif 2022;:e13273. [PMID: 35748106 DOI: 10.1111/cpr.13273] [Reference Citation Analysis]
670 Zhang Z, Shang J, Hu B, Shi H, Cao Y, Li J, Jiao T, Zhang W, Lu S. Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature. Front Immunol 2022;13:836576. [DOI: 10.3389/fimmu.2022.836576] [Reference Citation Analysis]
671 Hucke F, Pinter M, Hucke M, Bota S, Bolf D, Hackl M, Peck-radosavljevic M. Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018. Cancers 2022;14:3093. [DOI: 10.3390/cancers14133093] [Reference Citation Analysis]
672 He C, Ge N, Wang X, Li H, Chen S, Yang Y. Conversion Therapy of Large Unresectable Hepatocellular Carcinoma With Ipsilateral Portal Vein Tumor Thrombus Using Portal Vein Embolization Plus Transcatheter Arterial Chemoembolization. Front Oncol 2022;12:923566. [DOI: 10.3389/fonc.2022.923566] [Reference Citation Analysis]
673 Zhang WB, Hou SZ, Chen YL, Mao F, Dong Y, Chen JG, Wang WP. Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of α-Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients. Front Oncol 2022;12:862297. [PMID: 35720017 DOI: 10.3389/fonc.2022.862297] [Reference Citation Analysis]
674 Tian Z, Hong B, Chen J, Tang Z. Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis. Front Oncol 2022;12:891724. [PMID: 35719978 DOI: 10.3389/fonc.2022.891724] [Reference Citation Analysis]
675 Luo GL, Guo BQ, Wu LX, Shen YX, Xie T. Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study. Evid Based Complement Alternat Med 2022;2022:1976788. [PMID: 35711496 DOI: 10.1155/2022/1976788] [Reference Citation Analysis]
676 Menshikov KV, Sultanbaev AV, Musin SI, Menshikova IA, Abdeev RR, Sultanbaeva NI, Nigmatullin VG, Popova EV. Immunotherapy of advanced hepatocellular carcinoma: case report and literature review. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-9-31-39] [Reference Citation Analysis]
677 Yang D, Su Y, Zhao F, Chen C, Zhao K, Xiong X, Ding Y. A Practical Nomogram and Risk Stratification System Predicting Cancer-Specific Survival for Hepatocellular Carcinoma Patients With Severe Liver Fibrosis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.920589] [Reference Citation Analysis]
678 Hwang JA, Jeong WK, Kang HJ, Lee ES, Park HJ, Lee JM. Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma. Eur Radiol 2022. [PMID: 35705829 DOI: 10.1007/s00330-022-08900-6] [Reference Citation Analysis]
679 Degroote H, Geerts A, Verhelst X, Van Vlierberghe H. Different Models to Predict the Risk of Recurrent Hepatocellular Carcinoma in the Setting of Liver Transplantation. Cancers (Basel) 2022;14:2973. [PMID: 35740638 DOI: 10.3390/cancers14122973] [Reference Citation Analysis]
680 Kale A. Hepatocellular Carcinoma: Diagnosis and Surveillance. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.99839] [Reference Citation Analysis]
681 S. Ahmad M, Makhamrah O, Hjouj M. Multimodal Imaging of Hepatocellular Carcinoma Using Dynamic Liver Phantom. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.99861] [Reference Citation Analysis]
682 Giakoustidis A, Koffas A, Giakoustidis D, N. Papadopoulos V. Minimally Invasive Surgery for Hepatocellular Carcinoma; Latest Advances. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.99840] [Reference Citation Analysis]
683 Ding WZ, Liu S, Liu F, Cheng Z, Yu X, Han ZY, Yu J, Liang P. Are all local tumour progressions of HCC related to thermal ablation? A study of the causes and classification of local tumour progression. Eur Radiol 2022. [PMID: 35704110 DOI: 10.1007/s00330-022-08913-1] [Reference Citation Analysis]
684 Charonpongsuntorn C. Systemic Therapy in Hepatocellular Carcinoma. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.100257] [Reference Citation Analysis]
685 Popa A, Sporea I, Bende F, Popescu A, Fofiu R, Borlea A, Bâldea V, Pascu A, Foncea CG, Cotrău R, Șirli R. The Non-Invasive Ultrasound-Based Assessment of Liver Viscosity in a Healthy Cohort. Diagnostics 2022;12:1451. [DOI: 10.3390/diagnostics12061451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
686 Petrara MR, Shalaby S, Ruffoni E, Taborelli M, Carmona F, Giunco S, Del Bianco P, Piselli P, Serraino D, Cillo U, Dolcetti R, Burra P, De Rossi A. Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients. Front Oncol 2022;12:899170. [DOI: 10.3389/fonc.2022.899170] [Reference Citation Analysis]
687 Dong Y, Wang WP, Lee WJ, Meloni MF, Clevert DA, Chammas MC, Tannapfel A, Forgione A, Piscaglia F, Dietrich CF. Contrast-Enhanced Ultrasound Features of Histopathologically Proven Hepatocellular Carcinoma in the Non-cirrhotic Liver: A Multicenter Study. Ultrasound Med Biol 2022:S0301-5629(22)00393-3. [PMID: 35710501 DOI: 10.1016/j.ultrasmedbio.2022.05.005] [Reference Citation Analysis]
688 Fan W, Zhu B, Yue S, Zheng X, Zou X, Li F, Qiao L, Wu Y, Xue M, Wang H, Tang Y, Li J. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis. Cancer Med 2023;12:61-72. [PMID: 35698292 DOI: 10.1002/cam4.4937] [Reference Citation Analysis]
689 Li JX, Deng WX, Huang ST, Lin XF, Long MY, Zhang J, Su TS, Li LQ, Pang YD, Liang CF, Zhou HM, Lu HY, Liang SX, Xiang BD. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study. Radiat Oncol 2022;17:106. [PMID: 35690773 DOI: 10.1186/s13014-022-02075-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
690 Mo Q, Liu Y, Zhou Z, Li R, Gong W, Xiang B, Tang W, Yu H. Prognostic Value of Aspartate Transaminase/Alanine Transaminase Ratio in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Hepatectomy. Front Oncol 2022;12:876900. [PMID: 35664791 DOI: 10.3389/fonc.2022.876900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
691 Xing QQ, Li JM, Dong X, Zeng DY, Chen ZJ, Lin XY, Pan JS. Socioeconomics and attributable etiology of primary liver cancer, 1990-2019. World J Gastroenterol 2022; 28(21): 2361-2382 [DOI: 10.3748/wjg.v28.i21.2361] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
692 Abou-alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang Y, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng A, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence. [DOI: 10.1056/evidoa2100070] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
693 Jarosova J, Macinga P, Krupickova L, Fialova M, Hujova A, Mares J, Urban O, Hajer J, Spicak J, Striz I, Hucl T. Impact of Endoluminal Radiofrequency Ablation on Immunity in Pancreatic Cancer and Cholangiocarcinoma. Biomedicines 2022;10:1331. [DOI: 10.3390/biomedicines10061331] [Reference Citation Analysis]
694 Fang Y, Yan D, Wang L, Zhang J, He Q. Circulating microRNAs (miR-16, miR-22, miR-122) expression and early diagnosis of hepatocellular carcinoma. J Clin Lab Anal 2022;:e24541. [PMID: 35666610 DOI: 10.1002/jcla.24541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
695 Chen S, Huang C, Liao G, Sun H, Xie Y, Wang J, He M, Hu H, Dai Z, Ren X, Zeng X, Zeng Q, Zhang G, Liao C, Xie W, Shen S, Li S, Peng S, Kuang D, Zhao Q, Duda DG, Kuang M. Distinct Single-cell Immune Ecosystems Distinguish True and De Novo HBV-related Hepatocellular Carcinoma Recurrences.. [DOI: 10.1101/2022.06.02.494526] [Reference Citation Analysis]
696 Zhang W, Wu L, Chen L, Ren Y, Sun T, Sun B, Zhu L, Liu Y, Zheng C. The Efficacy and Safety of Transarterial Chemoembolization Plus Iodine 125 Seed Implantation in the Treatment of Hepatocellular Carcinoma With Oligometastases: A Case Series Reports. Front Oncol 2022;12:828850. [PMID: 35656512 DOI: 10.3389/fonc.2022.828850] [Reference Citation Analysis]
697 Xin C, Huang B, Chen M, Yan H, Zhu K, Chen L, Jiang C, Zhang J, Wu Y. Construction and validation of an immune-related LncRNA prognostic model for hepatocellular carcinoma. Cytokine 2022;156:155923. [PMID: 35667281 DOI: 10.1016/j.cyto.2022.155923] [Reference Citation Analysis]
698 Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattan S, Blanc JF, Lee KH, Maur M, Pant S, Kudo M, Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillén-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Delord JP. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res 2022;41:189. [PMID: 35655320 DOI: 10.1186/s13046-022-02383-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
699 Yu JI, Kang W, Yoo GS, Goh MJ, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW, Hong JY, Lim HY, Park B, Park HC. Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis. Front Oncol 2022;12:888755. [PMID: 35646674 DOI: 10.3389/fonc.2022.888755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
700 Yu H, Bai Y, Xie X, Feng Y, Yang Y, Zhu Q. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMJ Open 2022;12:e052294. [DOI: 10.1136/bmjopen-2021-052294] [Reference Citation Analysis]
701 Vitale A, Caregari S, Giannini EG. Need for independence of treatment allocation from prognostic evaluation for hepatocellular carcinoma. Liver Cancer International 2022;3:51-52. [DOI: 10.1002/lci2.49] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
702 Marques F, Ghallab M, Vibert E, Boleslawski E, Soubrane O, Adam R, Farges O, Mabrut JY, Régimbeau JM, Cherqui D, Allard MA, Sa Cunha A, Samuel D, Pruvot FR, Golse N. Prognostic impact of surgical margins for hepatocellular carcinoma according to preoperative alpha-fetoprotein level. HPB (Oxford) 2022;24:848-56. [PMID: 34785122 DOI: 10.1016/j.hpb.2021.10.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
703 Ahmadzadehfar H, Ilhan H, Lam MGEH, Sraieb M, Stegger L. Radioembolization, Principles and indications. Nuklearmedizin 2022;61:262-72. [PMID: 35354218 DOI: 10.1055/a-1759-4238] [Reference Citation Analysis]
704 Chen X, Li M, Guo R, Liu W, Li J, Zong X, Chen Q, Wang J. The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdom Radiol (NY) 2022;47:2057-70. [PMID: 35312822 DOI: 10.1007/s00261-022-03484-7] [Reference Citation Analysis]
705 Raphael MJ, Karanicolas PJ. Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When? J Clin Oncol 2022;:JCO2102505. [PMID: 35649228 DOI: 10.1200/JCO.21.02505] [Reference Citation Analysis]
706 Loosen SH, Kostev K, Demir M, Luedde M, Keitel V, Luedde T, Roderburg C. An elevated FIB-4 score is associated with an increased incidence of liver cancer: A longitudinal analysis among 248,224 outpatients in Germany. European Journal of Cancer 2022;168:41-50. [DOI: 10.1016/j.ejca.2022.03.010] [Reference Citation Analysis]
707 Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology 2022;75:1604-26. [PMID: 35253934 DOI: 10.1002/hep.32447] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
708 Liu J, Geng W, Sun H, Liu C, Huang F, Cao J, Xia L, Zhao H, Zhai J, Li Q, Zhang X, Kuang M, Shen S, Xia Q, Wong VW, Yu J. Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma. Gut 2022;71:1203-13. [PMID: 34344785 DOI: 10.1136/gutjnl-2021-325189] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
709 van Oorschot E, Koc ÖM, Oude Lashof AM, van Loo IH, Ackens R, Posthouwer D, Koek GH. Cascade of care among hepatitis B patients in Maastricht, the Netherlands, 1996 to 2018. Journal of Virus Eradication 2022;8:100075. [DOI: 10.1016/j.jve.2022.100075] [Reference Citation Analysis]
710 Delvecchio A, Conticchio M, Riccelli U, Ferraro V, Ratti F, Gelli M, Anelli FM, Laurent A, Vitali GC, Magistri P, Assirati G, Felli E, Wakabayashi T, Pessaux P, Piardi T, Di Benedetto F, de'Angelis N, Briceño-Delgado J, Adam R, Cherqui D, Aldrighetti L, Memeo R. Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: a propensity score matching analysis. HPB (Oxford) 2022;24:933-41. [PMID: 34815189 DOI: 10.1016/j.hpb.2021.10.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
711 Su Y, Liu Y, Hsiao C, Hsu C, Chen L. Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. JHC 2022;Volume 9:517-36. [DOI: 10.2147/jhc.s220978] [Reference Citation Analysis]
712 Ayoub WS, Jones PD, Yang JD, Martin P. Emerging drugs for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2022. [PMID: 35642526 DOI: 10.1080/14728214.2022.2083107] [Reference Citation Analysis]
713 Liu Y, Huang T, Shen L, Wu Y, Chen S, Fan W. Research progress on anti-tumor immune effect of cryoablation. Chin J Acad Radiol 2022;5:74-81. [DOI: 10.1007/s42058-022-00092-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
714 Zhao L, Chang N, Shi L, Li F, Meng F, Xie X, Xu Z, Wang F. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study. Heliyon 2022;8:e09538. [PMID: 35706954 DOI: 10.1016/j.heliyon.2022.e09538] [Reference Citation Analysis]
715 Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. Eur J Gastroenterol Hepatol 2022;34:698-706. [PMID: 35170529 DOI: 10.1097/MEG.0000000000002356] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
716 Ryu T, Takami Y, Wada Y, Saitsu H. Oncological Outcomes of Operative Microwave Ablation for Intermediate Stage Hepatocellular Carcinoma: Experience in 246 Consecutive Patients. J Gastrointest Surg 2022;26:1178-86. [PMID: 35064460 DOI: 10.1007/s11605-022-05254-8] [Reference Citation Analysis]
717 Purevsambuu T, Bota S, Hucke F, Hofer H, Ferenci P, Sieghart W, Peck‐radosavljevic M. Hepatocellular carcinoma incidence in chronic hepatitis C patients according to sustained virological response ( SVR ) with interferon‐based therapies and baseline characteristics. Liver Cancer International 2022;3:53-62. [DOI: 10.1002/lci2.52] [Reference Citation Analysis]
718 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
719 Rojas Á, Gil-Gómez A, de la Cruz-Ojeda P, Muñoz-Hernández R, Sánchez-Torrijos Y, Gallego-Durán R, Millán R, Rico MC, Montero-Vallejo R, Gato-Zambrano S, Maya-Miles D, Ferrer MT, Muntané J, Robles-Frías MJ, Ampuero J, Padillo FJ, Romero-Gómez M. Long non-coding RNA H19 as a biomarker for hepatocellular carcinoma. Liver Int 2022;42:1410-22. [PMID: 35243752 DOI: 10.1111/liv.15230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
720 Kim AK, Hamilton JP, Lin SY, Chang TT, Hann HW, Hu CT, Lou Y, Lin YJ, Gade TP, Park G, Luu H, Lee TJ, Wang J, Chen D, Goggins MG, Jain S, Song W, Su YH. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer 2022;126:1432-8. [PMID: 35046521 DOI: 10.1038/s41416-022-01706-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
721 An J, Kim HI, Oh B, Oh YJ, Oh JH, Kim W, Sung CO, Shim JH. Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study. Gut 2022;71:1234-6. [PMID: 34493591 DOI: 10.1136/gutjnl-2021-325844] [Reference Citation Analysis]
722 Wright M, Woodland H, Hudson B. Symptom control in advanced chronic liver disease: integrating anticipatory palliative and supportive care. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2022-102114] [Reference Citation Analysis]
723 Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2022;10:e004779. [PMID: 35738801 DOI: 10.1136/jitc-2022-004779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
724 Shribman S, Marjot T, Sharif A, Vimalesvaran S, Ala A, Alexander G, Dhawan A, Dooley J, Gillett GT, Kelly D, Mcneill A, Warner TT, Wheater V, Griffiths W, Bandmann O. Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver. The Lancet Gastroenterology & Hepatology 2022;7:560-75. [DOI: 10.1016/s2468-1253(22)00004-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
725 Reinoso-pereira GL, Paranaguá-vezozzo DC, Mazo DF, França JID, Ono SK, Carrilho FJ. HIGH VALUES OF LIVER STIFFNESS PLAY AN IMPORTANT ROLE IN STRATIFYING THE RISK OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC HEPATITIS C PATIENTS. Arq Gastroenterol 2022;59:204-211. [DOI: 10.1590/s0004-2803.202202000-38] [Reference Citation Analysis]
726 Chen R, Li L, Li Y, Song K, Shen C, Ma P, Wang Z. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study. J Gastrointest Oncol 2022;13:1367-75. [PMID: 35837188 DOI: 10.21037/jgo-22-525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
727 Huo TI, Liao JI, Ho SY. 3-Mercaptopyruvate sulfurtransferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor? Liver Int 2022;42:1475. [PMID: 35460171 DOI: 10.1111/liv.15279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
728 Sugumar K, Markt SC, Hue JJ, Hoehn RS, Lee RT, Chavin KD, Rothermel LD, Winter JM, Hardacre JM, Ammori JB, Ocuin LM. Black race is independently associated with underutilization of transplantation for clinical T1 hepatocellular carcinoma. HPB (Oxford) 2022;24:925-32. [PMID: 34872866 DOI: 10.1016/j.hpb.2021.10.023] [Reference Citation Analysis]
729 Dong SY, Yang YT, Wang WT, Zhu S, Sun W, Zeng MS, Rao SX. Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology. Acta Radiol 2022;63:734-42. [PMID: 33969700 DOI: 10.1177/02841851211014194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
730 Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol 2022;76:1348-61. [PMID: 35589255 DOI: 10.1016/j.jhep.2022.01.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
731 Canillas L, Parcerisa M, Coll S, García-retortillo M, Macià F, Bessa X, Castells X, Puigvehí M, Posso M. Prevalence and characteristics of hepatitis C virus-related hepatocellular carcinoma in a Spanish university hospital. Cancer Epidemiology 2022;78:102142. [DOI: 10.1016/j.canep.2022.102142] [Reference Citation Analysis]
732 Prieto Ortíz JE, Garzón Orjuela N, Sanchez Pardo S, Prieto Ortíz RG, Eslava Schmalbach JH. Hepatocarcinoma: experiencia de la vida real en un centro especializado de Bogotá, Colombia. Rev colomb Gastroenterol 2022;37:163-173. [DOI: 10.22516/25007440.823] [Reference Citation Analysis]
733 Huang Z, Zhou P, Li S, Li K. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis. Eur Radiol 2022. [PMID: 35639147 DOI: 10.1007/s00330-022-08872-7] [Reference Citation Analysis]
734 Meng D, Liang C, Zheng Y, Wang X, Liu K, Lin Z, Zhu Q, Zhao X. The value of gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase for predicting post-hepatectomy liver failure in HCC patients. Eur Radiol 2022. [PMID: 35639146 DOI: 10.1007/s00330-022-08874-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
735 Liu Y, Hu C, Qu X, Chen H, Liu L, Zhou L, Liu S, Li G, Zhou Y. Novel Role of Long Non-Coding RNA ASAP1-IT1 in Progression of Hepatocellular Carcinoma. Front Oncol 2022;12:746896. [DOI: 10.3389/fonc.2022.746896] [Reference Citation Analysis]
736 Graur F, Puia A, Mois EI, Moldovan S, Pusta A, Cristea C, Cavalu S, Puia C, Al Hajjar N. Nanotechnology in the Diagnostic and Therapy of Hepatocellular Carcinoma. Materials 2022;15:3893. [DOI: 10.3390/ma15113893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
737 Mishra G, Majeed A, Dev A, Eslick GD, Pinato DJ, Izumoto H, Hiraoka A, Huo T, Liu P, Johnson PJ, Roberts SK. Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. J Gastrointest Canc. [DOI: 10.1007/s12029-022-00832-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
738 Cabral LKD, Grisetti L, Pratama MY, Tiribelli C, Pascut D. Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals. Cancers (Basel) 2022;14:2700. [PMID: 35681679 DOI: 10.3390/cancers14112700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
739 Al-Noshokaty TM, Mesbah NM, Abo-Elmatty DM, Abulsoud AI, Abdel-Hamed AR. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis. Life Sci 2022;303:120675. [PMID: 35640776 DOI: 10.1016/j.lfs.2022.120675] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
740 Pascale F, Pelage JP, Wassef M, Ghegediban SH, Saint-Maurice JP, De Baere T, Denys A, Duran R, Deschamps F, Pellerin O, Maeda N, Laurent A, Namur J. Rabbit VX2 Liver Tumor Model: A Review of Clinical, Biology, Histology, and Tumor Microenvironment Characteristics. Front Oncol 2022;12:871829. [PMID: 35619923 DOI: 10.3389/fonc.2022.871829] [Reference Citation Analysis]
741 Lv K, Cao X, Du P, Fu JY, Geng DY, Zhang J. Radiomics for the detection of microvascular invasion in hepatocellular carcinoma. World J Gastroenterol 2022; 28(20): 2176-2183 [DOI: 10.3748/wjg.v28.i20.2176] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
742 Inzerillo A, Meloni MF, Taibbi A, Bartolotta TV. Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography. World J Hepatol 2022; 14(5): 911-922 [DOI: 10.4254/wjh.v14.i5.911] [Reference Citation Analysis]
743 Yao S, Wei Y, Song B. Providing higher value care for hepatocellular carcinoma rather than diagnosis: What can current radiologists do? World J Gastrointest Surg 2022; 14(5): 525-527 [DOI: 10.4240/wjgs.v14.i5.525] [Reference Citation Analysis]
744 Hendriks P, Rietbergen DDD, van Erkel AR, Coenraad MJ, Arntz MJ, Bennink RJ, Braat AE, Crobach ASLP, van Delden OM, van der Hulle T, Klümpen HJ, van der Meer RW, Nijsen JFW, van Rijswijk CSP, Roosen J, Ruijter BN, Smit F, Stam MK, Takkenberg RB, Tushuizen ME, van Velden FHP, de Geus-Oei LF, Burgmans MC; Dutch Hepatocellular Cholangiocarcinoma Group. Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patients-A Dose-Finding Study (HORA EST HCC Trial). Cardiovasc Intervent Radiol 2022. [PMID: 35618860 DOI: 10.1007/s00270-022-03162-7] [Reference Citation Analysis]
745 Cannella R, Cammà C, Matteini F, Celsa C, Giuffrida P, Enea M, Comelli A, Stefano A, Cammà C, Midiri M, Lagalla R, Brancatelli G, Vernuccio F. Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC. Diagnostics 2022;12:1308. [DOI: 10.3390/diagnostics12061308] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
746 Wu Y, Rong X, Pan M, Wang T, Yang H, Chen X, Xiao Z, Zhao C. Integrated Analysis Reveals the Gut Microbial Metabolite TMAO Promotes Inflammatory Hepatocellular Carcinoma by Upregulating POSTN. Front Cell Dev Biol 2022;10:840171. [DOI: 10.3389/fcell.2022.840171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
747 Wang J, Chen Z, Wang L, Feng S, Qiu Q, Chen D, Li N, Xiao Y. A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-12518-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
748 Bednarsch J, Czigany Z, Heij LR, Amygdalos I, Heise D, Bruners P, Ulmer TF, Neumann UP, Lang SA. The role of re-resection in recurrent hepatocellular carcinoma. Langenbecks Arch Surg. [DOI: 10.1007/s00423-022-02545-1] [Reference Citation Analysis]
749 Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M, Karp SJ, Moriyama M, Kogure H. Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. Cancers 2022;14:2549. [DOI: 10.3390/cancers14102549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
750 Dong Y, Wang G, Zhang J, Zhang S, Chen X, Guo Q, Qu F, Shou F. Robotic laser position versus freehand in CT-guided percutaneous microwave ablation for single hepatocellular carcinoma (diameter < 3 cm): a preliminary study. Int J Hyperthermia 2022;39:725-32. [PMID: 35584811 DOI: 10.1080/02656736.2022.2072526] [Reference Citation Analysis]
751 Kong SY, Song JJ, Jin YQ, Deng MJ, Yan JX. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Acta Clin Belg 2022;:1-9. [PMID: 35587164 DOI: 10.1080/17843286.2022.2076791] [Reference Citation Analysis]
752 Zhang S, Song W, Yang B, Jia H, Chen S, Li J, Yang C. A non-invasive model based on the virtual portal pressure gradient to predict the first variceal hemorrhage in cirrhotic patients. Hepatol Int 2022. [PMID: 35585289 DOI: 10.1007/s12072-022-10344-5] [Reference Citation Analysis]
753 Wu X, Ge L, Shen G, He Y, Xu Z, Li D, Mu C, Zhao L, Zhang W. 131I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2022;14:21848-59. [PMID: 35507826 DOI: 10.1021/acsami.2c00211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
754 Geyer T, Kazmierczak PM, Steffen IG, Malfertheiner P, Peynircioglu B, Loewe C, Delden OV, Vandecaveye V, Gebauer B, Pech M, Sengel C, Bargellini I, Iezzi R, Benito A, Zech CJ, Gasbarrini A, Schütte K, Ricke J, Seidensticker M. Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial. Biomedicines 2022;10:1156. [DOI: 10.3390/biomedicines10051156] [Reference Citation Analysis]
755 Gao L, Xiong M, Chen X, Han Z, Yan C, Ye R, Zhou L, Li Y. Multi-Region Radiomic Analysis Based on Multi-Sequence MRI Can Preoperatively Predict Microvascular Invasion in Hepatocellular Carcinoma. Front Oncol 2022;12:818681. [PMID: 35574328 DOI: 10.3389/fonc.2022.818681] [Reference Citation Analysis]
756 Zhao D, Cao J, Zhang L, Zhang S, Wu S. Targeted Molecular Imaging Probes Based on Magnetic Resonance Imaging for Hepatocellular Carcinoma Diagnosis and Treatment. Biosensors 2022;12:342. [DOI: 10.3390/bios12050342] [Reference Citation Analysis]
757 Hatzidakis A, Müller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers (Basel) 2022;14:2469. [PMID: 35626073 DOI: 10.3390/cancers14102469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
758 Mushtaq S, Hashmi AH, Khan A, Asad Raza Kazmi SM, Manzoor S. Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals. Front Pharmacol 2022;13:894460. [PMID: 35571102 DOI: 10.3389/fphar.2022.894460] [Reference Citation Analysis]
759 Huge N, Reinkens T, Buurman R, Sandbothe M, Bergmann A, Wallaschek H, Vajen B, Stalke A, Decker M, Eilers M, Schäffer V, Dittrich-Breiholz O, Gürlevik E, Kühnel F, Schlegelberger B, Illig T, Skawran B. MiR-129-5p exerts Wnt signaling-dependent tumor-suppressive functions in hepatocellular carcinoma by directly targeting hepatoma-derived growth factor HDGF. Cancer Cell Int 2022;22:192. [PMID: 35578240 DOI: 10.1186/s12935-022-02582-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
760 Tejedor M, Selzner N, Berenguer M. Are MELD and MELDNa Still Reliable Tools to Predict Mortality on the Liver Transplant Waiting List? Transplantation 2022. [PMID: 35594480 DOI: 10.1097/TP.0000000000004163] [Reference Citation Analysis]
761 Cui H, Rong W, Ma J, Zhu Q, Jiang B, Zhang L, Li C, Zhuo Z, Chen M. DNA N6-Adenine methylation in HBV-related hepatocellular carcinoma. Gene 2022;822:146353. [PMID: 35189250 DOI: 10.1016/j.gene.2022.146353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
762 Gairing SJ, Schattenberg JM. The unmet need of personalized HCC screening-Lessons learned from the Swedish nationwide registries. United European Gastroenterol J 2022. [PMID: 35567573 DOI: 10.1002/ueg2.12239] [Reference Citation Analysis]
763 Zou H, Li M, Lei Q, Luo Z, Xue Y, Yao D, Lai Y, Ung COL, Hu H. Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review. Front Public Health 2022;10:801981. [PMID: 35530735 DOI: 10.3389/fpubh.2022.801981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
764 Luerken L, Haimerl M, Doppler M, Uller W, Beyer LP, Stroszczynski C, Einspieler I. Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma. Rofo 2022. [PMID: 35545102 DOI: 10.1055/a-1768-0954] [Reference Citation Analysis]
765 Yu R, Cao Z, Huang Y, Zhang X, Chen J, Li Y. Establishment and Analysis of a Combined Diagnostic Model of Liver Cancer with Random Forest and Artificial Neural Network. Mathematical Problems in Engineering 2022;2022:1-17. [DOI: 10.1155/2022/5679837] [Reference Citation Analysis]
766 Bühler L, Enderle MD, Kahn N, Polke M, Schneider MA, Heußel CP, Herth FJF, Linzenbold W. Establishment of a Tissue-Mimicking Surrogate for Pulmonary Lesions to Improve the Development of RFA Instruments and Algorithms. Biomedicines 2022;10:1100. [DOI: 10.3390/biomedicines10051100] [Reference Citation Analysis]
767 Raman AG, Jones C, Weiss CR. Machine Learning for Hepatocellular Carcinoma Segmentation at MRI: Radiology In Training. Radiology 2022;:212386. [PMID: 35536132 DOI: 10.1148/radiol.212386] [Reference Citation Analysis]
768 Vernuccio F, Cannella R, Cabibbo G, Greco S, Celsa C, Matteini F, Giuffrida P, Midiri M, Di Marco V, Cammà C, Brancatelli G. Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals. Diagnostics 2022;12:1187. [DOI: 10.3390/diagnostics12051187] [Reference Citation Analysis]
769 Li Y, Zhang M, Li X, Wang Y, Wang Y, Li Y, Zhu H, Ding H, Li X, Sun S. Hydroxyacid Oxidase 2 (HAO2) Inhibits the Tumorigenicity of Hepatocellular Carcinoma and Is Negatively Regulated by miR-615-5p. J Immunol Res 2022;2022:5003930. [PMID: 35528616 DOI: 10.1155/2022/5003930] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
770 Wang Z, Rehman AU, Qin X, Zhu C, Wu S, Bukhari I. PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-18. [DOI: 10.1155/2022/7545666] [Reference Citation Analysis]
771 Beecroft S, O'Connell M, Nassar A, Noon K, Pollock KG, Palmer D, Cross TJS. Major variation in hepatocellular carcinoma treatment and outcomes in England: a retrospective cohort study. Frontline Gastroenterol 2023;14:19-24. [PMID: 36561791 DOI: 10.1136/flgastro-2022-102142] [Reference Citation Analysis]
772 Kudo M. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. Int J Clin Oncol. [DOI: 10.1007/s10147-022-02166-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
773 Korsic S, Levasic N, Dezman R, Zupan LAL, Trotovsek B, Jansa R, Smid A, Popovic P. Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma. Radiol Oncol 2022. [PMID: 35535426 DOI: 10.2478/raon-2022-0019] [Reference Citation Analysis]
774 Kim K, Lee J, Seong J. Skull Base Metastasis from Hepatocellular Carcinoma: Clinical Presentation and Efficacy of Radiotherapy. J Hepatocell Carcinoma 2022;9:357-66. [PMID: 35520947 DOI: 10.2147/JHC.S361045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
775 Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein H, Hegel JK, Sharma A, Madin K, Rolny V, Lisy M, Piratvisuth T. Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open. [DOI: 10.1002/jgh3.12720] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
776 Fulgenzi CAM, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs 2022;:1-11. [PMID: 35507361 DOI: 10.1080/13543784.2022.2072726] [Reference Citation Analysis]
777 Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2022;5:CD014798. [PMID: 35521901 DOI: 10.1002/14651858.CD014798.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
778 Burciu C, Șirli R, Bende F, Fofiu R, Popescu A, Sporea I, Ghiuchici A, Miuțescu B, Dănilă M. Usefulness of Imaging and Biological Tools for the Characterization of Portal Vein Thrombosis in Hepatocellular Carcinoma. Diagnostics 2022;12:1145. [DOI: 10.3390/diagnostics12051145] [Reference Citation Analysis]
779 Liu Y, Song J, Zhang H, Liao Z, Liu F, Su C, Wang W, Han M, Zhang L, Zhu H, Zhang Z, Liang H, Zhang L, Zhang B, Chen X. EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway. J Exp Clin Cancer Res 2022;41:164. [PMID: 35509064 DOI: 10.1186/s13046-022-02378-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
780 Shen H, Yu H, Li QY, Wei YT, Fu J, Dong H, Cao D, Guo LN, Chen L, Yang Y, Xu Y, Wu MC, Wang HY, Chen Y. Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells. Acta Pharmacol Sin 2022. [PMID: 35508720 DOI: 10.1038/s41401-022-00907-5] [Reference Citation Analysis]
781 Kuromatsu R, Ide T, Okamura S, Noda Y, Kamachi N, Nakano M, Shirono T, Shimose S, Iwamoto H, Kuwahara R, Arinaga-hino T, Niizeki T, Zaizen Y, Takaki H, Shirachi M, Koga H, Torimura T. Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. Cancers 2022;14:2295. [DOI: 10.3390/cancers14092295] [Reference Citation Analysis]
782 Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M, Ishikawa T, Takaguchi K, Tsutsui A, Toyoda H, Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment. Current Oncology 2022;29:3259-71. [DOI: 10.3390/curroncol29050266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
783 Lim Z, Mohd-Ismail NKB, Png E, Sze CW, Lin Q, Hong W, Lim SG, Tan YJ, Gunaratne J. Phosphoproteomics Unravel HBV Triggered Rewiring of Host Phosphosignaling Events. Int J Mol Sci 2022;23:5127. [PMID: 35563518 DOI: 10.3390/ijms23095127] [Reference Citation Analysis]
784 Santana-Salgado I, Bautista-Santos A, Moreno-Alcántar R. Risk factors for developing hepatocellular carcinoma in patients treated with direct-acting antivirals. Rev Gastroenterol Mex (Engl Ed) 2022:S2255-534X(22)00025-1. [PMID: 35523684 DOI: 10.1016/j.rgmxen.2021.09.005] [Reference Citation Analysis]
785 Duberg AS, Lybeck C, Fält A, Montgomery S, Aleman S. Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study. Hepatol Commun 2022;6:2418-30. [PMID: 35503810 DOI: 10.1002/hep4.1974] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
786 Akbulut S, Garzali IU, Hargura AS, Aloun A, Yilmaz S. Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review. J Gastrointest Canc. [DOI: 10.1007/s12029-022-00830-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
787 Ivanics T, Rajendran L, Abreu P, Claasen M, Shwaartz C, Patel M, Choi W, Doyle A, Muaddi H, Mcgilvray I, Selzner M, Beecroft R, Kachura J, Bhat M, Selzner N, Ghanekar A, Cattral M, Sayed B, Reichman T, Lilly L, Sapisochin G. Long-term outcomes of ablation, liver resection, and liver transplant as first-line treatment for solitary HCC of 3 cm or less using an intention-to-treat analysis: A retrospective cohort study. Annals of Medicine and Surgery 2022;77:103645. [DOI: 10.1016/j.amsu.2022.103645] [Reference Citation Analysis]
788 D'Avola D, Granito A, Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol 2022;76:1185-98. [PMID: 34793869 DOI: 10.1016/j.jhep.2021.11.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
789 Perales SR, Teramoto FD, Ataide ECD, Garcia A, de Macedo PRA, Cunha-silva M, Sevá-pereira T, Foratto A, Fernandes DP, Marcondes DC, Meneses CJ, da Costa LBE, Neto FC, Boin ISDFSF. Refinement of the Milan Criteria: Role of α-Fetoprotein In Liver Transplantation for Hepatocellular Carcinoma. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2022.04.011] [Reference Citation Analysis]
790 Agirrezabal I, Brennan VK, Colaone F, Shergill S, Pereira H, Chatellier G, Vilgrain V. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life. Adv Ther 2022;39:2035-51. [PMID: 35279814 DOI: 10.1007/s12325-022-02099-0] [Reference Citation Analysis]
791 Lu L, Shen L, Wu Z, Shi Y, Hou P, Xue Z, Lin C, Chen X. Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study. eClinicalMedicine 2022;47:101391. [DOI: 10.1016/j.eclinm.2022.101391] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
792 Ciardullo S, Mantovani A, Ciaccio A, Carbone M, Invernizzi P, Perseghin G. Hepatitis C virus infection and diabetes: A complex bidirectional relationship. Diabetes Research and Clinical Practice 2022;187:109870. [DOI: 10.1016/j.diabres.2022.109870] [Reference Citation Analysis]
793 Lebossé F, Caussy C. Editorial: screening for hepatocellular carcinoma in NAFLD-towards abbreviated MRI alternative in patients with obesity? Aliment Pharmacol Ther 2022;55:1210-1. [PMID: 35429036 DOI: 10.1111/apt.16887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
794 Jiang H, Wei J, Fu F, Wei H, Qin Y, Duan T, Chen W, Xie K, Lee JM, Bashir MR, Wang M, Song B, Tian J. Predicting microvascular invasion in hepatocellular carcinoma: A dual-institution study on gadoxetate disodium-enhanced MRI. Liver Int 2022;42:1158-72. [PMID: 35243749 DOI: 10.1111/liv.15231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
795 Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology 2022;75:1257-74. [PMID: 34918361 DOI: 10.1002/hep.32241] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
796 Viñal D, Minaya-Bravo A, Prieto I, Feliu J, Rodriguez-Salas N. Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies. Clin Transl Oncol 2022;24:796-808. [PMID: 35013882 DOI: 10.1007/s12094-021-02745-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
797 Young Park J, Min Lee S, Sub Lee J, Chang W, Hee Yoon J. Free-breathing dynamic T1WI using compressed sensing-golden angle radial sparse parallel imaging for liver MRI in patients with limited breath-holding capability. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110342] [Reference Citation Analysis]
798 Zhang L, Chen J, Jiang H, Rong D, Guo N, Yang H, Zhu J, Hu B, He B, Yin M, Venkatesh SK, Ehman RL, Wang J. MR Elastography as a biomarker for Prediction of Early and Late Recurrence in HBV-related Hepatocellular Carcinoma Patients before Hepatectomy. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110340] [Reference Citation Analysis]
799 Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El-Serag HB, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022;75:1289-99. [PMID: 34778999 DOI: 10.1002/hep.32240] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
800 Kim E, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P, Knešaurek K, Fischman A, Patel R, Nowakowski S, Llovet J, Taouli B, Lookstein R. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00091-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
801 Scheiner B, Pinter M. Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy". J Hepatol 2022;76:1233-4. [PMID: 35176440 DOI: 10.1016/j.jhep.2022.02.002] [Reference Citation Analysis]
802 Wen R, Lin P, Gao R, Wu Y, Peng J, Peng Y, Wen D, Yin H, Ma Z, Tang Z, He Y, Yang H. Diagnostic performance and interreader agreement of CEUS LI-RADS in ≤ 30 mm liver nodules with different experienced radiologists. Abdom Radiol (NY) 2022;47:1798-805. [PMID: 35260943 DOI: 10.1007/s00261-022-03468-7] [Reference Citation Analysis]
803 Sung PS, Park DJ, Roh PR, Mun KD, Cho SW, Lee GW, Jung ES, Lee SH, Jang JW, Bae SH, Choi JY, Choi J, Ahn J, Yoon SK. Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy. J Immunother Cancer 2022;10:e003618. [PMID: 35577505 DOI: 10.1136/jitc-2021-003618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
804 Chen M, Shu G, Lv X, Xu X, Lu C, Qiao E, Fang S, Shen L, Zhang N, Wang J, Chen C, Song J, Liu Z, Du Y, Ji J. HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma. Biomaterials 2022;284:121512. [DOI: 10.1016/j.biomaterials.2022.121512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
805 Grinspan LT, Villanueva A. Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. Semin Liver Dis 2022;42:188-201. [PMID: 35738257 DOI: 10.1055/s-0042-1748924] [Reference Citation Analysis]
806 Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100498] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
807 Cui R, Wang L, Zhang D, Zhang K, Dou J, Dong L, Zhang Y, Wu J, Tan L, Yu J, Liang P. Combination therapy using microwave ablation and D-mannose-chelated iron oxide nanoparticles inhibits hepatocellular carcinoma progression. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.05.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
808 Zhu QW, Yu Y, Zhang Y, Wang XH. VLCAD inhibits the proliferation and invasion of hepatocellular cancer cells through regulating PI3K/AKT axis. Clin Transl Oncol 2022;24:864-74. [PMID: 35001339 DOI: 10.1007/s12094-021-02733-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
809 Volkonsky MV, Zhikhorev RS, Makarkina TA, Filippova VM, Vasileva YV, Akopyan AA, Zhelezkova TA. Own Experience of Using Lenvatinib in Patients with Advanced Hepatocellular Carcinoma in Real Clinical Practice based on Moscow City Oncological Hospital №62. J Mod Onco 2022;24:106-109. [DOI: 10.26442/18151434.2022.1.201477] [Reference Citation Analysis]
810 Zhang G, Fan W, Wang H, Wen J, Tan J, Xue M, Li J. Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:844013. [DOI: 10.3389/fcell.2022.844013] [Reference Citation Analysis]
811 Bednarsch J, Tan X, Czigany Z, Wiltberger G, Buelow RD, Boor P, Lang SA, Ulmer TF, Neumann UP, Heij LR. Limitations of Nerve Fiber Density as a Prognostic Marker in Predicting Oncological Outcomes in Hepatocellular Carcinoma. Cancers 2022;14:2237. [DOI: 10.3390/cancers14092237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
812 Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun 2022. [PMID: 35481940 DOI: 10.1002/hep4.1927] [Reference Citation Analysis]
813 Pons M, Rivera-Esteban J, Manzano R, Bañares J, Bermúdez M, Vargas V, Salcedo-Allende MT, Castells L, Augustin S, Mínguez B, Pericàs JM. Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD. J Clin Med 2022;11:2466. [PMID: 35566592 DOI: 10.3390/jcm11092466] [Reference Citation Analysis]
814 Peng Z, Wu X, Li J, Pang H, Zhang Y, Lin M, Wang Z, Xiao H, Li B, Chen M, Feng S, Kuang M, Chen S. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion. Int J Hyperthermia 2022;39:688-96. [PMID: 35469522 DOI: 10.1080/02656736.2022.2051613] [Reference Citation Analysis]
815 Dakua SP, Nayak A. A review on treatments of hepatocellular carcinoma—role of radio wave ablation and possible improvements. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00191-2] [Reference Citation Analysis]
816 Zhang P, Yang X, Zha Z, Zhu Y, Zhang G, Li G. CBX3 regulated by miR-139 promotes the development of HCC by regulating cell cycle progression. Cell Cycle 2022;:1-13. [PMID: 35471148 DOI: 10.1080/15384101.2022.2068329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
817 Li W, Han L, Xiao B, Li X, Ye Z. A Predictive Nomogram of Early Recurrence for Patients with AFP-Negative Hepatocellular Carcinoma Underwent Curative Resection. Diagnostics 2022;12:1073. [DOI: 10.3390/diagnostics12051073] [Reference Citation Analysis]
818 Geh D, Watson R, Sen G, French JJ, Hammond J, Turner P, Hoare T, Anderson K, McNeil M, McPherson S, Masson S, Dyson J, Donnelly M, MacDougal L, Patel P, Hudson M, Anstee QM, White S, Robinson S, Pandanaboyana S, Walker L, McCain M, Bury Y, Raman S, Burt A, Parkinson D, Haugk B, Darne A, Wadd N, Asghar S, Mariappan L, Margetts J, Stenberg B, Scott J, Littler P, Manas DM, Reeves HL. COVID-19 and liver cancer: lost patients and larger tumours. BMJ Open Gastroenterol 2022;9:e000794. [PMID: 35450934 DOI: 10.1136/bmjgast-2021-000794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
819 Chen W, Fu M, Zhang C, Xing Q, Zhou F, Lin M, Dong X, Huang J, Lin S, Hong M, Zheng Q, Pan J. Deep Learning-Based Universal Expert-Level Recognizing Pathological Images of Hepatocellular Carcinoma and Beyond. Front Med 2022;9:853261. [DOI: 10.3389/fmed.2022.853261] [Reference Citation Analysis]
820 Bae BK, Park HC, Yoo GS, Choi MS, Oh JH, Yu JI. The Significance of Systemic Inflammation Markers in Intrahepatic Recurrence of Early-Stage Hepatocellular Carcinoma after Curative Treatment. Cancers 2022;14:2081. [DOI: 10.3390/cancers14092081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
821 Meng R, Cao Y, Zhou T, Hu H, Qiu Y. The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China. Front Public Health 2022;10:794131. [PMID: 35433574 DOI: 10.3389/fpubh.2022.794131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
822 Li L, Zheng W, Wang J, Han J, Guo Z, Hu Y, Li X, Zhou J. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection. AJR Am J Roentgenol 2022. [PMID: 35441534 DOI: 10.2214/AJR.22.27521] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
823 Miyata T, Matsumoto T, Nakao Y, Higashi T, Imai K, Hayashi H, Nitta H, Chikamoto A, Beppu T, Yamashita YI, Baba H. Major postoperative complications are associated with early recurrence of hepatocellular carcinoma following hepatectomy. Langenbecks Arch Surg 2022. [PMID: 35441947 DOI: 10.1007/s00423-022-02513-9] [Reference Citation Analysis]
824 Qiu Z, Wang G, Yan H, Qi H, Zuo M, Wang G, Jiang W, Chen Z, Xue J, Lu L, Zhang F, Gao F. TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension. Eur Radiol 2022. [PMID: 35441840 DOI: 10.1007/s00330-022-08705-7] [Reference Citation Analysis]
825 Shen Y, Liu J, Han Z, Jiang W, Cui H, Xun Y. Risk prediction models for hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy: a meta-analysis. Clin Res Hepatol Gastroenterol 2022;:101930. [PMID: 35460902 DOI: 10.1016/j.clinre.2022.101930] [Reference Citation Analysis]
826 Zheng K, Liao A, Yan L, Yang J, Wen T, Wang W, Li B, Wu H, Jiang L. Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas. Ann Surg Oncol 2022. [PMID: 35441310 DOI: 10.1245/s10434-022-11757-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
827 Lin SH, Lin CY, Hsu NT, Yen YH, Kee KM, Wang JH, Hu TH, Chen CH, Hung CH, Chen CH, Hu JT, Huang YH, Wang TE, Lu SN. Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. J Formos Med Assoc 2022:S0929-6646(22)00144-9. [PMID: 35450743 DOI: 10.1016/j.jfma.2022.04.001] [Reference Citation Analysis]
828 Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Med 2022. [PMID: 35441477 DOI: 10.1002/cam4.4763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
829 Liu YW, Yen YH, Li WF, Wang CC, Lu SN, Kee KM, Yong CC, Cheng YF, Wang JH, Hu TH, Hung CH, Chen CH. Minimally invasive surgery versus percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma: Results from a high-volume liver surgery center in East Asia. Surg Oncol 2022;42:101769. [PMID: 35468499 DOI: 10.1016/j.suronc.2022.101769] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
830 Teng W, Jeng WJ, Chen WT, Lin CC, Lin CY, Lin SM, Sheen IS. Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients. Cancer Med 2022. [PMID: 35435327 DOI: 10.1002/cam4.4760] [Reference Citation Analysis]
831 Wu J, Ding W, Wang Y, Liu S, Zhang X, Yang Q, Cai W, Yu X, Liu F, Kong D, Zhong H, Yu J, Liang P. Radiomics analysis of ultrasound to predict recurrence of hepatocellular carcinoma after microwave ablation. International Journal of Hyperthermia 2022;39:595-604. [DOI: 10.1080/02656736.2022.2062463] [Reference Citation Analysis]
832 Cabiati M, Gaggini M, De Simone P, Del Ry S. Data mining of key genes expression in hepatocellular carcinoma: novel potential biomarkers of diagnosis prognosis or progression. Clin Exp Metastasis 2022. [PMID: 35429302 DOI: 10.1007/s10585-022-10164-9] [Reference Citation Analysis]
833 Rich NE, Marrero JA. Hepatocellular carcinoma. Yamada's Textbook of Gastroenterology 2022. [DOI: 10.1002/9781119600206.ch101] [Reference Citation Analysis]
834 Christou CD, Tsoulfas G. Role of three-dimensional printing and artificial intelligence in the management of hepatocellular carcinoma: Challenges and opportunities. World J Gastrointest Oncol 2022; 14(4): 765-793 [DOI: 10.4251/wjgo.v14.i4.765] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
835 Ekert K, Kloth C, Nikolaou K, Grözinger G, Horger M, Thaiss W. Rim Enhancement after Technically Successful Transarterial Chemoembolization in Hepatocellular Carcinoma: A Potential Mimic of Incomplete Embolization or Reactive Hyperemia? Tomography 2022;8:1148-58. [PMID: 35448728 DOI: 10.3390/tomography8020094] [Reference Citation Analysis]
836 Wang YB, Ma R, Wang ZB, Shi QL, Zhang L, Chen WZ, Gong JP, Bai J. Transcatheter Arterial Chemoembolization in Combination With High-Intensity Focused Ultrasound for Intermediate and Advanced Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol 2022;12:797349. [PMID: 35419281 DOI: 10.3389/fonc.2022.797349] [Reference Citation Analysis]
837 Cassese G, Han H, Lee B, Lee HW, Cho JY, Troisi R. Leaping the Boundaries in Laparoscopic Liver Surgery for Hepatocellular Carcinoma. Cancers 2022;14:2012. [DOI: 10.3390/cancers14082012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
838 Da Fonseca LG, Leonardi PC, Hashizume PH, Sansone F, Saud LR, Carrilho FJ, Herman P. A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes. Clin Exp Hepatol 2022;8:42-8. [PMID: 35415264 DOI: 10.5114/ceh.2022.114297] [Reference Citation Analysis]
839 Abdel-Moety A, Baddour N, Salem P, Rady A, El-Shendidi A. ARID1A expression in hepatocellular carcinoma and relation to tumor recurrence after microwave ablation. Clin Exp Hepatol 2022;8:49-59. [PMID: 35415261 DOI: 10.5114/ceh.2022.114172] [Reference Citation Analysis]
840 Herrero A, Boivineau L, Cassese G, Assenat E, Riviere B, Faure S, Bedoya JU, Panaro F, Guiu B, Navarro F, Pageaux GP. Progression of AFP SCORE is a Preoperative Predictive Factor of Microvascular Invasion in Selected Patients Meeting Liver Transplantation Criteria for Hepatocellular Carcinoma. Transpl Int 2022;35:10412. [PMID: 35401038 DOI: 10.3389/ti.2022.10412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
841 Borde T, Nezami N, Gaupp FL, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022;:212426. [PMID: 35412368 DOI: 10.1148/radiol.212426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
842 Marasco G, Dajti E, Serenari M, Alemanni LV, Ravaioli F, Ravaioli M, Vestito A, Vara G, Festi D, Golfieri R, Cescon M, Renzulli M, Colecchia A. Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis. Cancers (Basel) 2022;14:1935. [PMID: 35454842 DOI: 10.3390/cancers14081935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
843 Xiang C, Xiao Y, Ma Z, Peng Y, Li X, Mao X, Li L. Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses. Asia Pac J Clin Oncol 2022. [PMID: 35404506 DOI: 10.1111/ajco.13777] [Reference Citation Analysis]
844 Yang XG, Huang YC, Wang CH, Sun YY, Huang Z, Xu GH. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined with Radiofrequency Ablation. Cancer Invest 2022;:1-31. [PMID: 35404178 DOI: 10.1080/07357907.2022.2065508] [Reference Citation Analysis]
845 Wang Z, Zhong Y, Zhang Z, Zhou K, Huang Z, Yu H, Liu L, Liu S, Yang H, Zhou J, Fan J, Wu L, Sun Y. Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma. Front Immunol 2022;13:847263. [PMID: 35371059 DOI: 10.3389/fimmu.2022.847263] [Reference Citation Analysis]
846 Kong Y, Chen H, Chen M, Li Y, Li J, Liu Q, Xiong H, Guo T, Xie Y, Yuan Y, Zhang XL. Abnormal ECA-Binding Membrane Glycans and Galactosylated CAT and P4HB in Lesion Tissues as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis. Front Oncol 2022;12:855952. [PMID: 35392238 DOI: 10.3389/fonc.2022.855952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
847 Xiang YJ, Wang K, Zheng YT, Feng S, Yu HM, Li XW, Cheng X, Cheng YQ, Feng JK, Zhou LP, Meng Y, Zhai J, Shan YF, Cheng SQ. Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory. Front Oncol 2022;12:839605. [PMID: 35387113 DOI: 10.3389/fonc.2022.839605] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
848 Toyoda H, Atsukawa M. The best predictive model for post-SVR HCC: can it be universal? Hepatol Int 2022. [PMID: 35396656 DOI: 10.1007/s12072-022-10336-5] [Reference Citation Analysis]
849 Moustafa M, Dähling K, Günther A, Riebandt L, Smit DJ, Riecken K, Schröder C, Zhuang R, Krech T, Kriegs M, Fehse B, Izbicki JR, Fischer L, Nashan B, Li J, Jücker M. Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model. Cancers 2022;14:1882. [DOI: 10.3390/cancers14081882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
850 Xia D, Wang Q, Bai W, Wang E, Wang Z, Mu W, Sun J, Huang M, Yin G, Li H, Zhao H, Zhang C, Li J, Wu J, Zhu X, Yang S, Pan X, Li J, Li Z, Xu G, Shi H, Zhang H, Zhang Y, Ding R, Yu H, Zheng L, Yang X, Wang G, You N, Feng L, Zhang S, Huang W, Xu T, Fan W, Li X, Yang X, Zhou W, Wang W, Li X, Wang Z, Luo B, Niu J, Yuan J, Lv Y, Li K, Guo W, Yin Z, Fan D, Xia J, Han G; China HCC-TACE Study Group. Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization. Eur Radiol 2022. [PMID: 35381853 DOI: 10.1007/s00330-022-08716-4] [Reference Citation Analysis]
851 Wu JL, Su TH, Chen PJ, Chen YR. Acute-phase serum amyloid A for early detection of hepatocellular carcinoma in cirrhotic patients with low AFP level. Sci Rep 2022;12:5799. [PMID: 35388082 DOI: 10.1038/s41598-022-09713-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
852 Zhang W, Wu L, Chen L, Sun T, Ren Y, Sun B, Zhu L, Han P, Zheng C. The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus. Sci Rep 2022;12:5725. [PMID: 35388064 DOI: 10.1038/s41598-022-09609-8] [Reference Citation Analysis]
853 Tiyarattanachai T, Fetzer DT, Kamaya A. Multicenter Study of ACR Ultrasound LI-RADS Visualization Scores on Serial Examinations: Implications for Changes in Surveillance Strategies. AJR Am J Roentgenol 2022. [PMID: 35383486 DOI: 10.2214/AJR.22.27405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
854 Ding DY, Liu L, Li HL, Gan XJ, Ding WB, Gu FM, Sun DP, Li W, Pan ZY, Yuan SX, Zhou WP. Development of preoperative prognostic models including radiological features for survival of singular nodular HCC patients. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00052-2. [PMID: 35428596 DOI: 10.1016/j.hbpd.2022.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
855 He X, Peng Y, Zhou Z, Li W. Immune Checkpoint Inhibitor-Based Systemic Therapy Shows Remarkable Curative Effect in a Hepatocellular Carcinoma Patient With Intractable Postoperative Recurrence and Metastases: A Case Report and Literature Review. Front Oncol 2022;12:784224. [PMID: 35372050 DOI: 10.3389/fonc.2022.784224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
856 Srivastava A, Parambath HK, Ramdulari AV, Saxena H, Kumar R, Pandey S, Shalimar, Gupta S, Jee B. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy? Int J Radiat Biol 2022;:1-15. [PMID: 35311612 DOI: 10.1080/09553002.2022.2055800] [Reference Citation Analysis]
857 Vardar BU, Meram E, Karaoglu K, Liang M, Yu M, Laeseke P, Ozkan OS. Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma. Cureus. [DOI: 10.7759/cureus.23783] [Reference Citation Analysis]
858 Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer 2022;10:e004656. [DOI: 10.1136/jitc-2022-004656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
859 Renzulli M, Mottola M, Coppola F, Cocozza MA, Malavasi S, Cattabriga A, Vara G, Ravaioli M, Cescon M, Vasuri F, Golfieri R, Bevilacqua A. Automatically Extracted Machine Learning Features from Preoperative CT to Early Predict Microvascular Invasion in HCC: The Role of the Zone of Transition (ZOT). Cancers 2022;14:1816. [DOI: 10.3390/cancers14071816] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
860 Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodríguez-Tajes S, Genescà J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol 2022;76:812-21. [PMID: 34871626 DOI: 10.1016/j.jhep.2021.11.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
861 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2021.10.009] [Reference Citation Analysis]
862 Guo Y, Ren Y, Dong X, Kan X, Zheng C. An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation. JHC 2022;Volume 9:343-55. [DOI: 10.2147/jhc.s358539] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
863 Barbier L, Cauchy F. What assessment of the liver before resection for hepatocellular carcinoma? Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101916] [Reference Citation Analysis]
864 Gao F, Wei Y, Zhang T, Jiang H, Li Q, Yuan Y, Yao S, Ye Z, Wan S, Wei X, Nie L, Tang H, Song B. New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients. Front Oncol 2022;12:812832. [PMID: 35356206 DOI: 10.3389/fonc.2022.812832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
865 Yan Q, Sun Y, An R, Liu F, Fang Q, Wang Z, Xu T, Chen L, Du J. Application and progress of the detection technologies in hepatocellular carcinoma. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.04.003] [Reference Citation Analysis]
866 Huang DQ, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez SJ, Gupta H, Sirlin CB, Marks RM, Loomba R. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. Aliment Pharmacol Ther 2022;55:820-7. [PMID: 35229334 DOI: 10.1111/apt.16844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
867 Luo J, Dong Z, Xie H, Zhang W, An L, Yu Z, Chang X, Chen Y, Yang W, Hu K, Liu F, Yang Y. Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellular carcinoma: A prospective multicenter study. Liver Int 2022;42:918-29. [PMID: 35065003 DOI: 10.1111/liv.15169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
868 Chandrapalan S, Bannaga A, Weidner A, Hitchins MP, Arasaradnam RP. A systematic review and meta-analysis: the diagnostic accuracy of methylated SEPTIN9 for the detection of hepatocellular carcinoma and the clinical evaluation of its use in combination with other surveillance modalities. Scand J Gastroenterol 2022;57:473-80. [PMID: 34957898 DOI: 10.1080/00365521.2021.2020331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
869 Ah Hwang J, Wook Kang T, Hye Min J, Kon Kim Y, Hyun Kim S, Hyun Sinn D, Kim K. Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110328] [Reference Citation Analysis]
870 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. II Consenso Mexicano de Carcinoma Hepatocelular. Parte I: Epidemiología y diagnóstico. Revista de Gastroenterología de México 2022;87:216-234. [DOI: 10.1016/j.rgmx.2021.10.002] [Reference Citation Analysis]
871 Sanduzzi-Zamparelli M, Mariño Z, Lens S, Sapena V, Iserte G, Pla A, Granel N, Bartres C, Llarch N, Vilana R, Nuñez I, Darnell A, Belmonte E, García-Criado A, Díaz A, Muñoz-Martinez S, Ayuso C, Bianchi L, Fuster-Anglada C, Rimola J, Forner A, Torres F, Bruix J, Forns X, Reig M. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. J Hepatol 2022;76:874-82. [PMID: 34856322 DOI: 10.1016/j.jhep.2021.11.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
872 An J, Kim D, Oh B, Oh YJ, Song J, Park N, Kim HI, Kang HJ, Oh JH, Kim W, Lee E, Sung CO, Song GW, Kim DG, Yu E, Letouzé E, Zucman-Rossi J, Lee HC, Shim JH. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas. Hepatology 2022;75:997-1011. [PMID: 34478159 DOI: 10.1002/hep.32135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
873 Scheiner B, Pinter M. Reply to: "Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?". J Hepatol 2022;76:988-9. [PMID: 34979133 DOI: 10.1016/j.jhep.2021.12.025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
874 Guo H, Huang J, Tan Y, Wu W, Huang T, Zhang N, Chen S, Zhang C, Xie X, Shuai X, Xu M. Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation. Nano Today 2022;43:101425. [DOI: 10.1016/j.nantod.2022.101425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
875 Gao Z, Fan T, Chen L, Yang M, Wai Wong VK, Chen D, Liu Z, Zhou Y, Wu W, Qiu Z, Zhang C, Li Y, Jiang Y. Design, synthesis and antitumor evaluation of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3η protein. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114402] [Reference Citation Analysis]
876 Shmanko K, Galle PR. Aktuelle Diagnostik und systemische Therapie des hepatozellulären Karzinoms. Onkologe 2022;28:269-277. [DOI: 10.1007/s00761-022-01113-y] [Reference Citation Analysis]
877 Azzi J, Dorival C, Cagnot C, Fontaine H, Lusivika-nzinga C, Leroy V, De Ledinghen V, Tran A, Zoulim F, Alric L, Gournay J, Bronowicki J, Decaens T, Riachi G, Mikhail N, Soliman R, Shiha G, Pol S, Carrat F, Ganne-carrié N. Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101923] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
878 Mcpherson S, Armstrong MJ, Cobbold JF, Corless L, Anstee QM, Aspinall RJ, Barclay ST, Brennan PN, Cacciottolo TM, Goldin RD, Hallsworth K, Hebditch V, Jack K, Jarvis H, Johnson J, Li W, Mansour D, Mccallum M, Mukhopadhya A, Parker R, Ross V, Rowe IA, Srivastava A, Thiagarajan P, Thompson AI, Tomlinson J, Tsochatzis EA, Yeoman A, Alazawi W. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00061-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
879 Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol 2022;23:521-30. [PMID: 35255263 DOI: 10.1016/S1470-2045(22)00078-X] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 42.0] [Reference Citation Analysis]
880 Özdemir Başer Ö, Oruç N. HEPATOSELLÜLER KARSİNOMA TANILI HASTALARDA ETİYOLOJİ VE DEMOGRAFİK ÖZELLİKLER. Bozok Tıp Dergisi 2022. [DOI: 10.16919/bozoktip.1055425] [Reference Citation Analysis]
881 Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer 2022;3:386-401. [PMID: 35484418 DOI: 10.1038/s43018-022-00357-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
882 Costa APDM, da Silva MACN, Castro RS, Sampaio ALDO, Alencar Júnior AM, da Silva MC, Ferreira ADSP. PAGE-B and REACH-B Predicts the Risk of Developing Hepatocellular Carcinoma in Chronic Hepatitis B Patients from Northeast, Brazil. Viruses 2022;14:732. [DOI: 10.3390/v14040732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
883 Zheng Z, Guan R, Jianxi W, Zhao Z, Peng T, Liu C, Lin Y, Jian Z, Wu YS. Microvascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/9567041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
884 Hu S, Wu X, Wei M, Ling Y, Zhu M, Wang Y, Chen Y, Jin M, Peng Z. Cost-Effectiveness Analysis of Follow-Up Schedule for Hepatocellular Carcinoma after Radiofrequency Ablation. J Oncol 2022;2022:3569644. [PMID: 35345515 DOI: 10.1155/2022/3569644] [Reference Citation Analysis]
885 Youn SY, Kim B, Kim DH, Choi HJ, Sung PS, Choi J. Liver Imaging-Reporting and Data System treatment response algorithm predicts postsurgical recurrence in locoregional therapy–treated hepatocellular carcinoma. Eur Radiol. [DOI: 10.1007/s00330-022-08720-8] [Reference Citation Analysis]
886 Renzulli M, Brandi N, Pecorelli A, Pastore LV, Granito A, Martinese G, Tovoli F, Simonetti M, Dajti E, Colecchia A, Golfieri R. Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers. Diagnostics 2022;12:834. [DOI: 10.3390/diagnostics12040834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
887 Kim BK, Cheon J, Kim H, Kang B, Ha Y, Kim DY, Hwang SG, Chon YE, Chon HJ. Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers (Basel) 2022;14:1747. [PMID: 35406518 DOI: 10.3390/cancers14071747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
888 Lee TH, Hunt CM, Maier MM, Lowy E, Beste LA. Hepatitis B Virus-Related Care Quality In Patients With Hepatitis B/Hiv Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study. Clin Infect Dis 2022:ciac227. [PMID: 35349635 DOI: 10.1093/cid/ciac227] [Reference Citation Analysis]
889 Gou H, Liu S, Zhu G, Peng Y, Li X, Yang X, He K. Effectiveness of radiofrequency ablation versus transarterial chemoembolization for recurrent hepatocellular carcinoma: A meta-analysis. Acta Radiologica Open 2022;11:205846012210855. [DOI: 10.1177/20584601221085514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
890 Fiz F, Jayakody Arachchige VS, Gionso M, Pecorella I, Selvam A, Wheeler DR, Sollini M, Viganò L. Radiomics of Biliary Tumors: A Systematic Review of Current Evidence. Diagnostics (Basel) 2022;12:826. [PMID: 35453878 DOI: 10.3390/diagnostics12040826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
891 Johnson PJ, Pinato DJ, Kalyuzhnyy A, Toyoda H. Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma. J Clin Oncol 2022;:JCO2102373. [PMID: 35344390 DOI: 10.1200/JCO.21.02373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
892 Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM. Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma. World J Hepatol 2022; 14(3): 623-633 [DOI: 10.4254/wjh.v14.i3.623] [Reference Citation Analysis]
893 Tombazzi CR, Howe CF, Slaughter JC, Obstein KL. Rate of and Factors Associated with Palliative Care Referral among Patients Declined for Liver Transplantation. J Palliat Med 2022. [PMID: 35333610 DOI: 10.1089/jpm.2021.0403] [Reference Citation Analysis]
894 Toniutto P. Special Issue "New Therapies of Liver Diseases". J Clin Med 2022;11:1798. [PMID: 35407406 DOI: 10.3390/jcm11071798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
895 Roth GS, Hernandez O, Daabek N, Brusset B, Teyssier Y, Ghelfi J, Hilleret MN, Sengel C, Bricault I, Decaens T, Costentin C. Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma. Cancers (Basel) 2022;14:1634. [PMID: 35406406 DOI: 10.3390/cancers14071634] [Reference Citation Analysis]
896 Neamatallah M, Serria MS, El‐bendary M, El‐gilany A, Alhawarey A, Abed S, Setate YA, Ammar OA. Association of Vitamin D Gene Polymorphisms With HCV Infection Outcome. Br J Biomed Sci 2022;79:10237. [DOI: 10.3389/bjbs.2021.10237] [Reference Citation Analysis]
897 Lee CH, Chen AH, Hung SP, Hsieh CE, Tseng JH, Chen PJ, Cheng JY, Chang JT, Chan KM, Lin SM, Lin CC, Chen WT, Chen WY, Huang BS. Proton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. Cancers (Basel) 2022;14:1616. [PMID: 35406392 DOI: 10.3390/cancers14071616] [Reference Citation Analysis]
898 Nicolosi A, Pellicano R, Caviglia GP. Surveillance of cirrhotic patients using the protein induced by vitamin K absence or antagonist II (PIVKA-II). Minerva Med 2022;113:106-8. [PMID: 35313441 DOI: 10.23736/S0026-4806.21.07952-0] [Reference Citation Analysis]
899 Tao X, Chen L, Zhao Y, Liu Y, Shi R, Jiang B, Mi Y, Xu L. A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease. Front Med 2022;9:862879. [DOI: 10.3389/fmed.2022.862879] [Reference Citation Analysis]
900 Teixeira AM, Ferreira I, Barbosa AL, Fonseca S. Hepatocellular Carcinoma With Right Atrium Metastases. Cureus 2022. [DOI: 10.7759/cureus.23416] [Reference Citation Analysis]
901 Papatheodoridi A, Papatheodoridis G. Hepatocellular carcinoma: The virus or the liver? Liver Int 2022. [PMID: 35319167 DOI: 10.1111/liv.15253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
902 Li L, Xu L, Zhou S, Wang P, Zhang M, Li B. Tumour site is a risk factor for hepatocellular carcinoma after hepatectomy: a 1:2 propensity score matching analysis. BMC Surg 2022;22:104. [PMID: 35313888 DOI: 10.1186/s12893-022-01564-5] [Reference Citation Analysis]
903 Wu Z, Tang H, Wang L, Jin X, Lei Z, Yang P, Zhou J. Postoperative survival analysis of hepatocellular carcinoma patients with liver cirrhosis based on propensity score matching. BMC Surg 2022;22:103. [PMID: 35313836 DOI: 10.1186/s12893-022-01556-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
904 Ridouani F, Ghosn M, Doustaly R, Gonzalez-Aguirre AJ, Ziv E, Solomon SB, Edward Boas F, Yarmohammadi H. Accuracy of a CBCT-based virtual injection software for vessel detection during hepatic arterial embolization. Eur J Radiol 2022;150:110273. [PMID: 35338952 DOI: 10.1016/j.ejrad.2022.110273] [Reference Citation Analysis]
905 Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L, Zhou J, Lin L, Cao B, Chen Y, Zhou J, Zhu K. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Front Immunol 2022;13:848387. [PMID: 35300325 DOI: 10.3389/fimmu.2022.848387] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
906 Sekiguchi S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, Kurosaki M, Izumi N. Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy. Cancer Rep (Hoboken) 2022;5:e1613. [PMID: 35302279 DOI: 10.1002/cnr2.1613] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
907 Masuda S, Tsukiyama T, Minagawa Y, Koizumi K, Kako M, Kinbara T, Haruki U. Hepatocellular carcinoma effective stereotactic body radiotherapy using Gold Anchor and the Synchrony system: Two case reports and review of literature. World J Clin Cases 2022; 10(8): 2591-2603 [DOI: 10.12998/wjcc.v10.i8.2591] [Reference Citation Analysis]
908 Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther 2022;:1-11. [PMID: 35263211 DOI: 10.1080/14737140.2022.2052276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
909 Müller L, Hahn F, Auer TA, Fehrenbach U, Gebauer B, Haubold J, Zensen S, Kim MS, Eisenblätter M, Diallo TD, Bettinger D, Steinle V, Chang DH, Zopfs D, Pinto Dos Santos D, Kloeckner R. Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems. Front Oncol 2022;12:850454. [PMID: 35280804 DOI: 10.3389/fonc.2022.850454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
910 Guo Y, Ren Y, Chen L, Sun T, Zhang W, Sun B, Zhu L, Xiong F, Zheng C. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma. BMC Cancer 2022;22:270. [PMID: 35287627 DOI: 10.1186/s12885-022-09325-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
911 Xiaochen M, Xiangyang S, Fubo X, Wencheng J, Qingliang W, Yang X, Caixia L, Kai Z. The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligand-1 in advanced hepatocellular carcinoma patients. Asia Pac J Clin Oncol 2022. [PMID: 35289092 DOI: 10.1111/ajco.13687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
912 Lei Z, Cheng N, Si A, Yang P, Guo G, Ma W, Yu Q, Wang X, Cheng Z. A Novel Nomogram for Predicting Postoperative Liver Failure After Major Hepatectomy for Hepatocellular Carcinoma. Front Oncol 2022;12:817895. [DOI: 10.3389/fonc.2022.817895] [Reference Citation Analysis]
913 Byun JK, Lee S, Kang GW, Lee YR, Park SY, Song IS, Yun JW, Lee J, Choi YK, Park KG. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma. J Exp Clin Cancer Res 2022;41:98. [PMID: 35287706 DOI: 10.1186/s13046-022-02296-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
914 Yang J, Wang J, Li H, Gao S, Fan Y, Wang K. IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Front Oncol 2022;12:746643. [DOI: 10.3389/fonc.2022.746643] [Reference Citation Analysis]
915 Yang Y, Yu H, Qi L, Liu C, Feng Y, Qi J, Li J, Zhu Q. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis. Int J Hyperthermia 2022;39:455-65. [PMID: 35271786 DOI: 10.1080/02656736.2022.2048095] [Reference Citation Analysis]
916 Du L, Wang M, Li H, Li N, Wang F, Mei J. Identification of CCL20 and LCN2 as Efficient Serological Tools for Detection of Hepatocellular Carcinoma. Disease Markers 2022;2022:1-7. [DOI: 10.1155/2022/7758735] [Reference Citation Analysis]
917 Cheng N, Lou B, Wang H. An intelligent serological SERS test toward early-stage hepatocellular carcinoma diagnosis through ultrasensitive nanobiosensing. Nano Res . [DOI: 10.1007/s12274-022-4114-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
918 Kotsifa E, Vergadis C, Vailas M, Machairas N, Kykalos S, Damaskos C, Garmpis N, Lianos GD, Schizas D. Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? JPM 2022;12:436. [DOI: 10.3390/jpm12030436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
919 Cococcia S, Dutta P, Moghim M, Hogan B, Tanwar S, Marshall A, Macdonald D, Yu D, O'Beirne J, Rosenberg WM, Trembling PM. The fate of indeterminate liver lesions: What proportion are precursors of hepatocellular carcinoma? BMC Gastroenterol 2022;22:118. [PMID: 35272611 DOI: 10.1186/s12876-022-02135-x] [Reference Citation Analysis]
920 Novick D, Rajan N, Wei A, Cheng R, Szende A, Baik R, Colman S. Treatment Patterns and Health Resource Utilization in Patients With Hepatocellular Carcinoma After Failure of Sorafenib in Real-World Setting in Taiwan. Value Health Reg Issues 2022;30:76-82. [PMID: 35278836 DOI: 10.1016/j.vhri.2022.01.001] [Reference Citation Analysis]
921 Soong RS, Chen YC, Chou TC, Chiang PH, Chen WM, Chiang MF, Shia BC, Wu SY. A Novel Predictive Scoring System for 90-Day Mortality among Patients with Hepatocellular Cell Carcinoma Receiving Major Hepatectomy. Cancers (Basel) 2022;14:1398. [PMID: 35326550 DOI: 10.3390/cancers14061398] [Reference Citation Analysis]
922 Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, Verhelst X, Aerts M, Vanlander A, Berrevoet F, Troisi RI, Van Vlierberghe H, Defreyne L. 90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology 2022;:211806. [PMID: 35258371 DOI: 10.1148/radiol.211806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
923 Yan X, Sun T, Song Y, Peng W, Xu Y, Luo G, Li M, Chen S, Fang W, Dong L, Xuan S, He T, Cao B, Lu Y. In situ Thermal-Responsive Magnetic Hydrogel for Multidisciplinary Therapy of Hepatocellular Carcinoma. Nano Lett . [DOI: 10.1021/acs.nanolett.1c04413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
924 He Y, Hu B, Zhu C, Xu W, Ge Y, Hao X, Dong B, Chen X, Dong Q, Zhou X. A Novel Multimodal Radiomics Model for Predicting Prognosis of Resected Hepatocellular Carcinoma. Front Oncol 2022;12:745258. [DOI: 10.3389/fonc.2022.745258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
925 El-shaarawy F, Abo Elazm MM, Mohamed RH, Radwan MI, Abo-elmatty DM, Mehanna ET. Relation of the methylation state of RUNX3 and p16 gene promoters with hepatocellular carcinoma in Egyptian patients. Egypt J Med Hum Genet 2022;23. [DOI: 10.1186/s43042-022-00256-2] [Reference Citation Analysis]
926 Liang T, He Y, Mo S, Chen Z, Liao X, Zhou X, Yang C, Zhao S, Han C, Zhu G, Su H, Ye X, Peng T. Gender disparity in hepatocellular carcinoma recurrence after curative hepatectomy. Ann Hepatol 2022;27:100695. [PMID: 35257933 DOI: 10.1016/j.aohep.2022.100695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
927 Lin N, Lin Y, Xu J, Liu D, Li D, Meng H, Gallant MA, Kubota N, Roy D, Li JS, Gorospe EC, Sherman M, Gish RG, Abou-Alfa GK, Nguyen MH, Taggart DJ, Van Etten RA, Hoshida Y, Li W. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. Hepatol Commun 2022. [PMID: 35244350 DOI: 10.1002/hep4.1918] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
928 Solbiati M, Ierace T, Muglia R, Pedicini V, Iezzi R, Passera KM, Rotilio AC, Goldberg SN, Solbiati LA. Thermal Ablation of Liver Tumors Guided by Augmented Reality: An Initial Clinical Experience. Cancers 2022;14:1312. [DOI: 10.3390/cancers14051312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
929 Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, Ito T, Tanaka T, Miyake N, Zou B, Wong C, Toyoda H, Esquivel CO, Bonham CA, Nguyen MH, Huang DQ. Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. Hepatol Commun 2022. [PMID: 35234371 DOI: 10.1002/hep4.1923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
930 Luna A. Editorial Comment: Integrated Diagnosis of Hepatocellular Carcinoma—An Opportunity for Abdominal Radiologists. American Journal of Roentgenology. [DOI: 10.2214/ajr.22.27611] [Reference Citation Analysis]
931 Shi Q, Liu J, Li T, Zhou C, Wang Y, Huang S, Yang C, Chen Y, Xiong B. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis: DEB-TACE vs cTACE for HCC beyond up-to-seven criteria. Clin Res Hepatol Gastroenterol 2022;:101893. [PMID: 35247625 DOI: 10.1016/j.clinre.2022.101893] [Reference Citation Analysis]
932 Liu X, Gao J, Sun Y, Zhang F, Guo W, Zhang S. Clotrimazole Inhibits HCC Migration and Invasion by Modulating the ERK-p65 Signaling Pathway. DDDT 2022;Volume 16:863-871. [DOI: 10.2147/dddt.s354205] [Reference Citation Analysis]
933 Zheng W, Huang H, She D, Xiong M, Chen X, Lin X, Cao D. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M. Abdom Radiol (NY) 2022;47:957-68. [PMID: 34964069 DOI: 10.1007/s00261-021-03380-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
934 Cai H, Zhu X, Li X, Shen Y, Huang C, Shi G, Tang M, Wu D, Deng M, Sun H. Future liver volume combined with platelet count predicts liver failure after major hepatectomy. The Surgeon 2022. [DOI: 10.1016/j.surge.2022.02.004] [Reference Citation Analysis]
935 Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, Saenz de Viteri C, Fobar A, Parikh ND. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 2022;75:541-9. [PMID: 34618932 DOI: 10.1002/hep.32185] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 21.0] [Reference Citation Analysis]
936 Santana-salgado I, Bautista-santos A, Moreno-alcántar R. Factores de riesgo para desarrollar carcinoma hepatocelular en pacientes tratados con antivirales de acción directa. Revista de Gastroenterología de México 2022. [DOI: 10.1016/j.rgmx.2021.03.007] [Reference Citation Analysis]
937 Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut 2022;71:593-604. [PMID: 33741640 DOI: 10.1136/gutjnl-2020-323663] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
938 Chuma M, Uojima H, Hattori N, Arase Y, Fukushima T, Hirose S, Kobayashi S, Ueno M, Tezuka S, Iwasaki S, Wada N, Kubota K, Tsuruya K, Shimma Y, Hiroki I, Takuya E, Tokoro C, Iwase S, Miura Y, Moriya S, Watanabe T, Hidaka H, Morimoto M, Numata K, Kusano C, Kagawa T, Maeda S. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatol Res 2022;52:269-80. [PMID: 34761470 DOI: 10.1111/hepr.13732] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
939 Facciorusso A, Paolillo R, Tartaglia N, Ramai D, Mohan BP, Cotsoglou C, Chandan S, Ambrosi A, Bargellini I, Renzulli M, Sacco R. Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis. Dig Liver Dis 2022;54:316-23. [PMID: 34193367 DOI: 10.1016/j.dld.2021.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
940 Kim BH, Yu SJ, Kang W, Cho SB, Park SY, Kim SU, Kim DY. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma. J Gastroenterol Hepatol 2022;37:428-39. [PMID: 34725855 DOI: 10.1111/jgh.15727] [Reference Citation Analysis]
941 Huang J, Guo Y, Huang W, Hong X, Quan Y, Lin L, Zhou J, Liang L, Zhang Y, Zhou J, Cai M, Zhu K. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. JHC 2022;Volume 9:157-70. [DOI: 10.2147/jhc.s353956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
942 Beleù A, Autelitano D, Geraci L, Aluffi G, Cardobi N, De Robertis R, Martone E, Conci S, Ruzzenente A, D'onofrio M. Radiofrequency ablation of hepatocellular carcinoma: CT texture analysis of the ablated area to predict local recurrence. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110250] [Reference Citation Analysis]
943 Lewis S, Barry A, Hawkins M. Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.02.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
944 Kimura Y, Ghosn M, Cheema W, Adusumilli PS, Solomon SB, Srimathveeralli G. Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors. Molecular Therapy - Oncolytics 2022;24:194-204. [DOI: 10.1016/j.omto.2021.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
945 Chong N, Schoenberger H, Yekkaluri S, Fetzer DT, Rich NE, Yokoo T, Gopal P, Manwaring C, Quirk L, Singal AG. Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study. Aliment Pharmacol Ther 2022;55:683-90. [PMID: 35170052 DOI: 10.1111/apt.16779] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
946 Ronot M. Performance of LI-RADS for the Noninvasive Diagnosis of HCC: Pathology Should Not Be the Only Acceptable Reference. Radiology 2022;:213224. [PMID: 35230189 DOI: 10.1148/radiol.213224] [Reference Citation Analysis]
947 Lüdemann W, Kahn J, Pustelnik D, Hardt J, Böning G, Jonczyk M, Amthauer H, Gebauer B, Hamm B, Wieners G. Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection. Eur Radiol 2022. [PMID: 35230518 DOI: 10.1007/s00330-022-08585-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
948 Rich NE, Singal AG. Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines? Hepatology 2022;75:740-53. [PMID: 34923659 DOI: 10.1002/hep.32284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
949 Minier C, Hermida M, Allimant C, Escal L, Pierredon-Foulongne MA, Belgour A, Piron L, Taourel P, Cassinotto C, Guiu B. Software-based assessment of tumor margins after percutaneous thermal ablation of liver tumors: A systematic review. Diagn Interv Imaging 2022:S2211-5684(22)00033-X. [PMID: 35246412 DOI: 10.1016/j.diii.2022.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
950 Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2022;7:219-29. [PMID: 35065058 DOI: 10.1016/S2468-1253(21)00385-X] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 21.0] [Reference Citation Analysis]
951 Choi JY, Ha J, Choi SH, Kang HJ, Kim SY, Kim KW. Comparison of gadoxetate disodium-enhanced MRI sequences for measuring hepatic observation size and its implication of LI-RADS classification. Abdom Radiol (NY) 2022;47:1024-31. [PMID: 35020008 DOI: 10.1007/s00261-021-03403-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
952 Pennisi G, Enea M, Romero-Gomez M, Viganò M, Bugianesi E, Wong VW, Fracanzani AL, Sebastiani G, Boursier J, Berzigotti A, Eslam M, Ampuero J, Benmassaoud A, La Mantia C, Mendoza YP, George J, Craxì A, Camma' C, de Ledinghen V, Petta S. Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. Aliment Pharmacol Ther 2022;55:604-15. [PMID: 34988994 DOI: 10.1111/apt.16763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
953 Elena Laino M, Viganò L, Ammirabile A, Lofino L, Generali E, Francone M, Lleo A, Saba L, Savevski V. The added value of Artificial Intelligence to LI-RADS categorization: a systematic review. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
954 Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou Α, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, Dalekos G, Kao JH, Hadziyannis S, Papatheodoridis GV. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver Int 2022;42:541-50. [PMID: 34890120 DOI: 10.1111/liv.15128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
955 Desjonqueres E, Campani C, Marra F, Zucman-Rossi J, Nault JC. Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver Int 2022;42:492-506. [PMID: 34982503 DOI: 10.1111/liv.15152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
956 Abrahamsson J, Sternby Eilard M, Rizell M, Bennett W, Åberg F. Reduced calcineurin inhibitor exposure with antibody induction and recurrent hepatocellular carcinoma after liver transplantation. Scand J Gastroenterol 2022;57:325-32. [PMID: 34871120 DOI: 10.1080/00365521.2021.2010799] [Reference Citation Analysis]
957 Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76:681-93. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 302] [Cited by in F6Publishing: 279] [Article Influence: 302.0] [Reference Citation Analysis]
958 Schrecker C, Waidmann O, El Youzouri H, Trojan J, Schnitzbauer AA, Bechstein WO, Zeuzem S, Koch C. Low Platelet Count Predicts Reduced Survival in Potentially Resectable Hepatocellular Carcinoma. Current Oncology 2022;29:1475-87. [DOI: 10.3390/curroncol29030124] [Reference Citation Analysis]
959 Zhang X, Zheng Q, Yue X, Yuan Z, Ling J, Yuan Y, Liang Y, Sun A, Liu Y, Li H, Xu K, He F, Wang J, Wu J, Zhao C, Tian C. ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation. J Exp Clin Cancer Res 2022;41:79. [PMID: 35227287 DOI: 10.1186/s13046-022-02288-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
960 Fassio E, Barreyro FJ, Pérez MS, Dávila D, Landeira G, Gualano G, Ruffillo G. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? WJH 2022; 14(2):354-71. [DOI: 10.4254/wjh.v14.i2.354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
961 Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato M, Tateishi R, Ogawa M, Mori H, Kitano M, Toyoda H, Ogawa C, Kudo M; JSUM A. I. investigators. Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts. J Gastroenterol. [DOI: 10.1007/s00535-022-01849-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
962 Yang JC, Hu JJ, Li YX, Luo W, Liu JZ, Ye DW. Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma. Front Oncol 2022;12:781820. [PMID: 35211399 DOI: 10.3389/fonc.2022.781820]